5' TO 3' EXONUCLEASE MUTATIONS OF THERMOSTABLE DNA POLYMERASES

Abstract: The present invention relates to thermostable DNA polymerases which exhibit a different level of 5' to 3' exonuclease activity than their respective native polymerases. Particular conserved amino acid domains in thermostable DNA polymerases are mutated or deleted to alter the 5' to 3' exonuclease activity of the polymerases. The present invention also relates to means for isolating and producing such altered polymerases.

Description: 5' TO 3' EXONUCLEASE MUTATIONS OF THERMOSTABLE DNA POLYMERASES Cross-Reference to Related Applications This is a continuation-in-part (CIP) of copending Serial Nos. 590,213, 590,466 and 590,490 all of which were filed on September 28, 1990, and all of which are CIPs of Serial No. 523,394, filed May 15, 1990, which is a CIP of abandoned Serial No. 143,441, filed January 12, 1988, which is a CIP of Serial No. 063,509, filed June 17, 1987, which issued as United States Patent No. 4,889,818 and which is a CIP of abandoned Serial No. 899,241, filed August 22, 1986. This is a also a CIP of Serial No. 746,121 filed August 15, 1991 which is a CIP of: 1) PCT/US90/07641, filed December 21, 1990, which is a CIP of Serial No. 585,471, filed September 20, 1990, which is a CIP of Serial No. 455,611, filed December 22, 1989, which is a CIP of Serial No. 143,441, filed January 12, 1988 and its ancestors as described above; and 2) Serial No. 609,157, filed November 2, 1990, which is a CIP of Serial No. 557,517, filed July 24, 1990. This CIP is also related to the following patent applications: U.S. Serial No. 523,394, filed May 15, 1990; U.S. Serial No. 455,967, filed December 22, 1989; PCT Application No. 91/05571, filed August 6, 1991; PCT Application No. 91/05753, filed August 13, 1991. All of the patent applications referenced in this section are incorporated herein by reference. Backcrround of the Invention Field of the Invention The present invention relates to thermostable DNA polymerases which have been altered or mutated such that a different level of 5' to 3' exonuclease activity is exhibited from that which is exhibited by the native enzyme. The present invention also relates to means for isolating and producing such altered polymerases. Thermostable DNA polymerases are useful in many recombinant DNA techniques, especially nucleic acid amplification by the polymerase chain reaction (PCR) self-sustained sequence replication (3SR) , and high temperature DNA sequencing. Background Art Extensive research has been conducted on the isolation of DNA polymerases from mesophilic microorganisms such as E___ coli. See, for example, Bessman et al. , 1957, J. Biol. Chem. 223:171-177 and Buttin and Kornberg, 1966, J. Biol. Chem. 241:5419-5427. Somewhat less investigation has been made on the isolation and purification of DNA polymerases from thermophiles such as Thermus aguaticus, Thermus thermophilus. Thermotoqa maritima , Thermus species sps 17, Thermus species Z05 and Thermosipho africanus. The use of thermostable enzymes to amplify existing nucleic acid sequences in amounts that are large compared to the amount initially present was described in United States Patent Nos. 4,683,195 and 4,683,202, which describe the PCR process, both disclosures of which are incorporated herein by reference. Primers, template, nucleoside triphosphates, the appropriate buffer and reaction conditions, and polymerase are used in the PCR process, which involves denaturation of target DNA, hybridization of primers, and synthesis of complementary strands. The extension product of each primer becomes a template for the production of the desired nucleic acid sequence. The two patents disclose that, if the polymerase employed is a thermostable enzyme, then polymerase need not be added after every denaturation step, because heat will not destroy the polymerase activity. United States Patent No. 4,889,818, European Patent Publication No. 258,017 and PCT Publication No. 89/06691, the disclosures of which are incorporated herein by reference, all describe the isolation and recombinant expression of an -94 kDa thermostable DNA polymerase from Thermus aαuaticus and the use of that polymerase in PCR. Although T. aquaticus DNA polymerase is especially preferred for use in PCR and other recombinant DNA techniques, there remains a need for other thermostable polymerases. Summary of the Invention In addressing the need for other thermostable polymerases, the present inventors found that some thermostable DNA polymerases such as that isolated from Thermus aquaticus (Tag) display a 5' to 3' exonuclease or structure-dependent single-stranded endonuclease (SDSSE) activity. As is explained in greater detail below, such 5' to 3' exonuclease activity is un- desirable in an enzyme to be used in PCR, because it may limit the amount of product produced and contribute to the plateau phenomenon in the normally exponential accumulation of product. Furthermore, the presence of 5' to 3' nuclease activity in a thermostable DNA polym- erase may contribute to an impaired ability to effi¬ ciently generate long PCR products greater than or equal to 10 kb particularly for G+C-rich targets. In DNA sequencing applications and cycle sequencing appli- tions, the presence of 5' to 3 ' nuclease activity may contribute to reduction in desired band intensities and/or generation of spurious or background bands. Finally, the absence of 5' to 3' nuclease activity may facilitate higher sensitivity allelic discrimination in a combined polymerase ligase chain reaction (PLCR) assay. However, an enhanced or greater amount of 5' to 3 ' exonuclease activity in a thermostable DNA polymerase may be desirable in such an enzyme which is used in a homogeneous assay system for the concurrent amplifica¬ tion and detection of a target nucleic acid sequence. Generally, an enhanced 5' to 3 ' exonuclease activity is defined an enhanced rate of exonuclease cleavage or an enhanced rate of nick-translation synthesis or by the displacement of a larger nucleotide fragment before cleavage of the fragment. Accordingly, the present invention was developed to meet the needs of the prior art by providing thermo¬ stable DNA polymerases which exhibit altered 5' to 3' exonuclease activity. Depending on the purpose for which the thermostable DNA polymerase will be used, the 5' to 3 ' exonuclease activity of the polymerase may be altered such that a range of 5' to 3' exonuclease activity may be expressed. This range of 5' to 3' exonuclease activity extends from an enhanced activity to a complete lack of activity. Although enhanced activity is useful in certain PCR applications, e. g. a homogeneous assay, as little 5' to 3' exonuclease activity as possible is desired in thermostable DNA polymerases utilized in most other PCR applications. It was also found that both site directed mutagenesis as well as deletion mutagenesis may result in the desired altered 5' to 3' exonuclease activity in the thermostable DNA polymerases of the present invention. Some mutations which alter the exonuclease activity have been shown to alter the processivity of the DNA polymerase. In many applications (e.g. amplification of moderate sized targets in the presence of a large amount of high complexity genomic DNA) reduced processivity may simplify the optimization of PCRs and contribute to enhanced specificity at high enzyme concentration. Some mutations which eliminate 5' to 3' exonuclease activity do not reduce and may enhance the processivity of the thermostable DNA polymerase and accordingly, these mutant enzymes may be preferred in other applications (e.g. generation of long PCR products) . Some mutations which eliminate the 5' to 3 ' exonuclease activity simultaneously enhance, relative to the wild type, the thermoresistance of the mutant thermostable polymerase, and thus, these mutant enzymes find additional utility in the amplification of G+c-rich or otherwise difficult to denature targets. Particular common regions or domains of thermo¬ stable DNA polymerase genomes have been identified as preferred sites for mutagenesis to affect the enzyme's 5' to 3 ' exonuclease. These domains can be isolated and inserted into a thermostable DNA polymerase having none or little natural 5' to 3' exonuclease activity to enhance its activity. Thus, methods of preparing chimeric thermostable DNA polymerases with altered 5' to 3' exonuclease are also encompassed by the present invention. Detailed Description of the Invention The present invention provides DNA sequences and expression vectors that encode thermostable DNA polymerases which have been mutated to alter the expression of 5' to 3' exonuclease. To facilitate understanding of the invention, a number of terms are defined below. The terms "cell", "cell line", and "cell culture" can be used interchangeably and all such designations include progeny. Thus, the words "transformants" or "transformed cells" include the primary transformed cell and cultures derived from that cell without regard to the number of transfers. All progeny may not be precisely identical in DNA content, due to deliberate or inadvertent mutations. Mutant progeny that have the same functionality as screened for in the originally transformed cell are included in the definition of transformants. The term "control sequences" refers to DNA sequences necessary for the expression of an operably linked coding sequence in a particular host organism. The control sequences that are suitable for procaryotes, for example, include a promoter, optionally an operator sequence, a ribosome binding site, and possibly other sequences. Eucaryotic cells are known to utilize promoters, polyadenylation signals, and enhancers. The term "expression system" refers to DNA sequences containing a desired coding sequence and control sequences in operable linkage, so that hosts transformed with these sequences are capable of producing the encoded proteins. To effect transformation, the expression system may be included on a vector; however, the relevant DNA may also be integrated into the host chromosome. The term "gene" refers to a DNA sequence that comprises control and coding sequences necessary for the production of a recoverable bioactive polypeptide or precursor. The polypeptide can be encoded by a full length coding sequence or by any portion of the coding sequence so long as the enzymatic activity is retained. The term "operably linked" refers to the positioning of the coding sequence such that control sequences will function to drive expression of the protein encoded by the coding sequence. Thus, a coding sequence "operably linked" to control sequences refers to a configuration wherein the coding sequences can be expressed under the direction of a control sequence. The term "mixture" as it relates to mixtures containing thermostable polymerases refers to a collection of materials which includes a desired thermostable polymerase but which can also include other proteins. If the desired thermostable polymerase is derived from recombinant host cells, the other proteins will ordinarily be those associated with the host. Where the host is bacterial, the contaminating proteins will, of course, be bacterial proteins. The term "non-ionic polymeric detergents" refers to surface-active agents that have no ionic charge and that are characterized for purposes of this invention, by an ability to stabilize thermostable polymerase enzymes at a pH range of from about 3.5 to about 9.5, preferably from 4 to 8.5. The term "oligonucleotide" as used herein is defined as a molecule comprised of two or more deoxyribonucleotides or ribonucleotides, preferably more than three, and usually more than ten. The exact size will depend on many factors, which in turn depends on the ultimate function or use of the oligonucleotide. The oligonucleotide may be derived synthetically or by cloning. The term "primer" as used herein refers to an oligonucleotide which is capable of acting as a point of initiation of synthesis when placed under conditions in which primer extension is initiated. An oligonucleotide "primer" may occur naturally, as in a purified restriction digest or be produced synthetically. Synthesis of a primer extension product which is complementary to a nucleic acid strand is initiated in the presence of four different nucleoside triphosphates and a thermostable polymerase enzyme in an appropriate buffer at a suitable temperature. A "buffer" includes cofactors (such as divalent metal ions) and salt (to provide the appropriate ionic strength) , adjusted to the desired pH. A primer is single-stranded for maximum efficiency in amplification, but may alternatively be double-stranded. If double-stranded, the primer is first treated to separate its strands before being used to prepare extension products. The primer is usually an oligodeoxyribonucleotide. The primer must be sufficiently long to prime the synthesis of extension products in the presence of the polymerase enzyme. The exact length of a primer will depend on many factors, such as source of primer and result desired, and the reaction temperature must be adjusted depending on primer length and nucleotide sequence to ensure proper annealing of primer to template. Depending on the complexity of the target sequence, an oligonucleotide primer typically contains 15 to 35 nucleotides. Short primer molecules generally require lower temperatures to form sufficiently stable complexes with template. A primer is selected to be "substantially" complementary to a strand of specific sequence of the template. A primer must be sufficiently complementary to hybridize with a template strand for primer elongation to occur. A primer sequence need not reflect the exact sequence of the template. For example, a non-complementary nucleotide fragment may be attached to the 5' end of the primer, with the remainder of the primer sequence being substantially complementary to the strand. Non-complementary bases or longer sequences can be interspersed into the primer, provided that the primer sequence has sufficient complementarity with the sequence of the template to hybridize and thereby form a template primer complex for synthesis of the extension product of the primer. The terms "restriction endonucleases" and "restriction enzymes" refer to bacterial enzymes which cut double-stranded DNA at or near a specific nucleotide sequence. The term "thermostable polymerase enzyme" refers to an enzyme which is stable to heat and is heat resistant and catalyzes (facilitates) combination of the nucleotides in the proper manner to form primer extension products that are complementary to a template nucleic acid strand. Generally, synthesis of a primer extension product begins at the 3' end of the primer and proceeds in the 5' direction along the template strand, until synthesis terminates. In order to further facilitate understanding of the invention, specific thermostable DNA polymerase enzymes are referred to throughout the specification to exemplify the broad concepts of the invention, and these references are not intended to limit the scope of the invention. The specific enzymes which are frequently referenced are set forth below with a common abbreviation which will be used in the specification and their respective nucleotide and amino acid Sequence ID numbers. Thermostable DNA Common Polymerase Abbr. SEP. ID NO: Thermus aquaticus Tag SEQ ID N0:l (nuc) SEQ ID NO:2 (a.a.) Thermotoga maritima Thermus species spsl7 Thermus species Z05 Thermus thermophilus Thermosipho africanus As summarized above, the present invention relates to thermostable DNA polymerases which exhibit altered 5' to 3' exonuclease activity from that of the native polymerase. Thus, the polymerases of the invention exhibit either an enhanced 5' to 3 ' exonuclease activity or an attenuated 5' to 3' exonuclease activity from that of the native polymerase. Thermostable DNA Polymerases With Attenuated 5 ' to 3 ' Exonuclease Activity DNA polymerases often possess multiple functions. In addition to the polymerization of nucleotides E. coli DNA polymerase I (pol I) , for example, catalyzes the pyrophosphorolysis of DNA as well as the hydrolysis of phosphodiester bonds. Two such hydrolytic activities have been characterized for pol I; one is a 3' to 5' exonuclease activity and the other a 5' to 3' exonuclease activity. The two exonuclease activities are associated with two different domains of the pol I molecule. However, the 5' to 3 ' exonuclease activity of pol I differs from that of thermostable DNA polymerases in that the 5' to 3' exonuclease activity of thermostable DNA polymerases has stricter structural requirements for the substrate on which it acts. An appropriate and sensitive assay for the 5' to 3 ' exonuclease activity of thermostable DNA polymerases takes advantage of the discovery of the structural requirement of the activity. An important feature of the design of the assay is an upstream oligonucleoside primer which positions the polymerase appropriately for exonuclease cleavage of a labeled downstream oligonucleotide probe. For an assay of polymerization- independent exonuclease activity (i.e., an assay performed in the absence of deoxynucleoside triphosphates) the probe must be positioned such that the region of probe complementary to the template is immediately adjacent to the 3'-end of the primer. Additionally, the probe should contain at least one, but preferably 2-10, or most preferably 3-5 nucleotides at the 5'-end of the probe which are not complementary to the template. The combination of the primer and probe when annealed to the template creates a double stranded structure containing a nick with a 3'-hydroxy1 5' of the nick, and a displaced single strand 3' of the nick. Alternatively, the assay can be performed as a polymerization-dependent reaction, in which case each deoxynucleoside triphosphate should be included at a concentration of between 1 μM and 2 mM, preferably between 10 μM and 200 μM, although limited dNTP addition (and thus limited dNTP inclusion) may be involved as dictated by the template sequence. When the assay is performed in the presence of dNTPs, the necessary structural requirements are an upstream oligonucleotide primer to direct the synthesis of the complementary strand of the template by the polymerase, and a labeled downstream oligonucleotide probe which will be contacted by the polymerase in the process of extending the upstream primer. An example of a polymerization-independent thermostable DNA polymerase 5' to 3 ' exonuclease assay follows. The synthetic 3' phosphorylated oligonucleotide probe (phosphorylated to preclude polymerase extension) BW33 (GATCGCTGCGCGTAACCACCACACCCGCCGCGCp) (SEQ ID NO:13) (100 pmol) was 32 P-labeled at the 5' end with gamma-[ 3 P] ATP (3000 Ci/mmol) and T4 polynucleotide kinase. The reaction mixture was extracted with phenol:chloroform:isoamyl alcohol, followed by ethanol precipitation. The 32 P-labeled oligonucleotide probe was redissolved in 100 μl of TE buffer, and unincorporated ATP was removed by gel filtration chromatography on a Sephadex G-50 spin column. Five pmol of 32 P-labeled BW33 probe, was annealed to 5 pmol of single-strand M13mpl0w DNA, in the presence of 5 pmol of the synthetic oligonucleotide primer BW37 (GCGCTAGGGCGCTGGCAAGTGTAGCGGTCA) (SEQ ID NO:14) in a 100 μl reaction containing 10 mM Tris-HCl (pH 8.3), 50 mM KC1, and 3 mM MgCl 2 . The annealing mixture was heated to 95"C for 5 minutes, cooled to 70°C over 10 minutes, incubated at 70°C for an additional 10 minutes, and then cooled to 25"C over a 30 minute period in a Perkin-Elmer Cetus DNA Thermal Cycler. Exonuclease reactions containing 10 μl of the annealing mixture were pre-incubated at 70°C for 1 minute. Thermostable DNA polymerase enzyme (approximately 0.01 to 1 unit of DNA polymerase activity, or 0.0005 to 0.05 pmol of enzyme) was added in a 2.5 μl volume to the pre-incubation reaction, and the reaction mixture was incubated at 70"C. Aliquots (5 μl) were removed after 1 minute and 5 minutes, and stopped by the addition of 1 μl of 60 mM EDTA. The reaction products were analyzed by homochromatography and exonuclease activity was quantified following autoradiography. Chromatography was carried out in a homochromatography mix containing 2% partially hydrolyzed yeast RNA in 7M urea on Polygram CEL 300 DEAE cellulose thin layer chromatography plates. The presence of 5' to 3' exonuclease activity results in the generation of small 3 P-labeled oligomers, which migrate up the TLC plate, and are easily differentiated on the autoradiogram from undegraded probe, which remains at the origin. The 5' to 3 ' exonuclease activity of the thermostable DNA polymerases excises 5' terminal regions of double-stranded DNA releasing 5'-mono- and oligonucleotides in a sequential manner. The preferred substrate for the exonuclease is displaced single- stranded DNA, with hydrolysis of the phosphodiester bond occurring between the displaced single-stranded DNA and the double-helical DNA. The preferred exonuclease cleavage site is a phosphodiester bond in the double helical region. Thus, the exonuclease activity can be better described as a structure-dependent single-stranded endonuclease (SDSSE) . Many thermostable polymerases exhibit this 5' to 3' exonuclease activity, including the DNA polymerases of Tag. Tma, Tspsl7, TZ05, Tth and Taf. When thermostable polymerases which have 5' to 3' exonuclease activity are utilized in the PCR process, a variety of undesirable results have been observed including a limitation of the amount of product produced, an impaired ability to generate long PCR products or amplify regions containing significant secondary structure, the production of shadow bands or the attenuation in signal strength of desired termination bands during DNA sequencing, the degradation of the 5'-end of oligonucleotide primers in the context of double-stranded primer-template complex, nick- translation synthesis during oligonucleotide-directed mutagenesis and the degradation of the RNA component of RNA:DNA hybrids. The limitation of the amount of PCR product produced is attributable to a plateau phenomenon in the otherwise exponential accumulation of product. Such a plateau phenomenon occurs in part because 5' to 3' exonuclease activity causes the hydrolysis or cleavage of phosphodiester bonds when a polymerase with 5' to 3' exonuclease activity encounters a forked structure on a PCR substrate. Such forked structures commonly exist in certain G- and C-rich DNA templates. The cleavage of these phosphodiester bonds under these circumstances is undesirable as it precludes the amplification of certain G- and C-rich targets by the PCR process. Furthermore, the phosphodiester bond cleavage also contributes to the plateau phenomenon in the generation of the later cycles of PCR when product strand concentration and renaturation kinetics result in forked structure substrates. In the context of DNA sequencing, the 5' to 3' exonuclease activity of DNA polymerases is again a hinderance with forked structure templates because the phosphodiester bond cleavage during the DNA extension reactions results in "false stops". These "false stops" in turn contribute to shadow bands, and in extreme circumstances may result in the absence of accurate and interpretable sequence data. When utilized in a PCR process with double-stranded primer-template complex, the 5' to 3' exonuclease activity of a DNA polymerase may result in the degradation of the 5'-end of the oligonucleotide primers. This activity is not only undesirable in PCR, but also in second-strand cDNA synthesis and sequencing processes. During optimally efficient oligonucleotide-directed mutagenesis processes, the DNA polymerase which is utilized must not have strand-displacement synthesis and/or nick-translation capability. Thus, the presence of 5' to 3' exonuclease activity in a polymerase used for oligonucleotide-directed mutagenesis is also undesirable. Finally, the 5' to 3' exonuclease activity of polymerases generally also contains an inherent RNase H activity. However, when the polymerase is also to be used as a reverse transcriptase, as in a PCR process including an RNA:DNA hybrid, such an inherent RNase H activity may be disadvantageous. Thus, one aspect of this invention involves the generation of thermostable DNA polymerase mutants displaying greatly reduced, attenuated or completely eliminated 5' to 3' exonuclease activity. Such mutant thermostable DNA polymerases will be more suitable and desirable for use in processes such as PCR, second- strand cDNA synthesis, sequencing and oligonucleotide- directed mutagenesis. The production of thermostable DNA polymerase mutants with attenuated or eliminated 5' to 3' exonuclease activity may be accomplished by processes such as site-directed mutagenesis and deletion mutagenesis. For example, a site-directed mutation of G to A in the second position of the codon for Gly at residue 46 in the Tag DNA polymerase amino acid sequence (i.e. mutation of G(137) to (A) in the DNA sequence has been found to result in an approximately 1000-fold reduction of 5' to 3' exonuclease activity with no apparent change in polymerase activity, processivity or extension rate. This site-directed mutation of the Tag DNA polymerase nucleotide sequence results in an amino acid change of Gly (46) to Asp. Glycine 46 of Tag DNA polymerase is conserved in Thermus species spsl7 DNA polymerase, but is located at residue 43, and the same Gly to Asp mutation has a similar effect on the 5' to 3' exonuclease activity of Tspsl7 DNA polymerase. Such a mutation of the con¬ served Gly of Tth (Gly 46), TZ05 (Gly 46), Tma (Gly 37) and Taf (Gly 37) DNA polymerases to Asp also has a similar attenuating effect on the 5' to 3' exonuclease activities of those polymerases. TSPS17 Gly 43, Tth Gly 46, TZ05 Gly 46, Tma Gly 37 and Taf Gly 37 are also found in a conserved A(V/T)YG (SEQ ID NO:15) seguence domain, and changing the glycine to aspartic acid within this conserved sequence domain of any polymerase is also expected to attenuate 5' to 3' exonuclease activity. Specifically, TSPS17 Gly 43, Tth Gly 46, TZ05 Gly 46, and Taf Gly 37 share the AVYG sequence domain, and Tma Gly 37 is found in the ATYG domain. Mutations of glycine to aspartic acid in other thermostable DNA polymerases containing the conserved A(V/T)YG (SEQ ID NO:15) domain can be accomplished utilizing the same principles and techniques used for the site-directed mutagenesis of Tag polymerase. Exemplary of such site-directed mutagenesis techniques are Example 5 of U.S. Serial No. 523,394, filed May 15, 1990, Example 4 of Attorney Docket No. 2583.1 filed September 27, 1991, Examples 4 and 5 of U.S. Serial No. 455,967, filed December 22, 1989 and Examples 5 and 8 of PCT Application No. 91/05753, filed August 13, 1991. Such site-directed mutagenesis is generally accomplished by site-specific primer-directed mutagenesis. This technique is now standard in the art, and is conducted using a synthetic oligonucleotide primer complementary to a single-stranded phage DNA to be mutagenized except for limited mismatching, representing the desired mutation. Briefly, the synthetic oligonucleotide is used as a primer to direct synthesis of a strand complementary to the phasmid or phage, and the resulting double-stranded DNA is transformed into a phage-supporting host bacterium. Cultures of the transformed bacteria are plated in top agar, permitting plaque formation from single cells that harbor the phage or plated on drug selective media for phasmid vectors. Theoretically, 50% of the new plaques will contain the phage having, as a single strand, the mutated form; 50% will have the original sequence. The plaques are tranferred to nitrocellulose filters and the "lifts" hybridized with kinased synthetic primer at a temperature that permits hybridization of an exact match, but at which the mismatches with the original strand are sufficient to prevent hybridization. Plaques that hybridize with the probe are then picked and cultured, and the DNA is recovered. In the constructions set forth below, correct ligations for plasmid construction are confirmed by first transforming E. coli strains DG98, DG101, DG116, or other suitable hosts, with the ligation mixture. Successful transformants are selected by ampicillin, tetracycline or other antibiotic resistance or using other markers, depending on the mode of plasmid construction, as is understood in the art. Plasmids from the transformants are then prepared according to the method of Clewell, D.B., et al., Proc. Natl. Acad. Sci. .USA. (1969) (52:1159, optionally following chloramphenicol amplification (Clewell, D.B., J. Bacteriol. (1972) 110: 667) . The isolated DNA is analyzed by restriction and/or sequenced by the dideoxy method of Sanger, F., et al., Proc. Natl. Acad. Sci. fUSA. (1977) 74 . :5463 as further described by Messing, et al., Nucleic Acids Res. (1981) 9 . :309, or by the method of Maxam, et al.. Methods in Enzymology (1980) 65:499. For cloning and sequencing, and for expression of constructions under control of most lac or P L promoters, E_j_ coli strains DG98, DG101, DG116 were used as the host. For expression under control of the P L N RB S promoter, E___ coli strain K12 MC1000 lambda lysogen, N 7 N 53 cI857 SusP 80/ ATCC 39531 may be used. Exemplary hosts used herein for expression of the thermostable DNA polymerases with altered 5' to 3' exonuclease activity are E_j_ coli DG116, which was deposited with ATCC (ATCC 53606) on April 7, 1987 and E. coli KB2, which was deposited with ATCC (ATCC 53075) on March 29, 1985. For M13 phage recombinants, E___ coli strains susceptible to phage infection, such as E ^ . coli K12 strain DG98, are employed. The DG98 strain has been deposited with ATCC July 13, 1984 and has accession number 39768. Mammalian expression can be accomplished in COS-7 COS-A2, CV-1, and murine cells, and insect cell-based expression in Spodoptera frugipeida. The thermostable DNA polymerases of the present invention are generally purified from E. coli strain DG116 containing the features of plasmid pLSG33. The primary features are a temperature regulated promoter (λ P L promoter) , a temperature regulated plasmid vector, a positive retro-regulatory element (PRE) (see U.S. 4,666,848, issued May 19, 1987), and a modified form of a thermostable DNA polymerase gene. As described at page 46 of the specification of U.S patent application Serial No. 455,967, pLSG33 was prepared by ligating the Ndel-BamHI restriction fragment of pLSG24 into expression vector pDG178. The resulting plasmids are ampicillin resistant and capable of expressing 5' to 3' exonuclease deficient forms of the thermostable DNA polymerases of the present invention. The seed flask for a 10 liter fermentation contains tryptone (20 g/1), yeast extract (10 g/1), NaCl (10 g/1) and 0.005% ampicillin. The seed flask is inoculated from colonies from an agar plate, or a frozen glycerol culture stock can be used. The seed is grown to between 0.5 and 1.0 O.D. (A 680 ) • The volume of seed culture inoculated into the fermentation is calculated such that the final concentration of bacteria will be 1 mg dry weight/liter. The 10 liter growth medium contained 25 mM KH 2 P0 4 , 10 mM (NH 4 ) 2 S0 4 , 4 mM sodium citrate, 0.4 mM FeCl 2 , 0.04 mM ZnCl 2 , 0.03 mM CoCl 2 , 0.03 mM CuCl 2 , and 0.03 mM H3BO3. The following sterile components are added: 4 mM MgS0 4 , 20 g/1 glucose, 20 mg/l thiamine-HCl and 50 mg/l ampicillin. The pH was adjusted to 6.8 with NaOH and controlled during the fermentation by added NH 4 0H. Glucose is continually added during the fermentation by coupling to NH 4 OH addition. Foaming is controlled by the addition of polypropylene glycol as necessary, as an anti-foaming agent. Dissolved oxygen concentration is maintained at 40%. The fermentation is inoculated as described above and the culture is grown at 30°C until an optical density of 21 (-&68 θ ) is reached. The temperature is then raised to 37°C to induce synthesis of the desired polymerase. Growth continues for eight hours after induction, and the cells are then harvested by concentration using cross flow filtration followed by centrifugation. The resulting cell paste is frozen at -70°C and yields about 500 grams of cell paste. Unless otherwise indicated, all purification steps are conducted at 4°C. A portion of the frozen (-70°C) E. coli K12 strain DG116 harboring plasmid pLSG33 or other suitable host as described above is warmed overnight to -20°C. To the cell pellet the following reagents are added: 1 volume of 2X TE (100 mM Tris-HCl, pH 7.5, 20 mM EDTA) , 1 mg/ml leupeptin and 144 mM PMSF (in dimethyl formamide) . The final concentration of leupeptin was 1 μg/ml and for PMSF, 2.4 mM. Preferably, dithiothreitol (DTT) is included in TE to provide a final concentration of 1 mM DTT. The mixture is homogenized at low speed in a blender. All glassware is baked prior to use, and solutions used in the purification are autoclaved, if possible, prior to use. The cells are lysed by passage twice through a Microfluidizer at 10,000 psi. The lysate is diluted with IX TE containing 1 mM DTT to a final volume of 5.5X cell wet weight. Leupeptin is added to 1 μg/ml and PMSF is added to 2.4 mM. The final volume (Fraction I) is approximately 1540 ml. Ammonium sulfate is gradually added to 0.2 M (26.4 g/1) and the lysate stirred. Upon addition of ammonium sulfate, a precipitate forms which is removed prior to the polyethylenimine (PEI) precipitation step, described below. The ammonium sulfate precipitate is removed by centrifugation of the suspension at 15,000 - 20,000 xg in a JA-14 rotor for 20 minutes. The supernatant is decanted and retained. The ammonium sulfate supernatant is then stirred on a heating plate until the supernatant reaches 75°C and then is placed in a 77"C bath and held there for 15 minutes with occasional stirring. The supernatant is then cooled in an ice bath to 20°C and a 10 ml aliquot is removed for PEI titration. PEI titration and agarose gel electrophoresis are used to determine that 0.3% PEI (commercially available from BDH as Poly inP) precipitates -90% of the macromolecular DNA and RNA, i.e., no DNA band is di¬ visible on an ethidium bromide stained agarose gel after treatment with PEI. PEI is added slowly with stirring to 0.3% from a 10% stock solution. The PEI treated supernatant is centrifuged at 10,000 RPM (17,000 xg) for 20 minutes in a JA-14 rotor. The supernatant is decanted and retained. The volume (Fraction II) is approximately 1340 ml. Fraction II is loaded onto a 2.6 x 13.3 cm (71 ml) phenyl sepharose CL-4B (Pharmacia-LKB) column following equilibration with 6 to 10 column volumes of TE containing 0.2 M ammonium sulfate. Fraction II is then loaded at a linear flow rate of 10 cm/hr. The flow rate is 0.9 ml/min. The column is washed with 3 column volumes of the equilibration buffer and then with 2 column volumes of TE to remove contaminating non-DNA polymerase proteins. The recombinant thermostable DNA polymerase is eluted with 4 column volumes of 2.5 M urea in TE containing 20% ethylene glycol. The DNA polymerase containing fractions are identified by optical absorption (A 280 ) , DNA polymerase activity assay and SDS-PAGE according to standard procedures. Peak fractions are pooled and filtered through a 0.2 micron sterile vacuum filtration apparatus. The volume (Fraction III) is approximately 195 ml. The resin is equilibrated and recycled according to the manufacturer's recommendations. A 2.6 x 1.75 cm (93 ml) heparin sepharose C1-6B column (Pharmacia-LKB) is eguilibrated with 6-10 column volumes of 0.05 M KCl, 50 mM Tris-HCl, pH 7.5, 0.1 mM EDTA and 0.2% Tween 20 , at 1 column volume/hour. Preferably, the buffer contains 1 mM DTT. The column is washed with 3 column volumes of the equilibration buffer. The desired thermostable DNA polymerase of the invention is eluted with a 10 column volume linear gradient of 50-750 mM KCl gradient in the same buffer. Fractions (one-tenth column volume) are collected in sterile tubes and the fractions containing the desired thermostable DNA polymerase are pooled (Fraction IV, volume 177 ml) . Fraction IV is concentrated to 10 ml on an Amicon YM30 membrane. For buffer exchange, diafiltration is done 5 times with 2.5X storage buffer (50 mM Tris-HCl, pH 7.5, 250 mM KCl, 0.25 mM EDTA 2.5 mM DTT and 0.5% Tween-20 ) by filling the concentrator to 20 ml and concentrating the volumes to 10 ml each time. The concentrator is emptied and rinsed with 10 ml 2.5X storage buffer which is combined with the concentrate to provide Fraction V. Anion exchange chromatography is used to remove residual DNA. The procedure is conducted in a biological safety hood and sterile techniques are used. A Waters Sep-Pak plus QMA cartridge with a 0.2 micron sterile disposable syringe tip filter unit is equilibrated with 30 ml of 2.5X storage buffer using a syringe at a rate of about 5 drops per second. Using a disposable syringe, Fraction V is passed through the cartridge at about 1 drop/second and collected in a sterile tube. The cartridge is flushed with 5 ml of 2.5 ml storage buffer and pushed dry with air. The eluant is diluted 1.5 X with 80% glycerol and stored at -20°C. The resulting final Fraction IV pool contains active thermostable DNA polymerase with altered 5' to 3' exonuclease activity. In addition to site-directed mutagenesis of a nucleotide sequence, deletion mutagenesis techniques may also be used to attenuate the 5' to 3' exonuclease activity of a thermostable DNA polymerase. One example of such a deletion mutation is the deletion of all amino terminal amino acids up to and including the glycine in the conserved A(V/T)YG (SEQ ID NO:15) domain of thermostable DNA polymerases. A second deletion mutation affecting 5' to 3' exonuclease activity is a deletion up to Ala 77 in Tag DNA polymerase. This amino acid (Ala 77) has been identified as the amino terminal amino acid in an approximately 85.5 kDa proteolytic product of Tag DNA polymerase. This proteolytic product has been identified in several native Tag DNA polymerase preparations and the protein appears to be stable. Since such a deletion up to Ala 77 includes Gly 46, it will also affect the 5' to 3' exonuclease activity of Tag DNA polymerase. However, a deletion mutant beginning with Ala 77 has the added advantage over a deletion mutant beginning with phenylalanine 47 in that the proteolytic evidence suggests that the peptide will remain stable. Furthermore, Ala 77 is found within the sequence HEAYG (SEQ ID NO:16) 5 amino acids prior to the sequence YKA in Tag DNA polymerase. A similar sequence motif HEAYE (SEQ ID NO:17) is found in Tth DNA polymerase, TZ05 DNA polymerase and Tspsl7 DNA polymerase. The alanine is 5 amino acids prior to the conserved motif YKA. The amino acids in the other exemplary thermostable DNA polymerases which correspond to Tag Ala 77 are Tth Ala 78, TZ05 Ala 78, Tspsl7 Ala 74, Tma Leu 72 and Taf lie 73. A deletion up to the alanine or corresponding amino acid in the motif HEAY(G/E) (SEQ ID NO:16 or SEQ ID NO:17) in a Thermus species thermostable DNA polymerase containing this sequence will attenuate its 5' to 3' exonuclease activity. The 5' to 3' exonuclease motif YKA is also conserved in Tma DNA polymerase (amino acids 76-78) and Taf DNA polymerase (amino acids 77-79) . In this thermostable polymerase family, the conserved motif (L/I)LET (SEQ ID NO:18) immediately proceeds the YKA motif. Taf DNA polymerase lie 73 is 5 residues prior to this YKA motif while TMA DNA polymerase Leu 72 is 5 residues prior to the YKA motif. A deletion of the Leu or lie in the motif (L/I)LETYKA (SEQ ID NO:19) in a thermostable DNA polymerase from the Thermotoga or Thermosipho genus will also attenuate 5' to 3' exonuclease activity. Thus, a conserved amino acid sequence which defines the 5' to 3' exonuclease activity of DNA polymerases of the Thermus genus as well as those of Thermotoga and Thermosipho has been identified as (I/L/A)X 3 YKA (SEQ ID NO:20), wherein X 3 is any sequence of three amino acids. Therefore, the 5' to 3' exonuclease activity of thermostable DNA polymerases may also be altered by mutating this conserved amino acid domain. Those of skill in the art recognize that when such a deletion mutant is to be expressed in recombinant host cells, a methionine codon is usually placed at the 5' end of the coding sequence, so that the amino terminal sequence of the deletion mutant protein would be MET-ALA in the Thermus genus examples above. The preferred techniques for performing deletion mutations involve utilization of known restriction sites on the nucleotide seguence of the thermostable DNA polymerase. Following identification of the particular amino acid or amino acids which are to be deleted, a restriction site is identified which when cleaved will cause the cleavage of the target DNA seguence at a position or slightly 3' distal to the position corresponding to the amino acid or domain to be deleted, but retains domains which code for other properties of the polymerase which are desired. Alternatively, restriction sites on either side (5' or 3') of the sequence coding for the target amino acid or domain may be utilized to cleave the sequence. However, a ligation of the two desired portions of the sequence will then be necessary. This ligation may be performed using techniques which are standard in the art and exemplified in Example 9 of Serial No. 523,394, filed May 15, 1990, Example 7 of PCT Application No. 91/05753, filed August 13, 1991 and Serial No. 590,490, filed September 28, 1990, all of which are incorporated herein by reference. Another technique for achieving a deletion mutation of the thermostable DNA polymerase is by utilizing the PCR mutagenesis process. In this process, primers are prepared which incorporate a restriction site domain and optionally a methionine codon if such a codon is not already present. Thus, the product of the PCR with this primer may be digested with an appropriate restriction enzyme to remove the domain which codes for 5' to 3' exonuclease activity of the enzyme. Then, the two remaining sections of the product are ligated to form the coding seguence for a thermostable DNA polymerase lacking 5' to 3' exonuclease activity. Such coding sequences can be utilized as expression vectors in appropriate host cells to produce the desired thermostable DNA polymerase lacking 5' to 3' exonuclease activity. In addition to the Tag DNA polymerase mutants with reduced 5' to 3' exonuclease activity, it has also been found that a truncated Tma DNA polymerase with reduced 5' to 3' exonuclease activity may be produced by recombinant techniques even when the complete coding sequence of the Tma DNA polymerase gene is present in an expression vector in E. coli. Such a truncated Tma DNA polymerase is formed by translation starting with the methionine codon at position 140. Furthermore, recombinant means may be used to produce a truncated polymerase corresponding to the protein produced by initiating translation at the methionine codon at position 284 of the Tma coding seguence. The Tma DNA polymerase lacking amino acids 1 though 139 (about 86 kDa) , and the Tma DNA polymerase lacking amino acids 1 through 283 (about 70 kDa) retain polymerase activity but have attenuated 5' to 3' exonuclease activity. An additional advantage of the 70 kDa Tma DNA polymerase is that it is significantly more thermostable than native Tma polymerase. Thus, it has been found that the entire sequence of the intact Tma DNA polymerase I enzyme is not required for activity. Portions of the Tma DNA polymerase I coding seguence can be used in recombinant DNA techniques to produce a biologically active gene product with DNA polymerase activity. Furthermore, the availability of DNA encoding the Tma DNA polymerase sequence provides the opportunity to modify the coding seguence so as to generate mutein (mutant protein) forms also having DNA polymerase activity but with attenuated 5' to 3' exonuclease activity. The amino(N)-terminal portion of the Tma DNA polymerase is not necessary for polymerase activity but rather encodes the 5' to 3' exonuclease activity of the protein. Thus, using recombinant DNA methodology, one can delete approximately up to one-third of the N-terminal coding sequence of the Tma gene, clone, and express a gene product that is quite active in polymerase assays but, depending on the extent of the deletion, has no 5' to 3' exonuclease activity. Because certain N-terminal shortened forms of the polymerase are active, the gene constructs used for expression of these polymerases can include the corresponding shortened forms of the coding sequence. In addition to the N-terminal deletions, individual amino acid residues in the peptide chain of Tma DNA polymerase or other thermostable DNA polymerases may be modified by oxidation, reduction, or other derivation, and the protein may be cleaved to obtain fragments that retain polymerase activity but have attenuated 5' to 3' exonuclease activity. Modifications to the primary structure of the Tma DNA polymerase coding sequence or the coding sequences of other thermostable DNA polymerases by deletion, addition, or alteration so as to change the amino acids incorporated into the thermostable DNA polymerase during translation of the mRNA produced from that coding seguence can be made without destroying the high temperature DNA polymerase activity of the protein. Another technique for preparing thermostable DNA polymerases containing novel properties such as reduced or enhanced 5' to 3' exonuclease activity is a "domain shuffling" technique for the construction of "thermostable chimeric DNA polymerases". For example, substitution of the Tma DNA polymerase coding sequence comprising codons about 291 through about 484 for the Tag DNA polymerase I codons 289-422 would yield a novel thermostable DNA polymerase containing the 5' to 3' exonuclease domain of Tag DNA polymerase (1-289) , the 3' to 5' exonuclease domain of Tma DNA polymerase (291-484) , and the DNA polymerase domain of Tag DNA polymerase (423-832). Alternatively, the 5' to 3' exonuclease domain and the 3' to 5' exonuclease domains of Tma DNA polymerase (ca. codons 1-484) may be fused to the DNA polymerase (dNTP binding and primer/template binding domains) portions of Tag DNA polymerase (ca. codons 423-832) . As is apparent, the donors and recipients for the creation of "thermostable chimeric DNA polymerase" by "domain shuffling" need not be limited to Tag and Tma DNA polymerases. Other thermostable polymerases provide analogous domains as Tag and Tma DNA polymerases. Furthermore, the 5' to 3' exonuclease domain may derive from a thermostable DNA polymerase with altered 5' to 3' nuclease activity. For example, the 1 to 289 5' to 3' nuclease domain of Tag DNA polymerase may derive from a Gly (46) to Asp mutant form of the Tag polymerase gene. Similarly, the 5' to 3' nuclease and 3' to 5' nuclease domains of Tma DNA polymerase may encode a 5' to 3' exonuclease deficient domain, and be retrieved as a Tma Gly (37) to Asp amino acid 1 to 484 encoding DNA fragment or alternatively a truncated Met 140 to amino acid 484 encoding DNA fragment. While any of a variety of means may be used to generate chimeric DNA polymerase coding sequences (possessing novel properties) , a preferred method employs "overlap" PCR. In this method, the intended junction seguence is designed into the PCR primers (at their 5'-ends) . Following the initial amplification of the individual domains, the various products are diluted (ca. 100 to 1000-fold) and combined, denatured, annealed, extended, and then the final forward and reverse primers are added for an otherwise standard PCR. Those of skill in the art recognize that the above thermostable DNA polymerases with attenuated 5' to 3' exonuclease activity are most easily constructed by recombinant DNA technigues. When one desires to produce one of the mutant enzymes of the present invention, with attenuated 5' to 3' exonuclease activity or a derivative or homologue of those enzymes, the production of a recombinant form of the enzyme typically involves the construction of an expression vector, the transformation of a host cell with the vector, and culture of the transformed host cell under conditions such that expression will occur. To construct the expression vector, a DNA is obtained that encodes the mature (used here to include all chimeras or muteins) enzyme or a fusion of the mutant polymerase to an additional seguence that does not destroy activity or to an additional sequence cleavable under controlled conditions (such as treatment with peptidase) to give an active protein. The coding sequence is then placed in operable linkage with suitable control sequences in an expression vector. The vector can be designed to replicate autonomously in the host cell or to integrate into the chromosomal DNA of the host cell. The vector is used to transform a suitable host, and the transformed host is cultured under conditions suitable for expression of the recombinant polymerase. Each of the foregoing steps can be done in a variety of ways. For example, the desired coding sequence may be obtained from genomic fragments and used directly in appropriate hosts. The construction for expression vectors operable in a variety of hosts is made using appropriate replicons and control sequences, as set forth generally below. Construction of suitable vectors containing the desired coding and control sequences employs standard ligation and restriction technigues that are well understood in the art. Isolated plasmids, DNA sequences, or synthesized oligonucleotides are cleaved, modified, and religated in the form desired. Suitable restriction sites can, if not normally available, be added to the ends of the coding sequence so as to facilitate construction of an expression vector, as exemplified below. Site-specific DNA cleavage is performed by treating with suitable restriction enzyme (or enzymes) under conditions that are generally understood in the art and specified by the manufacturers of commercially available restriction enzymes. See, e.g., New England Biolabs, Product Catalog. In general, about 1 μg of plasmid or other DNA is cleaved by one unit of enzyme ir about 20 μl of buffer solution; in the examples below, an excess of restriction enzyme is generally used to ensure complete digestion of the DNA. Incubation times of about one to two hours at about 37"C are typical, although variations can be tolerated. After each incubation, protein is removed by extraction with phenol and chloroform; this extraction can be followed by ether extraction and recovery of the DNA from aqueous fractions by precipitation with ethanol. If desired, size separation of the cleaved fragments may be performed by polyacrylamide gel or agarose gel electrophoresis using standard techniques. See, e.g.. Methods in Enzymology. 1980, 65:499-560. Restriction-cleaved fragments with single-strand "overhanging" termini can be made blunt-ended (double-strand ends) by treating with the large fragment of E. coli DNA polymerase I (Klenow) in the presence of the four deoxynucleoside triphosphates (dNTPs) using incubation times of about 15 to 25 minutes at 20°C to 25°C in 50 mM Tris-Cl pH 7.6, 50 mM NaCl, 10 mM MgCl 2 , 10 mM DTT, and 5 to 10 μM dNTPs. The Klenow fragment fills in at 5' protruding ends, but chews back protruding 3' single strands, even though the four dNTPs are present. If desired, selective repair can be performed by supplying only one of the, or selected, dNTPs within the limitations dictated by the nature of the protruding ends. After treatment with Klenow, the mixture is extracted with phenol/chloroform and ethanol precipitated. Similar results can be achieved using El nuclease, because treatment under appropriate conditions with Si nuclease results in hydrolysis of any single-stranded portion of a nucleic acid. Synthetic oligonucleotides can be prepared using the triester method of Matteucci et al. , 1981, J. Am. Chem. Soc. 103:3185-3191, or automated synthesis methods. Kinasing of single strands prior to annealing or for labeling is achieved using an excess, e.g., approximately 10 units, of polynucleotide kinase to 0.5 μM substrate in the presence of 50 mM Tris, pH 7.6, 10 mM MgCl 2 , 5 mM dithiothreitol (DTT), and 1 to 2 μM ATP. If kinasing is for labeling of probe, the ATP will contain high specific activity γ- 32 P. Ligations are performed in 15-30 μl volumes under the following standard conditions and temperatures: 20 mM Tris-Cl, pH 7.5, 10 mM MgCl 2 , 10 mM DTT, 33 μg/ml BSA, 10 mM-50 mM NaCl, and either 40 μM ATP and 0.01-0.02 (Weiss) units T4 DNA ligase at 0°C (for ligation of fragments with complementary single-stranded ends) or 1 mM ATP and 0.3-0.6 units T4 DNA ligase at 14°C (for "blunt end" ligation). Intermolecular ligations of fragments with complementary ends are usually performed at 33-100 μg/ml total DNA concentrations (5 to 100 nM total ends concentration) . Intermolecular blunt end ligations (usually employing a 20 to 30 fold molar excess of linkers, optionally) are performed at 1 μM total ends concentration. In vector construction, the vector fragment is commonly treated with bacterial or calf intestinal alkaline phosphatase (BAP or CIAP) to remove the 5' phosphate and prevent religation and reconstruction of the vector. BAP and CIAP digestion conditions are well known in the art, and published protocols usually accompany the commercially available BAP and CIAP enzymes. To recover the nucleic acid fragments, the preparation is extracted with phenol-chloroform and ethanol precipitated to remove the phosphatase and purify the DNA. Alternatively, religation of unwanted vector fragments can be prevented by restriction enzyme digestion before or after ligation, if appropriate restriction sites are available. For portions of vectors or coding sequences that require sequence modifications, a variety of site-specific primer-directed mutagenesis methods are available. The polymerase chain reaction (PCR) can be used to perform site-specific mutagenesis. In another technique now standard in the art, a synthetic oligonucleotide encoding the desired mutation is used as a primer to direct synthesis of a complementary nucleic acid sequence of a single-stranded vector, such as pBS13+, that serves as a template for construction of the extension product of the mutagenizing primer. The mutagenized DNA is transformed into a host bacterium, and cultures of the transformed bacteria are plated and identified. The identification of modified vectors may involve transfer of the DNA of selected transformants to a nitrocellulose filter or other membrane and the "lifts" hybridized with kinased synthetic primer at a temperature that permits hybridization of an exact match to the modified sequence but prevents hybridization with the original strand. Transformants that contain DNA that hybridizes with the probe are then cultured and serve as a reservoir of the modified DNA. In the constructions set forth below, correct ligations for plasmid construction are confirmed by first transforming E. coli strain DG101 or another suitable host with the ligation mixture. Successful transformants are selected by ampicillin, tetracycline or other antibiotic resistance or sensitivity or by using other markers, depending on the mode of plasmid construction, as is understood in the art. Plasmids from the transformants are then prepared according to the method of Clewell et al. , 1969, Proc. Natl. Acad. Sci. USA 62 . :1159, optionally following chloramphenicol amplification (Clewell, 1972, J. Bacteriol. 110:667.. Another method for obtaining plasmid DNA is described as the "Base-Acid" extraction method at page 11 of the Bethesda Research Laboratories publication Focus. volume 5, number 2, and very pure plasmid DNA can be obtained by replacing steps 12 through 17 of the protocol with CsCl/ethidium bromide ultracentrifugation of the DNA. The isolated DNA is analyzed by restriction enzyme digestion and/or sequenced by the dideoxy method of Sanger et al.. , 1977, Proc. Natl. Acad. Sci. USA 74.:5463, as further described by Messing et al. , 1981, Nuc. Acids Res. 9_:309, or by the method of Maxam et al. , 1980, Methods in Enzymology 65:499. The control sequences, expression vectors, and transformation methods are dependent on the type of host cell used to express the gene. Generally, procaryotic, yeast, insect, or mammalian cells are used as hosts. Procaryotic hosts are in general the most efficient and convenient for the production of recombinant proteins and are therefore preferred for the expression of the thermostable DNA polymerases of the present invention. The procaryote most frequently used to express recombinant proteins is E. coli. For cloning and sequencing, and for expression of constructions under control of most bacterial promoters, E. coli K12 strain MM294, obtained from the E. coli Genetic Stock Center under GCSC #6135, can be used as the host. For expression vectors with the PJNRBS control sequence, E. coli K12 strain MC1000 lambda lysogen, N 7 N 53 Cl g57 SusP 80 , ATCC 39531, may be used. E. coli DG116, which was deposited with the ATCC (ATCC 53606) on April 7, 1987, and E. coli KB2, which was deposited with the ATCC (ATCC 53075) on March 29, 1985, are also useful host cells. For M13 phage recombinants, E. coli strains susceptible to phage infection, such as E. coli K12 strain DG98, are employed. The DG98 strain was deposited with the ATCC (ATCC 39768) on July 13, 1984. However, microbial strains other than E. coli can also be used, such as bacilli, for example Bacillus subtilis, various species of Pseudomonas, and other bacterial strains, for recombinant expression of the thermostable DNA polymerases of the present invention. In such procaryotic systems, plasmid vectors that contain replication sites and control sequences derived from the host or a species compatible with the host are typically used. For example, E. coli is typically transformed using derivatives of pBR322, described by Bolivar et al.. 1977, Gene :95. Plasmid pBR322 contains genes for ampicillin and tetracycline resistance. These drug resistance markers can be either retained or destroyed in constructing the desired vector and so help to detect the presence of a desired recombinant. Commonly used procaryotic control sequences, i.e., a promoter for transcription initiation, optionally with an operator, along with a ribosome binding site seguence, include the β-lactamase (penicillinase) and lactose (lac) promoter systems (Chang et al. , 1977, Nature 198:1056) , the tryptophan (trp) promoter system (Goeddel et al. , 1980, Nuc. Acids Res. 8.:4057), and the lambda-derived P L promoter (Shimatake et al. , 1981, Nature 292:128) and N-gene ribosome binding site (N RBS ) . A portable control system cassette is set forth in United States Patent No. 4,711,845, issued December 8, 1987. This cassette comprises a P L promoter operably linked to the N R3S in turn positioned upstream of a third DNA seguence having at least one restriction site that permits cleavage within six bp 3' of the N RBS sequence. Also useful is the phosphatase A (phoA) system described by Chang et al. in European Patent Publication No. 196,864, published October 8, 1986. However, any available promoter system compatible with procaryotes can be used to construct a modified thermostable DNA polymerase expression vector of the invention. In addition to bacteria, eucaryotic microbes, such as yeast, can also be used as recombinant host cells. Laboratory strains of Saccharomyces cerevisiae. Baker's yeast, are most often used, although a number of other strains are commonly available. While vectors employing the two micron origin of replication are common (Broach, 1983, Meth. Enz. 101:307) , other plasmid vectors suitable for yeast expression are known (see, for example, Stinchcomb et al. , 1979, Nature 282:39; Tschempe et al. , 1980, Gene .10:157; and Clarke et a_l. , 1983, Meth. Enz. 101:300) . Control seguences for yeast vectors include promoters for the synthesis of glycolytic enzymes (Hess et al. , 1968, J. Adv. Enzyme Reg. :149; Holland et al. , 1978, Biotechnology 12:4900; and Holland et al. , 1981, J. Biol. Chem. 256:1385, . Additional promoters known in the art include the promoter for 3-phosphoglycerate kinase (Hitzeman et al. , 1980, J. Biol. Chem. 255:2073) and those for other glycolytic enzymes, such as glyceraldehyde 3-phosphate dehydrogenase, hexokinase, pyruvate decarboxylase, phosphofructokinase, glucose-6- phosphate isomerase, 3-phosphoglycerate mutase, pyruvate kinase, triosephosphate isomerase, phosphoglucose isomerase, and glucokinase. Other promoters that have the additional advantage of transcription controlled by growth conditions are the promoter regions for alcohol dehydrogenase 2, isocytochrome C, acid phosphatase, degradative enzymes associated with nitrogen metabolism, and enzymes responsible for maltose and galactose utilization (Holland, supra.. Terminator seguences may also be used to enhance expression when placed at the 3' end of the coding seguence. Such terminators are found in the 3' untranslated region following the coding sequences in yeast-derived genes. Any vector containing a yeast-compatible promoter, origin of replication, and other control sequences is suitable for use in constructing yeast expression vectors for the thermostable DNA polymerases of the present invention. The nucleotide sequences which code for the thermostable DNA polymerases of the present invention can also be expressed in eucaryotic host cell cultures derived from multicellular organisms. See, for example, Tissue Culture, Academic Press, Cruz and Patterson, editors (1973) . Useful host cell lines include COS-7, COS-A2, CV-l, murine cells such as murine myelomas N51 and VERO, HeLa cells, and Chinese hamster ovary (CHO) cells. Expression vectors for such cells ordinarily include promoters and control sequences compatible with mammalian cells such as, for example, the commonly used early and late promoters from Simian Virus 40 (SV 40) (Fiers et al. , 1978, Nature 273:113) . or other viral promoters such as those derived from polyoma, adenovirus 2, bovine papilloma virus (BPV) , or avian sarcoma viruses, or immunoglobulin promoters and heat shock promoters. A system for expressing DNA in mammalian systems using a BPV vector system is disclosed in U.S. Patent No. 4,419,446. A modification of this system is described in U.S. Patent No. 4,601,978. General aspects of mammalian cell host system transformations have been described by Axel, U.S. Patent No. 4,399,216. "Enhancer" regions are also important in optimizing expression; these are, generally, sequences found upstream of the promoter region. Origins of replication may be obtained, if needed, from viral sources. However, integration into the chromosome is a common mechanism for DNA replication in eucaryotes. Plant cells can also be used as hosts, and control sequences compatible with plant cells, such as the nopaline synthase promoter and polyadenylation signal sequences (Depicker et a_l. , 1982, J. Mol. Appl. Gen. l.:561) are available. Expression systems employing insect cells utilizing the control systems provided by baculovirus vectors have also been described (Miller et al. , 1986, Genetic Engineering (Setlow et al. , eds. , Plenum Publishing) 8.:277-297) . Insect cell-based expression can be accomplished in Spodoptera frugipeida. These systems can also be used to produce recombinant thermostable polymerases of the present invention. Depending on the host cell used, transformation is done using standard technigues appropriate to such cells. The calcium treatment employing calcium chloride, as described by Cohen, 1972, Proc. Natl. Acad. Sci. USA (59.:2110 is used for procaryotes or other cells that contain substantial cell wall barriers. Infection with Agrobacterium tumefaciens (Shaw et <l. , 1983, Gene 23.:315) is used for certain plant cells. For mammalian cells, the calcium phosphate precipitation method of Graham and van der Eb, 1978, Virology j52.:546 is preferred. Transformations into yeast are carried out according to the method of Van Solingen et _al. , 1977, J. Bact. 130:946 and Hsiao et al.. 1979, Proc. Natl. Acad. Sci. USA 76:3829. Once the desired thermostable DNA polymerase with altered 5' to 3' exonuclease activity has been expressed in a recombinant host cell, purification of the protein may be desired. Although a variety of purification procedures can be used to purify the recombinant thermostable polymerases of the invention, fewer steps may be necessary to yield an enzyme preparation of egual purity. Because E. coli host proteins are heat-sensitive, the recombinant thermostable DNA polymerases of the invention can be substantially enriched by heat inactivating the crude lysate. This step is done in the presence of a sufficient amount of salt (typically 0.2-0.3 M ammonium sulfate) to ensure dissociation of the thermostable DNA polymerase from the host DNA and to reduce ionic interactions of thermostable DNA polymerase with other cell lysate proteins. In addition, the presence of 0.3 M ammonium sulfate promotes hydrophobic interaction with a phenyl sepharose column. Hydrophobic interaction chromatography is a separation technique in which substances are separated on the basis of differing strengths of hydrophobic interaction with an uncharged bed material containing hydrophobic groups. Typically, the column is first equilibrated under conditions favorable to hydrophobic binding, such as high ionic strength. A descending salt gradient may then be used to elute the sample. According to the invention, an agueous mixture (containing the recombinant thermostable DNA polymerase with altered 5' to 3' exonuclease activity) is loaded onto a column containing a relatively strong hydrophobic gel such as phenyl sepharose (manufactured by Pharmacia) or Phenyl TSK (manufactured by Toyo Soda) . To promote hydrophobic interaction with a phenyl sepharose column, a solvent is used that contains, for example, greater than or egual to 0.3 M ammonium sulfate, with 0.3 M being preferred, or greater than or egual to 0.5 M KaCl. The column and the sample are adjusted to 0.3 M ammonium sulfate in 50 mM Tris (pH 7.5) and 1.0 mM EDTA ("TE") buffer that also contains 0.5 mM DTT, and the sample is applied to the column. The column is washed with the 0.3 M ammonium sulfate buffer. The enzyme may then be eluted with solvents that attenuate hydrophobic interactions, such as decreasing salt gradients, ethylene or propylene glycol, or urea. For long-term stability, the thermostable DNA polymerase enzymes of the present invention can be stored in a buffer that contains one or more non-ionic polymeric detergents. Such detergents are generally those that have a molecular weight in the range of approximately 100 to 250,000 daltons, preferably about 4,000 to 200,000 daltons, and stabilize the enzyme at a pH of from about 3.5 to about 9.5, preferably from about 4 to 8.5. Examples of such detergents include those specified on pages 295-298 of McCutcheon's E ulsifiers & Detergents. North American edition (1983) , published by the McCutcheon Division of MC Publishing Co., 175 Rock Road, Glen Rock, NJ (USA) and copending Serial No. 387,003, filed July 28, 1989, each of which is incorporated herein by reference. Preferably, the detergents are selected from the group comprising ethoxylated fatty alcohol ethers and lauryl ethers, ethoxylated alkyl phenols, octylphenoxy polyethoxy ethanol compounds, modified oxyethylated and/or oxypropylated straight-chain alcohols, polyethylene glycol monooleate compounds, polysorbate compounds, and phenolic fatty alcohol ethers. More particularly preferred are Tween 20, a polyoxyethylated (20) sorbitan monolaurate from ICI Americas Inc. , Wilmington, DE, and Iconol NP-40, an ethoxylated alkyl phenol (nonyl) from BASF Wyandotte Corp., Parsippany, NJ. The thermostable enzymes of this invention may be used for any purpose in which such enzyme activity is ecessary or desired. DNA seguencing by the Sanger dideoxynucleotide method (Sanger et al. , 1977, Proc. Natl. Acad. Sci. USA 24.5463-5467) has undergone significant refinement in recent years, including the development of novel vectors (Yanisch-Perron et al. , 1985, Gene 3.3:103-119), base analogs (Mills et al. , 1979, Proc. Natl. Acad. Sci. USA 26:2232-2235, and Barr et al. , 1986, BioTechniques 4 . :428-432) , enzymes (Tabor et al. , 1987, Proc. Natl. Acad. Sci. USA 84..4763-4771, and Innis, M.A. et |il. , 1988, Proc. Natl. Acad. Sci. USA iL5:9436:9440) , and instruments for partial automation of DNA sequence analysis (Smith et al. , 1986, Nature 3_2_1:674-679; Prober et al. , 1987, Science 238:336-341; and Ansorge et al. , 1987, Nuc. Acids Res. 15:4593-4602). The basic dideoxy sequencing procedure involves (i) annealing an oligonucleotide primer to a suitable single or denatured double stranded DNA template; (ii) extending the primer with DNA polymerase in four separate reactions, each containing one α-labeled dNTP or ddNTP (alternatively, a labeled primer can be used) , a mixture of unlabeled dNTPs, and one chain-terminating dideoxynucleotide-5'-triphosphate (ddNTP) ; (iii) resolving the four sets of reaction products on a high-resolution polyacrylamide-urea gel; and (iv) producing an autoradiographic image of the gel that can be examined to infer the DNA seguence. Alternatively, fluorescently labeled primers or nucleotides can be used to identify the reaction products. Known dideoxy seguencing methods utilize a DNA polymerase such as the Klenow fragment of J _. coli DNA polymerase I, reverse transcriptase, Tag DNA polymerase, or a modified T7 DNA polymerase. The introduction of commercial kits has vastly simplified the art, making DNA sequencing a routine technique for any laboratory. However, there is still a need in the art for sequencing protocols that work well with nucleic acids that contain secondary structure such as palindromic hairpin loops and with G+C-rich DNA. Single stranded DNAs can form secondary structure, such as a hairpin loop, that can seriously interfere with a dideoxy sequencing protocol, both through improper termination in the extension reaction, or in the case of an enzyme with 5' to 3' exonuclease activity, cleavage of the template strand at the juncture of the hairpin. Since high temperature destabilizes secondary structure, the ability to conduct the extension reaction at a high temperature, i.e., 70-75°C, with a thermostable DNA polymerase results in a significant improvement in the sequencing of DNA that contains such secondary structure. However, temperatures compatible with polymerase extension do not eliminate all secondary structure. A 5' to 3' exonuclease-deficient thermostable DNA polymerase would be a further improvement in the art, since the polymerase could synthesize through the hairpin in a strand displacement reaction, rather than cleaving the template, resulting in an improper termination, i.e., an extension run-off fragment. As an alternative to basic dideoxy sequencing, cycle dideoxy seguencing is a linear, asymmetric amplification of target seguences in the presence of dideoxy chain terminators. A single cycle produces a family of extension products of all possible lengths. Following denaturation of the extension reaction product from the DNA template, multiple cycles of primer annealing and primer extension occur in the presence of dideoxy terminators. The process is distinct from PCR in that only one primer is used, the growth of the seguencing reaction products in each cycle is linear, and the amplification products are heterogeneous in length and do not serve as template for the next reaction. Cycle dideoxy seguencing is a technique providing advantages for laboratories using automated DNA seguencing instruments and for other high volume seguencing laboratories. It is possible to directly sequence genomic DNA, without cloning, due to the specificity of the technigue and the increased amount of signal generated. Cycle seguencing protocols accommodate single and double stranded templates, including genomic, cloned, and PCR-amplified templates. Thermostable DNA polymerases have several advantages in cycle seguencing: they tolerate the stringent annealing temperatures which are reguired for specific hybridization of primer to genomic targets as well as tolerating the multiple cycles of high temperature denaturation which occur in each cycle. Performing the extension reaction at high temperatures, i.e., 70-75 β C, results in a significant improvement in seguencing results with DNA that contains secondary structure, due to the destabilization of secondary structure. However, such temperatures will not eliminate all secondary structure. A 5' to 3' exonuclease-deficient thermostable DNA polymerase would be a further improvement in the art, since the polymerase could synthesize through the hairpin in a strand displacement reaction, rather than cleaving the template and creating an improper termination. Additionally, like PCR, cycle seguencing suffers from the phenomenon of product strand renaturation. In the case of a thermostable DNA polymerase possessing 5' to 3' exonuclease activity, extension of a primer into a double stranded region created by product strand renaturation will result in cleavage of the renatured complementary product strand. The cleaved strand will be shorter and thus appear as an improper termination. In addition, the correct, previously synthesized termination signal will be attenuated. A thermostable DNA polymerase deficient in 5'' to 3' exonuclease activity will improve the art, in that such extension product fragments will not be formed. A variation of cycle seguencing, involves the simultaneous generation of seguencing ladders for each strand of a double stranded template while sustaining some degree of amplification (Ruano and Kidd, Proc. Natl. Acad. Sci. USA. 1991 8_8. 815-2819) . This method of coupled amplification and seguencing would benefit in a similar fashion as stranded cycle sequencing from the use of a thermostable DNA polymerase deficient in 5' to 3' exonuclease activity. In a particularly preferred embodiment, the enzymes in which the 5' to 3' exonuclease activity has been reduced or eliminated catalyze the nucleic acid amplification reaction known as PCR, and as stated above, with the resultant effect of producing a better yield of desired product than is achieved with the respective native enzymes which have greater amounts of the 5' to 3' exonuclease activity. Improved yields are the result of the inability to degrade previously synthesized product caused by 5' to 3' exonuclease activity. This process for amplifying nucleic acid seguences is disclosed and claimed in U.S. Patent Nos. 4,683,202 and 4,865,188, each of which is incorporated herein by reference. The PCR nucleic acid amplification method involves amplifying at least one specific nucleic acid seguence contained in a nucleic acid or a mixture of nucleic acids and in the most common embodiment, produces double-stranded DNA. Aside from improved yields, thermostable DNA polymerases with attenuated 5' to 3' exonuclease activity exhibit an improved ability to generate longer PCR products, an improved ability to produce products from G+C-rich templates and an improved ability to generate PCR products and DNA sequencing ladders from templates with a high degree of secondary structure. For ease of discussion, the protocol set forth below assumes that the specific seguence to be amplified is contained in a double-stranded nucleic acid. However, the process is equally useful in amplifying single-stranded nucleic acid, such as mRNA, although in the preferred embodiment the ultimate product is still double-stranded DNA. In the amplification of a single-stranded nucleic acid, the first step involves the synthesis of a complementary strand (one of the two amplification primers can be used for this purpose) , and the succeeding steps proceed as in the double-stranded amplification process described below. This amplification process comprises the steps of: (a) contacting each nucleic acid strand with four different nucleoside triphosphates and two oligonucleotide primers for each specific seguence being amplified, wherein each primer is selected to be substantially complementary to the different strands of the specific sequence, such that the extension product synthesized from one primer, when separated from its complement, can serve as a template for synthesis of the extension product of the other primer, said contacting being at a temperature that allows hybridization of each primer to a complementary nucleic acid strand; (b) contacting each nucleic acid strand, at the same time as or after step (a) , with a thermostable DNA polymerase of the present invention that enables combination of the nucleoside triphosphates to form primer extension products complementary to each strand of the specific nucleic acid sequence; (c) maintaining the mixture from step (b) at an effective temperature for an effective time to promote the activity of the enzyme and to synthesize, for each different seguence being amplified, an extension product of each primer that is complementary to each nucleic acid strand template, but not so high as to separate each extension product from the complementary strand template; (d) heating the mixture from step (c) for an effective time and at an effective temperature to separate the primer extension products from the templates on which they were synthesized to produce single-stranded molecules but not so high as to denature irreversibly the enzyme; (e) cooling the mixture from step (d) for an effective time and to an effective temperature to promote hybridization of a primer to each of the single-stranded molecules produced in step (d) ; and (f) maintaining the mixture from step (e) at an effective temperature for an effective time to promote the activity of the enzyme and to synthesize, for each different sequence being amplified, an extension product of each primer that is complementary to each nucleic acid template produced in step (d) but not so high as to separate each extension product from the complementary strand template. The effective times and temperatures in steps (e) and (f) may coincide, so that steps (e) and (f) can be carried out simultaneously. Steps (d)-(f) are repeated until the desired level of amplification is obtained. The amplification method is useful not only for producing large amounts of a specific nucleic acid sequence of known sequence but also for producing nucleic acid sequences that are known to exist but are not completely specified. One need know only a sufficient number of bases at both ends of the sequence in sufficient detail so that two oligonucleotide primers can be prepared that will hybridize to different strands of the desired seguence at relative positions along the sequence such that an extension product synthesized from one primer, when separated from the template (complement) , can serve as a template for extension of the other primer into a nucleic acid sequence of defined length. The greater the knowledge about the bases at both ends of the sequence, the greater can be the specificity of the primers for the target nucleic acid seguence and the efficiency of the process and specificity of the reaction. In any case, an initial copy of the sequence to be amplified must be available, although the seguence need not be pure or a discrete molecule. In general, the amplification process involves a chain reaction for producing, in exponential quantities relative to the number of reaction steps involved, at least one specific nucleic acid sequence given that (a) the ends of the required sequence are known in sufficient detail that oligonucleotides can be synthesized that will hybridize to them and (b) that a small amount of the seguence is available to initiate the chain reaction. The product of the chain reaction will be a discrete nucleic acid duplex with termini corresponding to the 5' ends of the specific primers employed. Any nucleic acid seguence, in purified or nonpurified form, can be utilized as the starting nucleic acid(s) , provided it contains or is suspected to contain the specific nucleic acid seguence one desires to amplify. The nucleic acid to be amplified can be obtained from any source, for example, from plasmids such as pBR322, from cloned DNA or RNA, or from natural DNA or RNA from any source, including bacteria, yeast, viruses, organelles, and higher organisms such as plants and animals. DNA or RNA may be extracted from blood, tissue material such as chorionic villi, or amniotic cells by a variety of techniques. See, e.g., Maniatis et al. , 1982, Molecular Cloning: A Laboratory Manual (Cold Spring Harbor Laboratory, Cold Spring Harbor, NY) pp. 280-281. Thus, the process may employ, for example, DNA or RNA, including messenger RNA, which DNA or RNA may be single-stranded or double-stranded. In addition, a DNA-RNA hybrid that contains one strand of each may be utilized. A mixture of any of these nucleic acids can also be employed as can nucleic acids produced from a previous amplification reaction (using the same or different primers) . The specific nucleic acid sequence to be amplified can be only a fraction of a large molecule or can be present initially as a discrete molecule, so that the specific sequence constitutes the entire nucleic acid. The sequence to be amplified need not be present initially in a pure form; the sequence can be a minor fraction of a complex mixture, such as a portion of the β-globin gene contained in whole human DNA (as exemplified in Saiki et al. , 1985, Science 230:1530-1534) or a portion of a nucleic acid sequence due to a particular microorganism, which organism might constitute only a very minor fraction of a particular biological sample. The cells can be directly used in the amplification process after suspension in hypotonic buffer and heat treatment at about 90°C-100°C until cell lysis and dispersion of intracellular components occur (generally 1 to 15 minutes) . After the heating step, the amplification reagents may be added directly to the lysed cells. The starting nucleic acid sequence can contain more than one desired specific nucleic acid seguence. The amplification process is useful not only for producing large amounts of one specific nucleic acid sequence but also for amplifying simultaneously more than one different specific nucleic acid seguence located on the same or different nucleic acid molecules. Primers play a key role in the PCR process. The word "primer" as used in describing the amplification process can refer to more than one primer, particularly in the case where there is some ambiguity in the information regarding the terminal seguence(s) of the fragment to be amplified or where one employs the degenerate primer process described in PCT Application No. 91/05753, filed August 13, 1991. For instance, in the case where a nucleic acid sequence is inferred from protein sequence information, a collection of primers containing sequences representing all possible codon variations based on degeneracy of the genetic code can be used for each strand. One primer from this collection will be sufficiently homologous with a portion of the desired sequence to be amplified so as to be useful for amplification. In addition, more than one specific nucleic acid sequence can be amplified from the first nucleic acid or mixture of nucleic acids, so long as the appropriate number of different oligonucleotide primers are utilized. For example, if two different specific nucleic acid seguences are to be produced, four primers are utilized. Two of the primers are specific for one of the specific nucleic acid seguences, and the other two primers are specific for the second specific nucleic acid seguence. In this manner, each of the two different specific seguences can be produced exponentially by the present process. A sequence within a given sequence can be amplified after a given number of amplification cycles to obtain greater specificity in the reaction by adding, after at least one cycle of amplification, a set of primers that are complementary to internal seguences (i.e., seguences that are not on the ends) of the sequence to be amplified. Such primers can be added at any stage and will provide a shorter amplified fragment. Alternatively, a longer fragment can be prepared by using primers with non-complementary ends but having some overlap with the primers previously utilized in the amplification. Primers also play a key role when the amplification process is used for jLn vitro mutagenesis. The product of an amplification reaction where the primers employed are not exactly complementary to the original template will contain the sequence of the primer rather than the template, so introducing an .in vitro mutation. In further cycles, this mutation will be amplified with an undiminished efficiency because no further mispaired priming is required. The process of making an altered DNA sequence as described above could be repeated on the altered DNA using different primers to induce further sequence changes. In this way, a series of mutated sequences can gradually be produced wherein each new addition to the series differs from the last in a minor way, but from the original DNA source seguence in an increasingly major way. Because the primer can contain as part of its seguence a non-complementary seguence, provided that a sufficient amount of the primer contains a seguence that is complementary to the strand to be amplified, many other advantages can be realized. For example, a nucleotide sequence that is not complementary to the template sequence (such as, e.g., a promoter, linker, coding sequence, etc.) may be attached at the 5' end of one or both of the primers and so appended to the product of the amplification process. After the extension primer is added, sufficient cycles are run to achieve the desired amount of new template containing the non-complementary nucleotide insert. This allows production of large guantities of the combined fragments in a relatively short period of time (e.g., two hours or less) using a simple technigue. Oligonucleotide primers can be prepared using any suitable method, such as, for example, the phosphotriester and phosphodiester methods described above, or automated embodiments thereof. In one such automated embodiment, diethylphosphoramidites are used as starting materials and can be synthesized as described by Beaucage et al. , 1981, Tetrahedron Letters 21:1859-1862. One method for synthesizing oligonucleotides on a modified solid support is described in U.S. Patent No. 4,458,066. One can also use a primer that has been isolated from a biological source (such as a restriction endonuclease digest) . No matter what primers are used, however, the reaction mixture must contain a template for PCR to occur, because the specific nucleic acid sequence is produced by using a nucleic acid containing that sequence as a template. The first step involves contacting each nucleic acid strand with four different nucleoside triphosphates and two oligonucleotide primers for each specific nucleic acid sequence being amplified or detected. If the nucleic acids to be amplified or detected are DNA, then the nucleoside triphosphates are usually dATP, dCTP, dGTP, and dTTP, although various nucleotide derivatives can also be used in the process. For example, when using PCR for the detection of a known sequence in a sample of unknown sequences, dTTP is often replaced by dUTP in order to reduce contamination between samples as taught in PCT Application No. 91/05210 filed July 23, 1991, incorporated herein by reference. The concentration of nucleoside triphosphates can vary widely. Typically, the concentration is 50 to 200 μM in each dNTP in the buffer for amplification, and MgCl 2 is present in the buffer in an amount of 1 to 3 mM to activate the polymerase and increase the specificity of the reaction. However, dNTP concentrations of 1 to 20 μM may be preferred for some applications, such as DNA seguencing or generating radiolabeled probes at high specific activity. The nucleic acid strands of the target nucleic acid serve as templates for the synthesis of additional nucleic acid strands, which are extension products of the primers. This synthesis can be performed using any suitable method, but generally occurs in a buffered aqueous solution, preferably at a pH of 7 to 9, most preferably about 8. To facilitate synthesis, a molar excess of the two oligonucleotide primers is added to the buffer containing the template strands. As a practical matter, the amount of primer added will generally be in molar excess over the amount of complementary strand (template) when the sequence to be amplified is contained in a mixture of complicated long-chain nucleic acid strands. A large molar excess is preferred to improve the efficiency of the process. Accordingly, primer:template ratios of at least 1000:1 or higher are generally employed for cloned DNA templates, and primer: template ratios of about 10 8 :1 or higher are generally employed for amplification from complex genomic samples. The mixture of template, primers, and nucleoside triphosphates is then treated according to whether the nucleic acids being amplified or detected are double- or single-stranded. If the nucleic acids are single-stranded, then no denaturation step need be employed prior to the first extension cycle, and the reaction mixture is held at a temperature that promotes hybridization of the primer to its complementary target (template) seguence. Such temperature is generally from about 35°C to 65°C or more, preferably about 37°C to 60°C for an effective time, generally from a few seconds to five minutes, preferably from 30 seconds to one minute. A hybridization temperature of 35°C to 70°C may be used for 5' to 3' exonuclease mutant thermostable DNA polymerases. Primers that are 15 nucleotides or longer in length are used to increase the specificity of primer hybridization. Shorter primers require lower hybridization temperatures. The complement to the original single-stranded nucleic acids can be synthesized by adding the thermostable DNA polymerase of the present invention in the presence of the appropriate buffer, dNTPs, and one or more oligonucleotide primers. If an appropriate single primer is added, the primer extension product will be complementary to the single-stranded nucleic acid and will be hybridized with the nucleic acid strand in a duplex of strands of equal or unequal length (depending on where the primer hybridizes to the template) , which may then be separated into single strands as described above to produce two single, separated, complementary strands. A second primer would then be added so that subseguent cycles of primer extension would occur using both the original single-stranded nucleic acid and the extension product of the first primer as templates. Alternatively, two or more appropriate primers (one of which will prime synthesis using the extension product of the other primer as a template) can be added to the single-stranded nucleic acid and the reaction carried out. If the nucleic acid contains two strands, as in the case of amplification of a double-stranded target or second-cycle amplification of a single-stranded target, the strands of nucleic acid must be separated before the primers are hybridized. This strand separation can be accomplished by any suitable denaturing method, including physical, chemical or enzymatic means. One preferred physical method of separating the strands of the nucleic acid involves heating the nucleic acid until complete (>99%) denaturation occurs. Typical heat denaturation involves temperatures ranging from about 80°C to 105°C for times generally ranging from about a few seconds to minutes, depending on the composition and size of the nucleic acid. Preferably, the effective denaturing temperature is 90°C-100°C for a few seconds to 1 minute. Strand separation may also be induced by an enzyme from the class of enzymes known as helicases or the enzyme RecA, which has helicase activity and in the presence of ATP is known to denature DNA. The reaction conditions suitable for separating the strands of nucleic acids with helicases are described by Kuhn Hoff ann-Berling, 1978, CSH-Ouantitative Biology 4.3:63, and techniques for using RecA are reviewed in Radding, 1982, Ann. Rev. Genetics .1(5:405-437. The denaturation produces two separated complementary strands of equal or unequal length. If the double-stranded nucleic acid is denatured by heat, the reaction mixture is allowed to cool to a temperature that promotes hybridization of each primer to the complementary target (template) sequence. This temperature is usually from about 35°C to 65°C or more, depending on reagents, preferably 37"C to 60°C. The hybridization temperature is maintained for an effective time, generally a few seconds to minutes, and preferably 10 seconds to 1 minute. In practical terms, the temperature is simply lowered from about 95°C to as low as 37°C, and hybridization occurs at a temperature within this range. Whether the nucleic acid is single- or double-stranded, the thermostable DNA polymerase of the present invention can be added prior to or during the denaturation step or when the temperature is being reduced to or is in the range for promoting hybridization. Although the thermostability of the polymerases of the invention allows one to add such polymerases to the reaction mixture at any time, one can substantially inhibit non-specific amplification by adding the polymerase to the reaction mixture at a point in time when the mixture will not be cooled below the stringent hybridization temperature. After hybridization, the reaction mixture is then heated to or maintained at a temperature at which the activity of the enzyme is promoted or optimized, i.e., a temperature sufficient to increase the activity of the enzyme in facilitating synthesis of the primer extension products from the hybridized primer and template. The temperature must actually be sufficient to synthesize an extension product of each primer that is complementary to each nucleic acid template, but must not be so high as to denature each extension product from its complementary template (i.e., the temperature is generally less than about 80°C to 90°C) . Depending on the nucleic acid(s) employed, the typical temperature effective for this synthesis reaction generally ranges from about 40"C to 80°C, preferably 50°C to 75 °C. The temperature more preferably ranges from about 65"C to 75"C for the thermostable DNA polymerases of the present invention. The period of time reguired for this synthesis may range from about 10 seconds to several minutes or more, depending mainly on the temperature, the length of the nucleic acid, the enzyme, and the complexity of the nucleic acid mixture. The extension time is usually about 30 seconds to a few minutes. If the nucleic acid is longer, a longer time period is generally reguired for complementary strand synthesis. The newly synthesized strand and the complement nucleic acid strand form a double-stranded molecule that is used in the succeeding steps of the amplification process. In the next step, the strands of the double-stranded molecule are separated by heat denaturation at a temperature and for a time effective to denature the molecule, but not at a temperature and for a period so long that the thermostable enzyme is completely and irreversibly denatured or inactivated. After this denaturation of template, the temperature is decreased to a level that promotes hybridization of the primer to the complementary single-stranded molecule (template) produced from the previous step, as described above. After this hybridization step, or concurrently with the hybridization step, the temperature is adjusted to a temperature that is effective to promote the activity of the thermostable enzyme to enable synthesis of a primer extension product using as a template both the newly synthesized and the original strands. The temperature again must not be so high as to separate (denature) the extension product from its template, as described above. Hybridization may occur during this step, so that the previous step of cooling after denaturation is not required. In such a case, using simultaneous steps, the preferred temperature range is 50°C to 70°C. The heating and cooling steps involved in one cycle of strand separation, hybridization, and extension product synthesis can be repeated as many times as needed to produce the desired guantity of the specific nucleic acid sequence. The only limitation is the amount of the primers, thermostable enzyme, and nucleoside triphosphates present. Usually, from 15 to 30 cycles are completed. For diagnostic detection of amplified DNA, the number of cycles will depend on the nature of the sample, the initial target concentration in the sample and the sensitivity of the detection process used after amplification. For a given sensitivity of detection, fewer cycles will be reguired if the sample being amplified is pure and the initial target concentration is high. If the sample is a complex mixture of nucleic acids and the initial target concentration is low, more cycles will be reguired to amplify the signal sufficiently for detection. For general amplification and detection, the process is repeated about 15 times. When amplification is used to generate sequences to be detected with labeled sequence-specific probes and when human genomic DNA is the target of amplification, the process is repeated 15 to 30 times to amplify the sequence sufficiently so that a clearly detectable signal is produced, i.e., so that background noise does not interfere with detection. No additional nucleotides, primers, or thermostable enzyme need be added after the initial addition, provided that no key reagent has been exhausted and that the enzyme has not become denatured or irreversibly inactivated, in which case additional polymerase or other reagent would have to be added for the reaction to continue. After the appropriate number of cycles has been completed to produce the desired amount of the specific nucleic acid seguence, the reaction can be halted in the usual manner, e.g., by inactivating the enzyme by adding EDTA, phenol, SDS, or CHCI 3 or by separating the components of the reaction. The amplification process can be conducted continuously. In one embodiment of an automated process, the reaction mixture can be temperature cycled such that the temperature is programmed to be controlled at a certain level for a certain time. One such instrument for this purpose is the automated machine for handling the amplification reaction developed and marketed by Perkin-Elmer Cetus Instruments. Detailed instructions for carrying out PCR with the instrument are available upon purchase of the instrument. The thermostable DNA polymerases of the present invention with altered 5' to 3' exonuclease activity are very useful in the diverse processes in which amplification of a nucleic acid sequence by PCR is useful. The amplification method may be utilized to clone a particular nucleic acid sequence for insertion into a suitable expression vector, as described in U.S. Patent No. 4,800,159. The vector may be used to transform an appropriate host organism to produce the gene product of the sequence by standard methods of recombinant DNA technology. Such cloning may involve direct ligation into a vector using blunt-end ligation, or use of restriction enzymes to cleave at sites contained within the primers. Other processes suitable for the thermostable DNA polymerases of the present invention include those described in U.S. Patent Nos. 4,683,195 and 4,683,202 and European Patent Publication Nos. 229,701; 237,362; and 258,017; these patents and publications are incorporated herein by reference. In addition, the present enzyme is useful in asymmetric PCR (see Gyllensten and Erlich, 1988, Proc. Natl. Acad. Sci. USA 8_5:7652-7656, incorporated herein by reference); inverse PCR (Ochman et al. , 1988, Genetics 120:621, incorporated herein by reference); and for DNA seguencing (see Innis et al. , 1988, Proc. Natl. Acad. Sci. USA 85.:9436-9440, and McConlogue et al. , 1988, Nuc. Acids Res. 6(20) :9869) , random amplification of cDNA ends (RACE) , random priming PCR which is used to amplify a series of DNA fragments, and PCR processes with single sided specificity such as anchor PCR and ligation-mediated anchor PCR as described by Loh, E. in METHODS: A Companion to Methods in Enzymology (1991) 2 : pp. 11-19. An additional process in which a 5' to 3' exonuclease deficient thermostable DNA polymerase would be useful is a process referred to as polymerase ligase chain reaction (PLCR) . As its name suggests, this process combines features of PCR with features of ligase chain reaction (LCR) . PLCR was developed in part as a technique to increase the specificity of allele-specific PCR in which the low concentrations of dNTPs utilized (-1 μM) limited the extent of amplification. In PLCR, DNA is denatured and four complementary, but not adjacent, oligonucleotide primers are added with dNTPs, a thermostable DNA polymerase and a thermostable ligase. The primers anneal to target DNA in a non-adjacent fashion and the thermostable DNA polymerase causes the addition of appropriate dNTPs to the 3' end of the downstream primer to fill the gap between the non-adjacent primers and thus render the primers adjacent. The thermostable ligase will then ligate the two adjacent oligonucleotide primers. However, the presence of 5' to 3' exonuclease activity in the thermostable DNA polymerase significantly decreases the probability of closing the gap between the two primers because such activity causes the excision of nucleotides or small oligonucleotides from the 5' end of the downstream primer thus preventing ligation of the primers. Therefore, a thermostable DNA polymerase with attenuated or eliminated 5' to 3' exonuclease activity would be particularly useful in PLCR. Briefly, the thermostable DNA polymerases of the present invention which have been mutated to have reduced, attenuated or eliminated 5' to 3' exonuclease activity are useful for the same procedures and technigues as their respective non-mutated polymerases except for procedures and technigues which reguire 5' to 3' exonuclease activity such as the homogeneous assay technique discussed below. Moreover, the mutated DNA polymerases of the present invention will oftentimes result in more efficient performance of the procedures and techniques due to the reduction or elimination of the inherent 5' to 3' exonuclease activity. Specific thermostable DNA polymerases with attenuated 5' to 3' exonuclease activity include the following mutated forms of Tag, Tma, Tspsl7. TZ05, Tth and Taf DNA polymerases. In the table below, and throughout the specification, deletion mutations are inclusive of the numbered nucleotides or amino acids which define the deletion. DNA Mutant Polymerase Mutation Designation Tag G(137) to A in nucleotide pRDA3-2 SED ID N0:1 Gly (46) to Asp in amino ASP46 Tag acid SEQ ID NO:2 Deletion of nucleotides pTAQd2-76 4-228 of nucleotide SEQ ID NO:l Deletion of amino acids MET-ALA 77 2-76 of amino acid Tag SEQ ID NO:2 Delection of nucleotides pTAQd2-46 4-138 of nucleotide SEQ ID NO:l Deletion of amino acids MET-PHE 47 2-46 of amino acid Tag SEQ ID NO:2 Deletion of nucleotides pTAQd2-155 4-462 of nucleotide SEQ ID NO:l Deletion of amino acids MET-VAL 155 2-154 of amino acid Tag SEQ ID NO:2 Deletion of nucleotides pTAQd2-202 4-606 of nucleotide SEQ ID N0:l Deletion of amino acids MET-THR 203 2-202 of amino acid Tag SEQ ID NO:2 Deletion of nucleotides pLSG8 4-867 of nucleotide SEQ ID NO:l Deletion of amino acids MET-SER 290 2-289 of amino acid Tag SEQ ID NO:2 (Stoffel fragment) Tma G(110) to A in nucleotide SEQ ID NO:3 Gly (37) to Asp in amino ASP37 Tma acid SEQ ID NO:4 Deletion of nucleotides pTMAd2-37 4-131 of nucleotide SEQ ID NO:3 Deletion of amino acids MET-VAL 38 2-37 of amino acid Tma SEQ ID NO:4 Deletion of nucleotides pTMAd2-20 4-60 of nucleotide SEQ ID NO:3 Deletion of amino acids MET-ASP 21 2-20 of amino acid Tma SEQ ID NO:4 Deletion of nucleotides pTMAd2-73 4-219 of nucleotide SEQ ID NO:3 Deletion of amino acids MET-GLU 74 2-73 amino acid Tma SEQ ID NO: 4 Deletion of nucleotides pTMA16 1-417 of nucleotide SEQ ID NO:3 Deletion of amino acids MET 140 1-139 of amino acid Tma SEQ ID NO:4 Deletion of nucleotides pTMA15 1-849 of nucleotide SEQ ID NO:3 Deletion of amino acids MET 284 1-283 of amino acid Tma SEQ ID NO:4 Tspsl7 G(128) to A in nucleotide SEQ ID NO:5 Gly (43) to Asp in amino ASP43 acid SEQ ID NO:6 Tspsl7 Deletion of nucleotides pSPSd2-43 4-129 of nucleotide SEQ ID NO:5 Deletion of amino acids MET-PHE 44 2-43 of amino acid Tspsl7 10 SEQ ID NO:6 Deletion of nucleotides pSPSd2-73 4-219 of nucleotide SEQ ID NO:5 15 Deletion of amino acids MET-ALA 74 2-73 of amino acid Tspsl7 SEQ ID NO:6 20 Deletion of nucleotides pSPSd2-151 4-453 of nucleotide SEQ ID NO:5 Deletion of amino acids MET-LEU 152 25 2-151 of amino acid Tspsl7 SEQ ID NO:6 Deletion of nucleotides pSPSd2-199 4-597 of nucleotide 30 SEQ ID NO:5 Deletion of amino acids MET-THR 200 2-199 of amino acid Tspsl7 SEQ ID NO:6 35 Deletion of nucleotides pSPSA288 4-861 of nucleotide SEQ ID NO:5 40 Deletion of amino acids MET-ALA 288 2-287 of amino acid Tsps 17 SEQ ID NO:6 TZ05 G(137) to A in nucleotide 45 SEQ ID NO:7 Gly (46) to Asp in amino ASP46 TZ05 acid SEQ ID NO:8 50 Deletion of nucleotides pZ05d2-46 4-138 of nucleotide SEQ ID NO:7 Deletion of amino acids MET-PHE 47 2-46 of amino acid TZ05 SEQ ID NO:8 Deletion of nucleotides pZ05d2-77 4-231 of nucleotide SEQ ID NO:7 Deletion of amino acids MET-ALA 78 2-77 of amino acid TZ05 SEQ ID NO:8 Deletion of nucleotides pZ05d2-155 4-475 of nucleotide SEQ ID NO:7 Deletion of amino acids MET-VAL 156 2-155 of amino acid TZ05 SEQ ID NO:8 Deletion of nucleotides pZ05d2-203 4-609 of nucleotide SEQ ID NO:7 Deletion of amino acids MET-THR 204 2-203 of amino acid TZ05 SEQ ID NO:8 Deletion of nucleotides pZ05A292 4-873 of nucleotide SEQ ID NO:7 Deletion of amino acids MET-ALA 292 2-291 of amino acid TZ05 SEQ ID NO:8 Tth G(137) to A in nucleotide SEQ ID NO:9 Gly (46) to Asp in amino ASP46 Tth acid SEQ ID NO:10 Deletion of nucleotides pTTHd2-46 4-138 of nucleotide SEQ ID NO:9 Deletion of amino acids MET-PHE 47 2-46 of amino acid Tth SEQ ID NO:10 Deletion of nucleotides pTTHd2-77 4-231 of nucleotide SEQ ID NO:9 Deletion of amino acids MET-ALA 78 2-77 of amino acid Tth SEQ ID NO:10 Deletion of nucleotides pTTHd2-155 4-465 of nucleotide SEQ ID NO:9 Deletion of amino acids MET-VAL 156 2-155 of amino acid Tth SEQ ID NO:10 Deletion of nucleotides pTTHd2-203 4-609 of nucleotide SEQ ID NO:9 Deletion of amino acids MET-THR 204 2-203 of amino acid Tth SEQ ID NO:10 Deletion of nucleotides pTTHA292 4-873 of nucleotide SEQ ID NO:9 Deletion of amino acids MET-ALA 292 2-291 of amino acid Tth SEQ ID NO:10 Taf G(110) to A and A(lll) to T in nucleotide SEQ ID NO:11 Gly (37) to Asp in amino ASP37 Taf acid SEQ ID NO:12 Deletion of nucleotides pTAFd2-37 4-111 of nucleotide SEQ ID NO:11 Deletion of amino acids MET-LEU 38 2-37 of amino acid Taf SEQ ID NO:12 Deletion of nucleotides pTAF09 4-279 of nucleotide SEQ ID NO: 11 Deletion of amino acids MET-TYR 94 2-93 amino acid Taf SEQ ID NO:12 Deletion of nucleotides pTAFll 4-417 of nucleotide SEQ ID NO:11 Deletion of amino acids MET-GLU 140 2-139 of amino acid Taf SEQ ID NO:12 Deletion of nucleotides pTAFd2-203 4-609 of nucleotide SEQ ID NO:11 Deletion of amino acids MET-THR 204 2-203 of amino acid Taf SEQ ID NO:12 Deletion of nucleotides pTAFI285 4-852 of nucleotide SEQ ID NO:11 Deletion of amino acids MET-ILE 285 2-284 of amino acid Taf SEQ ID NO:12 Thermostable DNA Polymerases With Enhanced 5' to 3' Exonuclease Activity Another aspect of the present invention involves the generation of thermostable DNA polymerases which exhibit enhanced or increased 5' to 3' exonuclease activity over that of their respective native polymerases. The thermostable DNA polymerases of the present invention which have increased or enhanced 5' to 3' exonuclease activity are particularly useful in the homogeneous assay system described in PCT application No. 91/05571 filed August 6, 1991, which is incorporated herein by reference. Briefly, this system is a process for the detection of a target amino acid sequence in a sample comprising: (a) contacting a sample comprising single-stranded nucleic acids with an oligonucleotide containing a seguence complementary to a region of the target nucleic acid and a labeled oligonucleotide containing a seguence complementary to a second region of the same target nucleic acid strand, but not including the nucleic acid seguence defined by the first oligonucleotide, to create a mixture of duplexes during hybridization conditions, wherein the duplexes comprise the target nucleic acid annealed to the first oligonucleotide and to the labeled oligonucleotide such that the 3' end of the first oligonucleotide is adjacent to the 5' end of the labeled oligonucleotide; (b) maintaining the mixture of step (a) with a template-dependent nucleic acid polymerase having a 5' to 3' nuclease activity under conditions sufficient to permit the 5' to 3' nuclease activity of the polymerase to cleave the annealed, labeled oligonucleotide and release labeled fragments; and (c) detecting and/or measuring the release of labeled fragments. This homogeneous assay system is one which generates signal while the target sequence is amplified, thus, minimizing the post-amplification handling of the amplified product which is common to other assay systems. Furthermore, a particularly preferred use of the thermostable DNA polymerases with increased 5' to 3' exonuclease activity is in a homogeneous assay system which utilizes PCR technology. This particular assay system involves: (a) providing to a PCR assay containing said sample, at least one labeled oligonucleotide containing a seguence complementary to a region of the target nucleic acid, wherein said labeled oligonucleotide anneals within the target nucleic acid seguence bounded by the oligonucleotide primers of step (b) ; (b) providing a set of oligonucleotide primers, wherein a first primer contains a seguence complementary to a region in one strand of the target nucleic acid seguence and primes the synthesis of a complementary DNA strand, and a second primer contains a seguence complementary to a region in a second strand of the target nucleic acid seguence and primes the synthesis of a complementary DNA strand; and wherein each oligonucleotide primer is selected to anneal to its complementary template upstream of any labeled oligonucleotide annealed to the same nucleic acid strand; (c) amplifying the target nucleic acid seguence employing a nucleic acid polymerase having 5' to 3' nuclease activity as a template-dependent polymerizing agent under conditions which are permissive for PCR cycling steps of (i) annealing of primers and labeled oligonucleotide to a template nucleic acid seguence contained within the target region, and (ii) extending the primer, wherein said nucleic acid polymerase synthesizes a primer extension product while the 5' to 3' nuclease activity of the nucleic acid polymerase simultaneously releases labeled fragments from the annealed duplexes comprising labeled oligonucleotide and its complementary template nucleic acid seguences, thereby creating detectable labeled fragments; and (d) detecting and/or measuring the release of labeled fragments to determine the presence or absence of target seguence in the sample. The increased 5' to 3' exonuclease activity of the thermostable DNA polymerases of the present invention when used in the homogeneous assay systems causes the cleavage of mononucleotides or small oligonucleotides from an oligonucleotide annealed to its larger, complementary polynucleotide. In order for cleavage to occur efficiently, an upstream oligonucleotide must also be annealed to the same larger polynucleotide. The 3' end of this upstream oligonucleotide provides the initial binding site for the nucleic acid polymerase. As soon as the bound polymerase encounters the 5' end of the downstream oligonucleotide, the polymerase can cleave mononucleotides or small oligonucleotides therefrom. The two oligonucleotides can be designed such that they anneal in close proximity on the complementary target nucleic acid such that binding of the nucleic acid polymerase to the 3' end of the upstream oligonucleotide automatically puts it in contact with the 5' end of the downstream oligonucleotide. This process, because polymerization is not reguired to bring the nucleic acid polymerase into position to accomplish the cleavage, is called "polymerization- independent cleavage". Alternatively, if the two oligonucleotides anneal to more distantly spaced regions of the template nucleic acid target, polymerization must occur before the nucleic acid polymerase encounters the 5' end of the downstream oligonucleotide. As the polymerization continues, the polymerase progressively cleaves mononucleotides or small oligonucleotides from the 5' end of the downstream oligonucleotide. This cleaving continues until the remainder of the downstream oligonucleotide has been destabilized to the extent that it dissociates from the template molecule. This process is called "polymerization-dependent cleavage". The attachment of label to the downstream oligonucleotide permits the detection of the cleaved mononucleotides and small oligonucleotides. Subsequently, any of several strategies may be employed to distinguish the uncleaved labelled oligonucleotide from the cleaved fragments thereof. In this manner, nucleic acid samples which contain seguences complementary to the upstream and downstream oligonucleotides can be identified. Stated differently, a labelled oligonucleotide is added concomittantly with the primer at the start of PCR, and the signal generated from hydrolysis of the labelled nucleotide(s) of the probe provides a means for detection of the target sequence during its amplification. In the homogeneous assay system process, a sample is provided which is suspected of containing the particular oligonucleotide seguence of interest, the "target nucleic acid". The target nucleic acid contained in the sample may be first reverse transcribed into cDNA, if necessary, and then denatured, using any suitable denaturing method, including physical, chemical, or enzymatic means, which are known to those of skill in the art. A preferred physical means for strand separation involves heating the nucleic acid until it is completely (>99%) denatured. Typical heat denaturation involves temperatures ranging from about 80°C to about 105°C, for times ranging from a few seconds to minutes. As an alternative to denaturation, the target nucleic acid may exist in a single-stranded form in the sample, such as, for example, single-stranded RNA or DNA viruses. The denatured nucleic acid strands are then incubated with preselected oligonucleotide primers and labeled oligonucleotide (also referred to herein as "probe") under hybridization conditions, conditions which enable the binding of the primers and probes to the single nucleic acid strands. As known in the art, the primers are selected so that their relative positions along a duplex seguence are such that an extension product synthesized from one primer, when the extension product is separated from its template (complement) , serves as a template for the extension of the other primer to yield a replicate chain of defined length. Because the complementary strands are longer than either the probe or primer, the strands have more points of contact and thus a greater chance of finding each other over any given period of time. A high molar excess of probe, plus the primer, helps tip the balance toward primer and probe annealing rather than template reannealing. The primer must be sufficiently long to prime the synthesis of extension products in the presence of the agent for polymerization. The exact length and composition of the primer will depend on many factors, including temperature of the annealing reaction, source and composition of the primer, proximity of the probe annealing site to the primer annealing site, and ratio of primer:probe concentration. For example, depending on the complexity of the target sequence, the oligonucleotide primer typically contains about 15-30 nucleotides, although a primer may contain more or fewer nucleotides. The primers must be sufficiently complementary to anneal to their respective strands selectively and form stable duplexes. The primers used herein are selected to be "substantially" complementary to the different strands of each specific seguence to be amplified. The primers need not reflect the exact sequence of the template, but must be sufficiently complementary to hybridize selectively to their respective strands. Non-complementary bases or longer seguences can be interspersed into the primer or located at the ends of the primer, provided the primer retains sufficient complementarity with a template strand to form a stable duplex therewith. The non-complementary nucleotide sequences of the primers may include restriction enzyme sites. In the practice of the homogeneous assay system, the labeled oligonucleotide probe must be first annealed to a complementary nucleic acid before the nucleic acid polymerase encounters this duplex region, thereby permitting the 5' to 3' exonuclease activity to cleave and release labeled oligonucleotide fragments. To enhance the likelihood that the labeled oligonucleotide will have annealed to a complementary nucleic acid before primer extension polymerization reaches this duplex region, or before the polymerase attaches to the upstream oligonucleotide in the polymerization-independent process, a variety of techniques may be employed. For the polymerization- dependent process, one can position the probe so that the 5'-end of the probe is relatively far from the 3'-end of the primer, thereby giving the probe more time to anneal before primer extension blocks the probe binding site. Short primer molecules generally reguire lower temperatures to form sufficiently stable hybrid complexes with the target nucleic acid. Therefore, the labeled oligonucleotide can be designed to be longer than the primer so that the labeled oligonucleotide anneals preferentially to the target at higher temperatures relative to primer annealing. One can also use primers and labeled oligonucleotides having differential thermal stability. For example, the nucleotide composition of the labeled oligonucleotide can be chosen to have greater G/C content and, consequently, greater thermal stability than the primer. In similar fashion, one can incorporate modified nucleotides into the probe, which modified nucleotides contain base analogs that form more stable base pairs than the bases that are typically present in naturally occurring nucleic acids. Modifications of the probe that may facilitate probe binding prior to primer binding to maximize the efficiency of the present assay include the incorporation of positively charged or neutral phosphodiester linkages in the probe to decrease the repulsion of the polyanionic backbones of the probe and target (see Letsinger et al. , 1988, J. Amer. Chem. Soc. 110:4470) ; the incorporation of alkylated or halogenated bases, such as 5-bromouridine, in the probe to increase base stacking; the incorporation of ribonucleotides into the probe to force the probe:target duplex into an "A" structure, which has increased base stacking; and the substitution of 2,6-diaminopurine (amino adenosine) for some or all of the adenosines in the probe. In preparing such modified probes of the invention, one should recognize that the rate limiting step of duplex formation is "nucleation", the formation of a single base pair, and therefore, altering the biophysical characteristic of a portion of the probe, for instance, only the 3' or 5' terminal portion, can suffice to achieve the desired result. In addition, because the 3' terminal portion of the probe (the 3' terminal 8 to 12 nucleotides) dissociates following exonuclease degradation of the 5' terminus by the polymerase, modifications of the 3' terminus can be made without concern about interference with polymerase/nuclease activity. The thermocycling parameters can also be varied to take advantage of the differential thermal stability of the labeled oligonucleotide and primer. For example, following the denaturation step in thermocycling, an intermediate temperature may be introduced which is permissible for labeled oligonucleotide binding but not primer binding, and then the temperature is further reduced to permit primer annealing and extension. One should note, however, that probe cleavage need only occur in later cycles of the PCR process for suitable results. Thus, one could set up the reaction mixture so that even though primers initially bind preferentially to probes, primer concentration is reduced through primer extension so that, in later cycles, probes bind preferentially to primers. To favor binding of the labeled oligonucleotide before the primer, a high molar excess of labeled oligonucleotide to primer concentration can also be used. In this embodiment, labeled oligonucleotide concentrations are typically in the range of about 2 to 20 times higher than the respective primer concentration, which is generally 0.5 - 5 x 10~ 7 M. Those of skill recognize that oligonucleotide concentration, length, and base composition are each important factors that affect the m of any particular oligonucleotide in a reaction mixture. Each of these factors can be manipulated to create a thermodynamic bias to favor probe annealing over primer annealing. Of course, the homogeneous assay system can be applied to systems that do not involve amplification. In fact, the present invention does not even reguire that polymerization occur. One advantage of the polymerization-independent process lies in the elimination of the need for amplification of the target seguence. In the absence of primer extension, the target nucleic acid is substantially single-stranded. Provided the primer and labeled oligonucleotide are adjacently bound to the target nucleic acid, seguential rounds of oligonucleotide annealing and cleavage of labeled fragments can occur. Thus, a sufficient amount of labeled fragments can be generated, making detection possible in the absence of polymerization. As would be appreciated by those skilled in the art, the signal generated during PCR amplification could be augmented by this polymerization-independent activity. In addition to the homogeneous assay systems described above, the thermostable DNA polymerases of the present invention with enhanced 5' to 3' exonuclease activity are also useful in other amplification systems, such as the transcription amplification system, in which one of the PCR primers encodes a promoter that is used to make RNA copies of the target seguence. In similar fashion, the present invention can be used in a self-sustained seguence replication (3SR) system, in which a variety of enzymes are used to make RNA transcripts that are then used to make DNA copies, all at a single temperature. By incorporating a polymerase with 5' to 3' exonuclease activity into a ligase chain reaction (LCR) system, together with appropriate oligonucleotides, one can also employ the present invention to detect LCR products. Also, just as 5' to 3' exonuclease deficient thermostable DNA polymerases are useful in PLCR, other thermostable DNA polymerases which have 5' to 3' exonuclease activity are also useful in PLCR under different circumstances. Such is the case when the 5' tail of the downstream primer in PLCR is non-complementary to the target DNA. Such non-complementarity causes a forked structure where the 5' end of the upstream primer would normally anneal to the target DNA. Thermostable ligases cannot act on such forked structures. However, the presence of 5' to 3' exonuclease activity in the thermostable DNA polymerase will cause the excision of the forked 5' tail of the upstream primer, thus permitting the ligase to act. The same processes and techniques which are described above as effective for preparing thermostable DNA polymerases with attenuated 5' to 3' exonuclease activity are also effective for preparing the thermostable DNA polymerases with enhanced 5' to 3' exonuclease activity. As described above, these processes include such techniques as site-directed mutagenesis, deletion mutagenesis and "domain shuffling". Of particular usefulness in preparing the thermostable DNA polymerases with enhanced 5' to 3' exonuclease activity is the "domain shuffling" technigue described above. To briefly summarize, this technique involves the cleavage of a specific domain of a polymerase which is recognized as coding for a very active 5' to 3' exonuclease activity of that polymerase, and then transferring that domain into the appropriate area of • a second thermostable DNA polymerase gene which encodes a lower level or no 5' to 3' exonuclease activity. The desired domain may replace a domain which encodes an undesired property of the second thermostable DNA polymerase or be added to the nucleotide sequence of the second thermostable DNA polymerase. A particular "domain shuffling" example is set forth above in which the Tma DNA polymerase coding sequence comprising codons about 291 through 484 is substituted for the Tag DNA polymerase I codons 289 through 422. This substitution yields a novel thermostable DNA polymerase containing the 5' to 3' exonuclease domain of Tag DNA polymerase (codons 1-289), the 3' to 5' exonuclease domain of Tma DNA polymerase (codons 291-484) and the DNA polymerase domain of Tag DNA polymerase (codons 423-832) . However, those skilled in the art will recognize that other substitutions can be made in order to construct a thermostable DNA polymerase with certain desired characteristics such as enhanced 5' to 3' exonuclease activity. The following examples are offered by way of illustration only and are by no means intended to limit the scope of the claimed invention. In these examples, all percentages are by weight if for solids and by volume if for liquids, unless otherwise noted, and all temperatures are given in degrees Celsius. Example 1 Preparation of a 5' to 3' Exonuclease Mutant of Tag DNA Polymerase by Random Mutagenesis PCR of the Known 5' to 3' Exonuclease Domain Preparation of Insert Plasmid pLSG12 was used as a template for PCR. This plasmid is a Hindlll minus version of pLSG5 in which the Tag polymerase gene nucleotides 616 - 621 of SEQ ID N0:1 were changed from AAGCTT to AAGCTG. This change eliminated the Hindlll recognition seguence within the Tag polymerase gene without altering encoded protein seguence. Using oligonucleotides MK61 (AGGACTACAACTGCCACACACC) (SEQ ID NO:21) and RA01 (CGAGGCGCGCCAGCCCCAGGAGATCTACC- AGCTCCTTG) (SEQ ID NO:22) as primers and pLSG12 as the template, PCR was conducted to amplify a 384 bp fragment containing the ATG start of the Tag polymerase gene, as well as an additional 331 bp of coding sequence downstream of the ATG start codon. A 100 μl PCR was conducted for 25 cycles utilizing the following amounts of the following agents and reactants: 50 pmol of primer MK61 (SEQ ID NO:21); 50 pmol of primer RA01 (SEQ ID NO:22) ; 50 μM of each dNTP; 10 mM Tris-HCl, pH 8.3; 50 mM KCl; 1.5 mM MgCl 2 ; 75.6 pg pLSG12; 2.5 units AmpliTaq DNA polymerase. The PCR reaction mixture described was placed in a Perkin-Elmer Cetus Thermocycler and run through the following profile. The reaction mixture was first ramped up to 98°C over 1 minute and 45 seconds, and held at 98°C for 25 seconds. The reaction mixture was then ramped down to 55"C over 45 seconds and held at that temperature for 20 seconds. Finally, the mixture was ramped up to 72°C over 45 seconds, and held at 72°C for 30 seconds. A final 5 minute extension occurred at 72°C. The PCR product was then extracted with chloroform and precipitated with isopropanol using technigues which are well known in the art. A 300 ng sample of the PCR product was digested with 20 U of Hindlll (in 30 μl reaction) for 2 hours at 37°C. Then, an additional digestion was made with 8 U of BssHII for an 2 hours at 50°C. This series of digestions yielded a 330 bp fragment for cloning. A vector was prepared by digesting 5.3 μg of pLSG12 with 20 U Hindlll (in 40 μl) for 2 hours at 37°C. This digestion was followed by addition of 12 U of BssHII and incubation for 2 hours at 50°C. The vector was dephosphorylated by treatment with CIAP (calf intestinal alkaline phosphatase) , specifically 0.04 U CIAP for 30 minutes at 30°C. Then, 4 μl of 500 mM EGTA was added to the vector preparation to stop the reaction, and the phosphatase was inactivated by incubation at 65°C for 45 minutes. 225 ng of the phosphatased vector described above was ligated at a 1:1 molar ratio with 10 ng of the PCR-derived insert. Then, DG116 cells were transformed with one fifth of the ligation mixture, and ampicillin-resistant transformants were selected at 30°C. Appropriate colonies were grown overnight at 30°C to OD 600 0.7. Cells containing the P L vectors were induced at 37°C in a shaking water bath for 4, 9, or 20 hours, and the preparations were sonicated and heat treated at 75°C in the presence of 0.2 M ammonium sulfate. Finally, the extracts were assayed for polymerase activity and 5' to 3' exonuclease activity. The 5' to 3' exonuclease activity was guantified utilizing the 5' to 3' exonuclease assay described above. Specifically, the synthetic 3' phosphorylated oligonucleotide probe (phosphorylated to preclude polymerase extension) BW33 (GATCGCTGCGCGTAACCACCA- CACCCGCCGCGCp) (SEQ ID N0:13) (100 pmol) was 32 P-labeled at the 5' end with gamma-[ 32 P] ATP (3000 Ci/mmol) and T4 polynucleotide kinase. The reaction mixture was extracted with phenol:chloroform:isoamyl alcohol, followed by ethanol precipitation. The 32 P-labeled oligonucleotide probe was redissolved in 100 μl of TE buffer, and unincorporated ATP was removed by gel filtration chromatography on a Sephadex G-50 spin column. Five pmol of 32 P-labeled BW33 probe, was annealed to 5 pmol of single-strand M13mpl0w DNA, in the presence of 5 pmol of the synthetic oligonucleotide primer BW37 (GCGCTAGGGCGCTGGCAAGTGTAGCGGTCA) (SEQ ID NO:14) in a 100 μl reaction containing 10 mM Tris-HCl (pH 8.3), 50 mM KCl, and 3 mM MgCl 2 . The annealing mixture was heated to 95"C for 5 minutes, cooled to 70°C over 10 minutes, incubated at 70°C for an additional 10 minutes, and then cooled to 25"C over a 30 minute period in a Perkin-Elmer Cetus DNA thermal cycler. Exonuclease reactions containing 10 μl of the annealing mixture were pre-incubated at 70°C for 1 minute. The thermostable DNA polymerase preparations of the invention (approximately 0.3 U of enzyme activity) were added in a 2.5 μl volume to the pre-incubation reaction, and the reaction mixture was incubated at 70°C. Aliquots (5 μl) were removed after 1 minute and 5 minutes, and stopped by the addition of 1 μl of 60 mM EDTA. The reaction products were analyzed by homochromatography and exonuclease activity was quantified following autoradiography. Chromatography was carried out in a homochromatography mix containing 2% partially hydrolyzed yeast RNA in 7M urea on Polygram CEL 300 DEAE cellulose thin layer chromatography plates. The presence of 5' to 3' exonuclease activity resulted in the generation of small 32 P-labeled oligomers, which migrated up the TLC plate, and were easily differentiated on the autoradiogram from undegraded probe, which remained at the origin. The clone 3-2 had an expected level of polymerase activity but barely detectable 5' to 3' exonuclease activity. This represented a greater than 1000-fold reduction in 5' to 3' exonuclease activity from that present in native Tag DNA polymerase. This clone was then sequenced and it was found that G (137) was mutated to an A in the DNA sequence. This mutation results in a Gly (46) to Asp mutation in the amino acid sequence of the Tag DNA polymerase, thus yielding a thermostable DNA polymerase of the present invention with significantly attenuated 5' to 3' exonuclease activity. The recovered protein was purified according to the Tag DNA polymerase protocol which is taught in Serial No. 523,394 filed May 15, 1990, incorporated herein by reference. Example 2 Construction of Met 289 (Δ289) 544 Amino Acid Form of Tag Polymerase As indicated in Example 9 of U.S. Serial No. 523,394, filed May 15, 1990, during a purification of native Tag polymerase an altered form of Tag polymerase was obtained that catalyzed the template dependent incorporation of dNTP at 70°C. This altered form of Tag polymerase was immunologically related to the approximate 90 kd form of purified native Tag polymerase but was of lower molecular weight. Based on mobility, relative to BSA and ovalbumin following SDS-PAGE electrophoresis, the apparent molecular weight of this form is approximately 61 kd. This altered form of the enzyme is not present in carefully prepared crude extracts of Thermus aguaticus cells as determined by SDS-PAGE Western blot analysis or jLn situ DNA polymerase activity determination (Spanos, A. , and Hubscher, U. (1983) Meth. Enz. £1:263-277) following SDS-PAGE gel electrophoresis. This form appears to be a proteolytic artifact that may arise during sample handling. This lower molecular weight form was purified to homogeneity and subjected to N-terminal seguence determination on an ABI automated gas phase sequencer. Comparison of the obtained N-terminal sequence with the predicted amino acid seguence of the Tag polymerase gene (SEQ ID N0:1) indicates this shorter form arose as a result of proteolytic cleavage between Glu(289) and Ser(290) . To obtain a further truncated form of a Tag polymerase gene that would direct the synthesis of a 544 amino acid primary translation production plasmids pFC54.t, pSYC1578 and the complementary synthetic oligonucleotides DG29 (5'-AGCTTATGTCTCCAAAAGCT) (SEQ ID NO:23) and DG30 (5'-AGCTTTTGGAGACATA) (SEQ ID NO:24) were used. Plasmid pFC54.t was digested to completion with Hindlll and BamHI. Plasmid pSYC1578 was digested with BstXI (at nucleotides 872 to 883 of SEQ ID NO:l) and treated with E___ coli DNA polymerase I Klenow fragment in the presence of all 4 dNTPs to remove the 4 nucleotide 3' cohesive end and generate a CTG-terminated duplex blunt end encoding Leu294 in the Tag polymerase sequence (see Taq polymerase SEQ ID NO:l nucleotides 880-882) . The DNA sample was digested to completion with Bglll and the approximate 1.6 kb BstXI (repaired)/Bglll Tag DNA fragment was purified by agarose gel electrophoresis and electroelution. The pFC54.t plasmid digest (0.1 pmole) was ligated with the Tag polymerase gene fragment (0.3 pmole) and annealed nonphosphorylated DG29/DG30 duplex adaptor (0.5 pmole) under sticky ligase conditions at 30 μg/ml, 15"C overnight. The DNA was diluted to approximately 10 microgram per ml and ligation continued under blunt end conditions. The ligated DNA sample was digested with Xbal to linearize (inactivate) any IL-2 mutein-encoding ligation products. 80 nanograms of the ligated and digested' DNA was used to transform E_ s _ coli K12 strain DG116 to ampicillin resistance. Amp R candidates were screened for the presence of an approximate 7.17 kb plasmid which yielded the expected digestion products with EcoRI (4,781 bp + 2,386 bp) , Pstl (4,138 bp + 3,029 bp) , Apal (7,167 bp) and Hindlll/PstI (3,400 bp + 3,029 bp + 738 bp) . E . coli colonies harboring candidate plasmids were screened by single colony immunoblot for the temperature-inducible synthesis of an approximate 61 kd Tag polymerase related polypeptide. In addition, candidate plasmids were subjected to DNA sequence determination at the 5' λP L promoter:Taq DNA junction and the 3' Taq DNA:BT cry PRE junction. One of the plasmids encoding the intended DNA sequence and directing the synthesis of a temperature-inducible 61 kd Taq polymerase related polypeptide was designated pLSG68. Expression of 61 kDa Tag Pol I. Cultures containing pLSG8 were grown as taught in Serial No. 523,364 and described in Example 3 below. The 61 kDa Tag Pol I appears not to be degraded upon heat-induction at 41°C. After 21 hours at 41°C, a heat-treated crude extract from a culture harboring pLSG8 had 12,310 units of heat-stable DNA polymerase activity per mg crude extract protein, a 24-fold increase over an uninduced culture. A heat-treated extract from a 21 hour 37°C-induced pLSGδ culture had 9,503 units of activity per mg crude extract protein. A nine-fold increase in accumulated levels of Tag Pol I was observed between a 5 hour and 21 hour induction at 37°C and a nearly four-fold increase between a 5 hour and 21 hour induction at 41°C. The same total protein and heat-treated extracts were analyzed by SDS-PAGE. 20 μg crude extract protein or heat-treated crude extract from 20 μg crude extract protein were applied to each lane of the gel. The major bands readily apparent in both the 17°C and 41°C, 21 hour-induced total protein lanes are egually intense as their heat-treated counterparts. Heat-treated crude extracts from 20 μg of total protein from 37°C and 41°C, 21 hour samples contain 186 units and 243 units of thermostable DNA polymerase activity, respectively. To determine the usefulness of 61 kDa Taq DNA polymerase in PCR, PCR assays were performed using heat-treated crude extracts from induced cultures of pLSG8. Heat-treated crude extract from induced cultures of pLSG5 were used as the source of full-length Tag Pol I in PCR. PCR product was observed in reactions utilizing 4 units and 2 units of truncated enzyme. There was more product in those 5 PCRs than in anyof the full-length enzyme reactions. In addition, no non-specific higher molecular weight products were visible. Purification of 61 kDa Taq Pol I. Purification of 61 kDa Taq Pol I from induced pLSG8/DG116 cells 10 proceeded as the purification of full-length Tag Pol I as in Example 12 of U.S. Serial No. 523,394, filed May 15, 1990 with some modifications. Induced pLSG8/DG116 cells (15.6 g) were homogenized and lysed as described in U.S. Serial No. 523,394, 15 filed May 15, 1990 and in Example 3 below. Fraction I contained 1.87 g protein and 1.047 x 10 6 units of activity. Fraction II, obtained as a 0.2 M ammonium sulfate supernant contained 1.84 g protein and 1.28 x 10 6 units of activity in 74 ml. 20 Following heat treatment, Polymin P (pH 7.5) was added slowly to 0.7%. Following centrifugation, the supernant, Fraction III contained 155 mg protein and 1.48 x 10 6 units of activity. Fraction III was loaded onto a 1.15 x 3.1 cm (3.2 25 ml) phenyl sepharose column at 10 ml/cm 2 /hour. All of the applied activity was retained on the column. The column was washed with 15 ml of the eguilibration buffer and then 5 ml (1.5 column volumes) of 0.1M KCl in TE. The polymerase activity was eluted with 2 M 30 urea in TE containing 20% ethylene glycol. Fractions (0.5 ml each) with polymerase activity were pooled (8.5 ml) and dialyzed into heparin sepharose buffer containing 0.1 M KCl. The dialyzed material, Fraction IV (12.5 ml), contained 5.63 mg of protein and 1.29 x 35 10 6 units of activity. Fraction IV was loaded onto a 1.0 ml bed volume heparin sepharose column equilibrated as above. The column was washed with 6 ml of the same buffer (A 280 to baseline) and eluted with a 15 ml linear 0.1-0.5 M KCl gradient in the same buffer. Fractions (0.15 ml) eluting between 0.16 and 0.27 M KCl were analyzed by SDS-PAGE. A minor (<1%) contaminating approximately 47 kDa protein copurified with 61 kDa Taq Pol I. Fractions eluting between 0.165 and 0.255 M KCl were pooled (2.5 ml) and diafiltered on a Centricon 30 membrane into 2.5X storage buffer. Fraction V contained 2.8 mg of protein and 1.033 x 10 6 units of 61 kDa Tag Pol I. PCR Using Purified 61 kDa Taq Pol I. PCR reactions (50 μl) containing 0.5 ng lambda DNA, 10 pmol each of two lambda-specific primers, 200 μM each dNTPs, 10 mM Tris-Cl, pH 8.3, 3 mM MgCl 2 , 10 mM KCl and 3.5 units of 61 kDa Tag Pol I were performed. As a comparison, PCR reactions were performed with 1.25 units of full-length Tag Pol I, as above, with the substitution of 2 mM MgCl 2 and 50 mM KCl. Thermocycling conditions were 1 minute at 95°C and 1 minute at 60°C for 23 cycles, with a final 5 minute extension at 75°C. The amount of DNA per reaction was guantitated by the Hoechst fluorescent dye assay. 1.11 μg of product was obtained with 61 kDa Taq Pol I (2.2 x 10 5 -fold amplification), as compared with 0.70 μg of DNA with full-length Tag Pol I (1.4 x 10 5 -fold amplification) . Thermostabilitv of 61 kDa Tag Pol I. Steady state thermal inactivation of recombinant 94 kDa Taq Pol I and 61 kDa Tag Pol I was performed 97.5°C under buffer conditions mimicking PCR. 94 kDa Taq Pol I has an apparent half-life of approximately 9 minute at 97.5°C, whereas the half-life of 61 kDa Taq Pol I was approximately 21 minutes. The thermal inactivation of 61 kDa Tag Pol I was unaffected by KCl concentration over a range from 0 to 50 mM. Yet another truncated Tag polymerase gene contained within the -2.68 kb HindIII-Asp718 fragment of plasmid pFC85 can be expressed using, for example, plasmid P p L N RB S ATG ' b y operably linking the amino-terminal Hindlll restriction site encoding the Taq pol gene to an ATG initiation codon. The product of this fusion upon expression will yield an -70,000-72,000 dalton truncated polymerase. This specific construction can be made by digesting plasmid pFC85 with Hindlll and treating with Klenow fragment in the presence of dATP and dGTP. The resulting fragment is treated further with SI nuclease to remove any single-stranded extensions and the resulting DNA digested with Asp718 and treated with Klenow fragment in the presence of all four dNTPs. The recovered fragment can be ligated using T4 DNA ligase to dephosphorylated plasmid pP L N RBS ATG, which had been digested with Sacl and treated with Klenow fragment in the presence of dGTP to construct an ATG blunt end. This ligation mixture can then be used to transform E. coli DG116 and the transformants screened for production of Taq polymerase. Expression can be confirmed by Western immunoblot cinalysis and activity analysis. Example 3 Construction, Expression and Purification of a Truncated 5' to 3' Exonuclease Deficient Tma Polymerase (MET284) To express a 5' to 3 ' exonuclease deficient Tma DNA polymerase lacking amino acids 1-283 of native Tma DNA polymerase the following steps were performed. Plasmid pTmal2-l was digested with BspHI (nucleotide position 848) and Hindlll (nucleotide position 2629) . A 1781 base pair fragment was isolated by agarose gel purification. To separate the agarose from the DNA, a gel slice containing the desired fragment was frozen at -20 β C in a Costar spinex filter unit. After thawing at room temperature, the unit was spun in a microfuge. The filtrate containing the DNA was concentrated in a Speed Vac concentrator, and the DNA was precipitated with ethanol. The isolated fragment was cloned into plasmid pTmal2-l digested with Ncol and Hindlll. Because Ncol digestion leaves the same cohesive end sequence as digestion with BspHI, the 1781 base pair fragment has the same cohesive ends as the full length fragment excised from plasmid pTmal2-l by digestion with Ncol and Hindlll. The ligation of the isolated fragment with the digested plasmid results in a fragment switch and was used to create a plasmid designated pTmal4. Plasmid pTmal5 was similarly constructed by cloning the same isolated fragment into pTmal3. As with pTmal4, pTmalδ drives expression of a polymerase that lacks amino acids 1 through 283 of native Tma DNA polymerase; translation initiates at the methionine codon at position 284 of the native coding seguence. Both the pTmal4 and pTmal5 expression plasmids expressed at a high level a biologically active thermostable DNA polymerase devoid of 5' to 3' exonuclease activity of molecular weight of about 70 kDa; plasmid pTmal5 expressed polymerase at a higher level than did pTmal4. Based on similarities with E. coli Pol I Klenow fragment, such as conservation of amino acid sequence motifs in all three domains that are critical for 3' to 5' exonuclease activity, distance from the amino terminus to the first domain critical for exonuclease activity, and length of the expressed protein, the shortened form (MET284) of Tma DNA polymerase exhibits 3' to 5' exonuclease or proof-reading activity but lacks 5' to 3' exonuclease activity. Initial SDS activity gel assays and solution assays for 3' to 5' exonuclease activity suggest attenuation in the level of proof-reading activity of the polymerase expressed by E. coli host cells harboring plasmid pTmal5. MET284 Tma DNA polymerase was purified from E. coli strain DG116 containing plasmid pTmal5. The seed flask for a 10 L fermentation contained tryptone (20 g/1) , yeast extract (10 g/1) , NaCl (10 g/1) , glucose (10 g/1) , ampicillin (50 mg/l) , and thiamine (10 mg/l) . The seed flask was innoculated with a colony from an agar plate (a frozen glycerol culture can be used) . The seed flask was grown at 30°C to between 0.5 to 2.0 O.D. (A 680 ) • The volume of seed culture inoculated into the fermentor is calculated such that the bacterial concentration is 0.5 mg dry weight/liter. The 10 liter growth medium contained 25 mM KH 2 P0 4 , 10 mM (NH 4 ) 2 S0 4 , 4 mM sodium citrate, 0.4 mM FeCl 3 , 0.04 mM ZnCl 2 , 0.03 mM CoCl 2 , 0.03 mM CuCl 2 , and 0.03 mM H 3 B0 3 . The following sterile components were added: 4 mM MgS0 4 , 20 g/1 glucose, 20 mg/l thiamine, and 50 mg/l ampicillin. The pH was adjusted to 6.8 with NaOH and controlled during the fermentation by added NH 4 0H. Glucose was continually added by coupling to NH 0H addition. Foaming was controlled by the addition of propylene glycol as necessary, as an antifoaming agent. Dissolved oxygen concentration was maintained at 40%. The fermentor was inoculated as described above, and the culture was grown at 30°C to a cell density of 0.5 to 1.0 X 10 10 cells/ml (optical density [A 680 ] of 15). The growth temperature was shifted to 38°C to induce the synthesis of MET284 Tma DNA polymerase. The temperature shift increases the copy number of the pTmalδ plasmid and simultaneously derepresses the lambda P j *. promoter controlling transcription of the modified Tma DNA polymerase gene through inactivation of the temperature-sensitive cl repressor encoded by the defective prophage lysogen in the host. The cells were grown for 6 hours to an optical density of 37 (A 680 ) and harvested by centrifugation. The cell mass (ca. 95 g/1) was resuspended in an equivalent volume of buffer containing 50 mM Tris-Cl, pH 7.6, 20 mM EDTA and 20% (w/v) glycerol. The suspension was slowly dripped into liguid nitrogen to freeze the suspension as "beads" or small pellets. The frozen cells were stored at -70°C. To 200 g of frozen beads (containing 100 g wet weight cell) were added 100 ml of IX TE (50 mM Tris-Cl, pH 7.5, 10 mM EDTA) and DTT to 0.3 mM, PMSF to 2.4 mM, leupeptin to 1 μg/ml and TLCK (a protease inhibitor) to 0.2 mM. The sample was thawed on ice and uniformly resuspended in a blender at low speed. The cell suspension was lysed in an Aminco french pressure cell at 20,000 psi. To reduce viscosity, the lysed cell sample was sonicated 4 times for 3 min. each at 50% duty cycle and 70% output. The sonicate was adjusted to 550 ml with IX TE containing 1 mM DTT, 2.4 mM PMSF, 1 μg/ml leupeptin and 0.2 mM TLCK (Fraction I). After addition of ammonium sulfate to 0.3 M, the crude lysate was rapidly brought to 75°C in a boiling water bath and transferred to a 75"C water bath for 15 min. to denature and inactivate E. coli host proteins. The heat-treated sample was chilled rapidly to 0°C and incubated on ice for 20 min. Precipitated proteins and cell membranes were removed by centrifugation at 20,000 X G for 30 min. at 5 β C and the supernatant (Fraction II) saved. The heat-treated supernatant (Fraction II) was treated with polyethyleneimine (PEI) to remove most of the DNA and RNA. Polymin P (34.96 ml of 10% [w/v], pH 7.5) was slowly added to 437 ml of Fraction II at 0 β C while stirring rapidly. After 30 min. at 0 β C, the sample was centrifuged at 20,000 X G for 30 min. The supernatant (Fraction III) was applied at 80 ml/hr to a 100 ml phenylsepharose column (3.2 x 12.5 cm) that had been equilibrated in 50 mM Tris-Cl, pH 7.5, 0.3 M ammonium sulfate, 10 mM EDTA, and 1 mM DTT. The column was washed with about 200 ml of the same buffer (A 280 to baseline) and then with 150 ml of 50 mM Tris-Cl, pH 7.5, 100 mM KCl, 10 mM EDTA and 1 mM DTT. The MET284 Tma DNA polymerase was then eluted from the column with buffer containing 50 mM Tris-Cl, pH 7.5, 2 M urea, 20% (w/v) ethylene glycol, 10 mM EDTA, and 1 mM DTT, and fractions containing DNA polymerase activity were pooled (Fraction IV) . Fraction IV is adjusted to a conductivity equivalent to 50 mM KCl in 50 mM Tris-Cl, pH 7.5, 1 mM EDTA, and 1 mM DTT. The sample was applied (at 9 ml/hr) to a 15 ml heparin-sepharose column that had been equilibrated in the same buffer. The column was washed with the same buffer at ca. 14 ml/hr (3.5 column volumes) and eluted with a 150 ml 0.05 to 0.5 M KCl gradient in the same buffer. The DNA polymerase activity eluted between 0.11-0.22 M KCl. Fractions containing the pTmal5 encoded modifed Tma DNA polymerase are pooled, concentrated, and diafiltered against 2.5X storage buffer (50 mM Tris-Cl, pH 8.0, 250 mM KCl, 0.25 mM EDTA, 2.5 mM DTT, and 0.5% Tween 20), subseguently mixed with 1.5 volumes of sterile 80% (w/v) glycerol, and stored at -20°C. Optionally, the heparin sepharose-eluted DNA polymerase or the phenyl sepharose-eluted DNA polymerase can be dialyzed or adjusted to a conductivity equivalent to 50 mM KCl in 50 mM Tris-Cl, pH 7.5, 1 mM DTT, 1 mM EDTA, and 0.2% Tween 20 and applied (1 mg protein/ml resin) to an affigel blue column that has been equilibrated in the same buffer. The column is washed with three to five column volumes of the same buffer and eluted with a 10 column volume KCl gradient (0.05 to 0.8 M) in the same buffer. Fractions containing DNA polymerase activity (eluting between 0.25 and 0.4 M KCl) are pooled, concentrated, diafiltered, and stored as above. The relative thermoresistance of various DNA polymerases has been compared. At 97.5°C the half-life of native Tma DNA polymerase is more than twice the half-life of either native or recombinant Tag DNA (i.e., AmpliTag ) DNA polymerase. Surprisingly, the half-life at 97.5 β C of MET284 Tma DNA polymerase is 2.5 to 3 times longer than the half-life of native Tma DNA polymerase. PCR tubes containing 10 mM Tris-Cl, pH 8.3, and 1.5 mM MgCl 2 (for Tag or native Tma DNA polymerase) or 3 mM MgCl (for MET284 Tma DNA polymerase) , 50 mM KCl (for Taq. native Tma and MET284 Tma DNA polymerases) or no KCl (for MET284 Tma PNA polymerase), 0.5 μM each of primers PCR01 and PCR02, 1 ng of lambda template PNA, 200 μM of each dNTP except dCTP, and 4 units of each enzyme were incubated at 97.5°C in a large water bath for times ranging from 0 to 60 min. Samples were withdrawn with time, stored at 0°C, and 5 μl assayed at 75°C for 10 min. in a standard activity assay for residual activity. Taq PNA polymerase had a half-life of about 10 min. at 97.5°C, while native Tma DNA polymerase had a half-life of about 21 to 22 min. at 97.5°C. Surprisingly, the MET284 form of Tma DNA polymerase had a significanlty longer half-life (50 to 55 min.) than either Taq or native Tma DNA polymerase. The improved thermoresistance of MET284 Tma DNA polymerase will find applications in PCR, particularly where G+C-rich 5 targets are difficult to amplify because the strand-separation temperature reguired for complete denaturation of target and PCR product seguences leads to enzyme inactivation. PCR tubes containing 50 μl of 10 mM Tris-Cl, pH 10 8.3, 3 mM MgCl 2 , 200 μM of each dNTP, 0.5 ng bacteriophage lambda DNA, 0.5 μM of primer PCR01, 4 units of MET284 Tma DNA polymerase, and 0.5 μM of primer PCR02 or PL10 were cycled for 25 cycles using τ den of 96°c for x min - and anneal-extend of 60°c for 15 2 min. Lambda DNA template, deoxynucleotide stock solutions, and primers PCR01 and PCR02 were part of the PECI GeneAmp kit. Primer PL10 has the seguence: 5'-GGCGTACCTTTGTCTCACGGGCAAC-3' (SEQ ID NO:25) and is complementary to bacteriophage lambda nucleotides 20 8106-8130. The primers PCR01 and PCR02 amplify a 500 bp product from lambda. The primer pair PCR01 and PL10 amplify a 1 kb product from lambda. After amplification with the respective primer sets, 5 μl 25 aliguots were subjected to agarose gel electrophoresis and the specific intended product bands visualized with ethidium bromide staining. Abundant levels of product were generated with both primer sets, showing that MET284 Tma DNA polymerase successfully amplified the 30 intended target seguence. Example 4 Expression of Truncated Tma DNA Polymerase To express a 5' to 3' exonuclease deficient form of Tma DNA polymerase which initiates translation at MET 140 the coding region corresponding to amino acids 1 through 139 was deleted from the expression vector. The protocol for constructing such a deletion is similar to the construction described in Examples 2 and 3: a shortened gene fragment is excised and then reinserted into a vector from which a full length fragment has been excised. However, the shortened fragment can be obtained as a PCR amplification product rather than purified from a restriction digest. This methodology allows a new upstream restriction site (or other seguences) to be incorporated where useful. To delete the region up to the methionine codon at position 140, an SphI site was introduced into pTmal2-l and pTmal3 using PCR. A forward primer corresponding to nucleotides 409-436 of Tma DNA polymerase SEQ ID NO:3 (FL63) was designed to introduce an SphI site just upstream of the methionine codon at position 140. The reverse primer corresponding to the complement of nucleotides 608-634 of Tma DNA polymerase SEQ ID NO:3 (FL69) was chosen to include an Xbal site at position 621. Plasmid pTmal2-l linearized with Smal was used as the PCR template, yielding an approximate 225 bp PCR product. Before digestion, the PCR product was treated with 50 μg/ml of Proteinase K in PCR reaction mix plus 0.5% SDS and 5 mM EDTA. After incubating for 30 minutes at 37°C, the Proteinase K was heat inactivated at 68°C for 10 minutes. This procedure eliminated any Taq polymerase bound to the product that could inhibit subseguent restriction digests. The buffer was changed to a TE buffer, and the excess PCR primers were removed with a Centricon 100 microconcentrator. The amplified fragment was digested with SphI. then treated with Klenow to create a blunt end at the Sphl-cleaved end, and finally digested with Xbal. The resulting fragment was ligated with plasmid pTmal3 (pTmal2-l would have been suitable) that had been digested with Ncol. repaired with Klenow, and then digested with Xbal. The ligation yielded an in-frame coding sequence with the region following the Ncol site (at the first methionine codon of the coding seguence) and the introduced SphI site (upstream of the methionine codon at position 140) deleted. The resulting expression vector was designated pTmal6. The primers used in this example are given below and in the Sequence Listing section. Primer SEQ ID NO: Seguence FL63 SEQ ID NO:26 5'GATAAAGGCATGCTTCAGCTTGTGAACG FL69 SEQ ID NO:27 5'TGTACTTCTCTAGAAGCTGAACAGCAG Example 5 Elimination of Undesired RBS in MET140 Expression Vectors Reduced expression of the MET140 form of Tma DNA polymerase can be achieved by eliminating the ribosome binding site (RBS) upstream of the methionine codon at position 140. The RBS was be eliminated via oligonucleotide site-directed mutagenesis without changing the amino acid sequence. Taking advantage of the redundancy of the genetic code, one can make changes in the third position of codons to alter the nucleic acid sequence, thereby eliminating the RBS, without changing the amino acid sequence of the encoded protein. A mutagenic primer (FL64) containing the modified seguence was synthesized and phosphorylated. Single-stranded pTma09 (a full length clone having an Ncol site) was prepared by coinfecting with the helper phage R408, commercially available from Stratagene. A "gapped duplex" of single stranded pTma09 and the large fragment from the PvuII digestion of pBS13+ was created by mixing the two plasmids, heating to boiling for 2 minutes, and cooling to 65"C for 5 minutes. The phosphorylated primer was then annealed with the "gapped duplex" by mixing, heating to 80°C for 2 minutes, and then cooling slowly to room temperature. The remaining gaps were filled by extension with Klenow and the fragments ligated with T4 DNA ligase, both reactions taking place in 200 μM of each dNTP and 40 μM ATP in standard salts at 37°C for 30 minutes. The resulting circular fragment was transformed into DG101 host cells by plate transformations on nitrocellulose filters. Duplicate filters were made and the presence of the correct plasmid was detected by probing with a γ 32 P-phosphorylated probe (FL65) . The vector that resulted was designated pTmal9. The RBS minus portion from pTmal9 was cloned into pTmal2-l via an Ncol/Xbal fragment switch. Plasmid pTmal9 was digested with Ncol and Xbal. and the 620 bp fragment was purified by gel electrophoresis, as in Example 3, above. Plasmid pTmal2-l was digested with Ncol, Xbal, and Xc l. The Xcml cleavage inactivates the RBS+ fragment for the subseguent ligation step, which is done under conditions suitable for ligating "sticky" ends (dilute ligase and 40 μM ATP) . Finally, the ligation product is transformed into DG116 host cells for expression and designated pTmal9-RBS. The oligonucleotide sequences used in this example are listed below and in the Sequence Listing section. Oligo SEQ ID NO: Seguence FL64 SEQ ID NO:28 5'CTGAAGCATGTCTTTGTCACCGGT- TACTATGAATAT FL65 SEQ ID NO:29 5'TAGTAACCGGTGACAAAG Example 6 Expression of Truncated Tma DNA Polymerases MET-ASP21 and MET-GLU74 To effect translation initiation at the aspartic acid codon at position 21 of the Tma DNA polymerase gene coding seguence, a methionine codon is introduced before the codon, and the region from the initial Ncol site to this introduced methionine codon is deleted. Similar to Example 4, the deletion process involved PCR with the same downstream primer described above (FL69) and an upstream primer (FL66) designed to incorporate an Ncol site and a methionine codon to yield a 570 base pair product. The amplified product was concentrated with a Centricon-100 microconcentrator to eliminate excess primers and buffer. The product was concentrated in a Speed Vac concentrator and then resuspended in the digestion mix. The amplified product was digested with Ncol and Xbal. Likewise, pTmal2-l, pTmal3, or pTmal9-RBS was digested with the same two restriction enzymes, and the digested, amplified fragment is ligated with the digested expression vector. The resulting construct has a deletion from the Ncol site upstream of the start codon of the native Tma coding seguence to the new methionine codon introduced upstream of the aspartic acid codon at position 21 of the native Tma coding seguence. Similarly, a deletion mutant was created such that translation initiation begins at Glu74, the glutamic acid codon at position 74 of the native Tma coding sequence. An upstream primer (FL67) is designed to introduce a methionine codon and an Ncol site before Glu74. The downstream primer and cloning protocol used are as described above for the MET-ASP21 construct. The upstream primer seguences used in this example are listed below and in the Seguence Listing section. Oligo SEQ ID NO: Seguence FL66 SEQ ID NO:30 5'CTATGCCATGGATAGATCGCTT- TCTACTTCC FL67 SEQ ID NO:31 5'CAAGCCCATGGAAACTTACAAG- GCTCAAAGA Example 7 Expression of Truncated Taf Polymerase Mutein forms of the Taf polymerase lacking 5' to 3' exonuclease activity were constructed by introducing deletions in the 5'end of the Taf polymerase gene. Both 279 and 417 base pair deletions were created using the following protocol; an expression plasmid was digested with restriction enzymes to excise the desired fragment, the fragment ends were repaired with Klenow and all four dNTP/s, to produce blunt ends, and the products were ligated to produce a new circular plasmid with the desired deletion. To express a 93 kilodalton, 5' to 3' exonuclease-deficient form of Taf polymerase, a 279 bp deletion comprising amino acids 2-93 was generated. To express an 88 kilodalton, 5' to 3' exonuclease-deficient form of Taf polymerase, 417 bp deletion comprising amino acids 2-139 was generated. To create a plasmid with codons 2-93 deleted, pTaf03 was digested with Ncol and Ndel and the ends were repaired by Klenow treatment. The digested and repaired plasmid was diluted to 5 μg/ml and ligated under blunt end conditions. The dilute plasmid concentration favors intramolecular ligations. The ligated plasmid was transformed into DG116. Mini-screen DNA preparations were subjected to restriction analysis and correct plasmids were confirmed by DNA seguence analysis. The resulting expression vector created by deleting a segment from pTaf03 was designated pTaf09. A similar vector created from pTaf05 was designated pTaflO. Expression vectors also were created with codons 2-139 deleted. The same protocol was used with the exception that the initial restriction digestion was performed with Ncol and Bglll. The expression vector created from pTaf03 was designated pTafll and the expression vector created from pTaf05 was designated pTaf12. Example 8 Derivation and Expression of 5' to 3' Exonuclease-Deficient, Thermostable DNA Polymerase of Thermus species, Z05 Comprising Amino Acids 292 Through 834 To obtain a DNA fragment encoding a 5' to 3' exonuclease-deficient thermostable DNA polymerase from Thermus species Z05, a portion of the DNA polymerase gene comprising amino acids 292 through 834 is selectively amplified in a PCR with forward primer TZA292 and reverse primer TZR01 as follows: 50 pmoles TZA292 50 pmoles TZR01 10 ng Thermus sp. Z05 genomic DNA 2.5 units AmpliTag DNA polymerase 5 50 μM each dATP, dGTP, dCTP, dTTP in an 80 μl solution containing 10 mM Tris-HCl pH 8.3, 50 mM KCl and overlaid with 100 μl of mineral oil. The reaction was initiated by addition of 20 μl containing 10 7.5 mM MgCl 2 after the tubes had been placed in an 80°C preheated cycler. The genomic DNA was digested to completion with restriction endonuclease Asp.718, denatured at 98°C for 5 minutes and cooled rapidly to 0°C. The sample was 15 cycled in a Perkin-Elmer Cetus Thermal Cycler according to the following profile: STEP CYCLE to 96°C and hold for 20 seconds. STEP CYCLE to 55°C and hold for 30 seconds. 20 RAMP to 72"C over 30 seconds and hold for 1 minute. REPEAT profile for 3 cycles. STEP CYCLE to 96°C and hold for 20 seconds. STEP CYCLE to 65°C and hold for 2 minutes. 25 REPEAT profile for 25 cycles. After last cycle HOLD for 5 minutes. The intended 1.65 kb PCR product is purified by agarose gel elecctrophoresis, and recovered following 30 phenol-chloroform extraction and ethanol precipitation. The purified product is digested with restriction endonucleases Ndel and Bglll and ligated with Ndel/BamHI-digested and dephosphorylated plasmid vector pDG164 (U.S. Serial No. 455,967, filed December 22, 35 1989, Example 6B incorporated herein by reference) . Ampicillin-resistant transformants of E___ coli strain DG116 are selected at 30°C and screened for the desired recombinant plasmid. Plasmid pZ05A292 encodes a 544 amino acid, 5' to 3' exonuclease-deficient Thermus sp. Z05 thermostable DNA polymerase analogous to the pLSG8 encoded protein of Example 2. The DNA polymerase activity is purified as in Example 2. The purified protein is deficient in 5' to 3' exonuclease activity, is more thermoresistant than the corresponding native enzyme and is particularly useful in PCR of G+C-rich templates. Primer SEQ ID NO: SEQUENCE TZA292 SEQ ID NO:32 GTCGGCATATGGCTCCTGCTCCTCTTGAGGA- GGCCCCCTGGCCCCCGCC TZR01 SEQ ID NO:33 GACGCAGATCTCAGCCCTTGGCGGAAAGCCA- GTCCTC Example 9 Derivation and Expression of 5' to 3' Exonuclease-Deficient, Thermostable DNA Polymerase of Thermus species SPS17 Comprising Amino Acids 288 Through 830 To obtain a DNA fragment encoding 5' to 3' exonuclease-deficient thermostable DNA polymerase from Thermus species SPS17, a portion of the DNA polymerase gene comprising amino acids 288 through 830 is selectively amplified in a PCR with forward primer TSA288 and reverse primer TSR01 as follows: 50 pmoles TSA288 50 pmoles TSR01 10 ng Thermus sp. SPS17 genomic DNA 2.5 units AmpliTag DNA polymerase 5 50 μM each dATP, dGTP, dCTP, dTTP in an 80 μl solution containing 10 mM Tris-HCl pH 8.3, 50 mM KCl and overlaid with 100 μl of mineral oil. The reaction was initiated by addition of 20 μl containing 10 7.5 mM MgCl 2 after the tubes had been placed in an 80°C preheated cycler. The genomic DNA was denatured at 98°C for 5 minutes and cooled rapidly to 0°C. The sample was cycled in a 15 Perkin-Elmer Cetus Thermal Cycler according to the following profile: STEP CYCLE to 96°C and hold for 20 seconds. STEP CYCLE to 55°C and hold for 30 seconds. 20 RAMP to 72°C over 30 seconds and hold for 1 minute. REPEAT profile for 3 cycles. STEP CYCLE to 96°C and hold for 20 seconds. STEP CYCLE to 65°C and hold for 2 minutes. 25 REPEAT profile for 25 cycles. After last cycle HOLD for 5 minutes. The intended 1.65 kb PCR product is purified by agarose gel electrophoresis, and recovered following 30 phenol-chloroform extraction and ethanol precipitation. The purified product is digested with restriction endonucleases Ndel and Bglll and ligated with Ndel/BainHI-digested and dephosphorylated plasmid vector pDG164 (U.S. Serial No. 455,967, filed December 12, 35 1989, Example 6B) . Ampicillin- resistant transformants of E. coli strain DG116 are selected at 30°C and screened for the desired recombinant plasmid. Plasmid pSPSA288 encodes a 544 amino acid, 5' to 3' exonuclease-deficient Thermus sp. SPS17 thermostable DNA polymerase analogous to the pLSG8 encoded protein of Example 2. The DNA polymerase activity is purified as in Example 2. The purified protein is deficient in 5' to 3' exonuclease activity, is more thermoresistant than the corresponding native enzyme and is particularly useful in PCR of G+C-rich templates. Primer SEQ ID NO: SEQUENCE TSA288 SEQ ID NO:34 GTCGGCATATGGCTCCTAAAGAAGCTGAGGA- GGCCCCCTGGCCCCCGCC TSR01 SEQ ID NO:35 GACGCAGATCTCAGGCCTTGGCGGAAAGCCA- GTCCTC Example 10 Derivation and Expression of 5' to 3' Exonuclease-Deficient, Thermostable DNA Polymerase of Thermus Thermophilus Comprising Amino Acids 292 Through 834 To obtain a DNA fragment encoding a 5' to 3' exonuclease-deficient thermostable DNA polymerase from Thermus thermophilus, a portion of the DNA polymerase gene comprising amino acids 292 through 834 is selectively amplified in a PCR with forward primer TZA292 and reverse primer DG122 as follows; 50 pmoles TZA292 50 pmoles DG122 1 ng EcoRI digested plasmid pLSG22 2.5 units AmpliTaq DNA polymerase 50 μM each dATP, dGTP, dCTP, dTTP in an 80 μl solution containing 10 mM Tris-HCl pH 8.3, 50 mM KCl and overlaid with 100 μl of mineral oil. The reaction was initiated by addition of 20 μl containing 7.5 mM MgCl 2 after the tubes had been placed in an 80°C preheated cycler. Plasmid pLSG22 (U.S. Serial No. 455,967, filed December 22, 1989, Example 4A, incorporated herein by reference) was digested to completion with restriction endonuclease EcoRI, denatured at 98"C for 5 minutes and cooled rapidly to 0°C. The sample was cycled in a Perkin-Elmer Cetus Thermal Cycler according to the following profile: STEP CYCLE to 96°C and hold for 20 seconds. STEP CYCLE to 55°C and hold for 30 seconds. RAMP to 72 β C over 30 seconds and hold for 1 minute. REPEAT profile for 3 cycles. STEP CYCLE to 96°C and hold for 20 seconds. STEP CYCLE to 65°C and hold for 2 minutes. REPEAT profile for 20 cycles. After last cycle HOLD for 5 minutes. The intended 1.66 kb PCR product is purified by agarose gel electrophoresis, and recovered following phenol-chloroform extraction and ethanol precipitation. The purified product is digested with restriction endonucleases Ndel and Bglll and ligated with Ndel/BamHI-digested and dephosphorylated plasmid vector pDG164 (U.S. Serial No. 455,967, filed December 12, 1989, Example 6B) . Ampicillin- resistant transformants of E_i . coli strain DG116 are selected at 30°C and screened for the desired recombinant plasmid. Plasmid pTTHA292 encodes a 544 amino acid, 5' to 3' exonuclease-deficient Thermus thermophilus thermostable DNA polymerase analogous to the pLSG8 encoded protein of Example 2. The DNA polymerase activity is purified as in Example 2. The purified protein is deficient in 5' to 3' exonuclease activity, is more thermoresistant than the corresponding native enzyme and is particularly useful in PCR of G+C-rich templates. Primer SEQ ID NO: SEQUENCE TZA292 SEQ ID NO:32 GTCGGCATATGGCTCCTGCTCCTCTTGAGGA- GGCCCCCTGGCCCCCGCC DG122 SEQ ID NO:36 CCTCTAAACGGCAGATCTGATATCAACCCTT- GGCGGAAAGC Example 11 Derivation and Expression of 5' to 3' Exonuclease-Deficient. Thermostable DNA Polymerase of Thermosipho Africanus Comprising Amino Acids 285 Through 892 To obtain a DNA fragment encoding a 5' to 3' exonuclease-deficient thermostable DNA polymerase from Thermosipho africanus. a portion of the DNA polymerase gene comprising amino acids 285 through 892 is selectively amplified in a PCR with forward primer TAFI285 and reverse primer TAFR01 as follows: 50 pmoles TAFI285 50 pmoles TAFR01 1 ng plasmid pBSM:TafRV3' DNA 2.5 units AmpliTaq DNA polymerase 50 μM each dATP, dGTP, dCTP, dTTP in an 80 μl solution containing 10 mM Tris-HCl pH 8.3, 50 mM KCl and overlaid with 100 μl of mineral oil. The reaction was initiated by addition of 20 μl containing 7.5 mM MgCl 2 after the tubes had been placed in an 80°C preheated cycler. 5 Plasmid pBSM:TafRV3 (obtained as described in CETUS CASE 2583.1, EX 4, p53, incorporated herein by reference) was digested with EcoRI to completion and the DNA was denatured at 98°C for 5 minutes and cooled rapidly to 0"C. The sample was cycled in a 10 Perkin-Elmer Cetus Thermal Cycler according to the following profile: STEP CYCLE to 95°C and hold for 30 seconds. STEP CYCLE to 55°C and hold for 30 seconds. 15 RAMP to 72°C over 30 seconds and hold for 1 minute. REPEAT profile for 3 cycles. STEP CYCLE to 95°C and hold for 30 minutes. STEP CYCLE to 65°C and hold for 2 minutes. 20 REPEAT profile for 20 cycles. After last cycle HOLD for 5 minutes. The intended 1.86 kb PCR product is purified by agarose gel electrophoresis, and recovered following 25 phenol-chloroform extraction and ethanol precipitation. The purified product is digested with restriction endonucleases Ndel and BamHI and ligated with Ndel/^amHI-digested and dephosphorylated plasmid vector pDG164 (U.S. Serial No. 455,967, filed December 22, 30 1989, Example 6B) . Ampicillin- resistant transformants of E___ coli strain DG116 are selected at 30°C and screened for the desired recombinant plasmid. Plasmid pTAFI285 encodes a 609 amino acid, 5' to 3' exonuclease-deficient Thermosipho africanus 35 thermostable DNA polymerase analogous to the pTMA15-encoded protein of Example 3. The DNA polymerase activity is purified as in Example 3. The purified protein is deficient in 5' to 3' exonuclease activity, is more thermoresistant than the corresponding native enzyme and is particularly useful in PCR of G+C-rich templates. Primer SEQ ID NO: SEQUENCE TAFI285 SEQ ID NO:37 GTCGGCATATGATTAAAGAACTTAATTTACA- AGAAAAATTAGAAAAGG TAFR01 SEQ ID NO:38 CCTTTACCCCAGGATCCTCATTCCCACTCTT- TTCCATAATAAACAT The foregoing written specification is considered to be sufficient to enable one skilled in the art to practice the invention. The present invention is not to be limited in scope by the cell lines deposited, since the deposited embodiment is intended as a single illustration of one aspect of the invention and any cell lines that are functionally eguivalent are within the scope of this invention. The deposits of materials therein does not constitute an admission that the written description herein contained is inadeguate to enable the practice of any aspect of the invention, including the best mode thereof, nor are the deposits to be construed as limiting the scope of the claims to the specific illustrations that they represent. Indeed, various modifications of the invention in addition to those shown and described herein will become apparent to those skilled in the art from the foregoing description and fall within the scope of the appended claims. SEQUENCE LISTING (1) GENERAL INFORMATION: (i) APPLICANT: Gelfand, David H. Abramson, Richard D. (ii) TITLE OF INVENTION: 5' TO 3' EXONUCLEASE MUTATIONS OF THERMOSTABLE DNA POLYMERASES (iii) NUMBER OF SEQUENCES: 38 (iv) CORRESPONDENCE ADDRESS: (A) ADDRESSEE: Cetus Corporation (B) STREET: 1400 Fifty-third Street (C) CITY: Emeryville (D) STATE: California (F) ZIP: 94608 (v) COMPUTER READABLE FORM: (A) MEDIUM TYPE: Floppy disk (B) COMPUTER: IBM PC compatible (C) OPERATING SYSTEM: PC-DOS/MS-DOS (D) SOFTWARE: WordPerfect 5.0 (vi) CURRENT APPLICATION DATA: (A) APPLICATION NUMBER: WO (B) FILING DATE: (C) CLASSIFICATION: (vii) PRIOR APPLICATION DATA: (A) APPLICATION NUMBER: US 590,490 (B) FILING DATE: 28-SEP-1990 (vii) PRIOR APPLICATION DATA: (A) APPLICATION NUMBER: US 590,466 (B) FILING DATE: 28-SEP-1990 (vii) PRIOR APPLICATION DATA: (A) APPLICATION NUMBER: US 590,213 (B) FILING DATE: 28-SEP-1990 (vii) PRIOR APPLICATION DATA: (A) APPLICATION NUMBER: US 523,394 (B) FILING DATE: 15-MAY-1990 (vii) PRIOR APPLICATION DATA: (A) APPLICATION NUMBER: US 143,441 (B) FILING DATE: 12-JAN-1988 (vii) PRIOR APPLICATION DATA: (A) APPLICATION NUMBER: US 063,509 (B) FILING DATE: 17-JUN-1987 (vii) PRIOR APPLICATION DATA: (A) APPLICATION NUMBER: US 899,241 (B) FILING DATE: 22-AUG-1986 (vii) PRIOR APPLICATION DATA: (A) APPLICATION NUMBER: US 746,121 (B) FILING DATE: 15-AUG-1991 (vii) PRIOR APPLICATION DATA: (A) APPLICATION NUMBER: WO PCT/US90/07641 (B) FILING DATE: 21-DEC-1990 (vii) PRIOR APPLICATION DATA: (A) APPLICATION NUMBER: US 585,471 (B) FILING DATE: 20-SEP-1990 (vii) PRIOR APPLICATION DATA: (A) APPLICATION NUMBER: US 455,611 (B) FILING DATE: 22-DEC-1989 (vii) PRIOR APPLICATION DATA: (A) APPLICATION NUMBER: US 609,157 (B) FILING DATE: 02-NOV-1990 (vii) PRIOR APPLICATION DATA: (A) APPLICATION NUMBER: US 557,517 (B) FILING DATE: 24-JUL-1990 (viii) ATTORNEY/AGENT INFORMATION: (A) NAME: Sias Ph.D, Stacey R. (B) REGISTRATION NUMBER: 32,630 (C) REFERENCE/DOCKET NUMBER: Case No. 2580 (ix) TELECOMMUNICATION INFORMATION: (A) TELEPHONE: 415-420-3300 (2) INFORMATION FOR SEQ ID N0:1: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2499 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Thermus aquaticus (ix) FEATURE : (A) NAME/KEY: CDS (B) LOCATION: 1..2496 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:l: ATG AGG GGG ATG CTG CCC CTC TTT GAG CCC AAG GGC CGG GTC CTC CTG 48 Met Arg Gly Met Leu Pro Leu Phe Glu Pro Lys Gly Arg Val Leu Leu 1 5 10 15 GTG GAC GGC CAC CAC CTG GCC TAC CGC ACC TTC CAC GCC CTG AAG GGC 96 Val Asp Gly His His Leu Ala Tyr Arg Thr Phe His Ala Leu Lys Gly 20 25 30 CTC ACC ACC AGC CGG GGG GAG CCG GTG CAG GCG GTC TAC GGC TTC GCC 144 Leu Thr Thr Ser Arg Gly Glu Pro Val Gin Ala Val Tyr Gly Phe Ala 35 40 45 AAG AGC CTC CTC AAG GCC CTC AAG GAG GAC GGG GAC GCG GTG ATC GTG 192 Lys Ser Leu Leu Lys Ala Leu Lys Glu Asp Gly Asp Ala Val lie Val 50 55 60 GTC TTT GAC GCC AAG GCC CCC TCC TTC CGC CAC GAG GCC TAC GGG GGG 240 Val Phe Asp Ala Lys Ala Pro Ser Phe Arg His Glu Ala Tyr Gly Gly 65 70 75 80 TAC AAG GCG GGC CGG GCC CCC ACG CCG GAG GAC TTT CCC CGG CAA CTC 288 Tyr Lys Ala Gly Arg Ala Pro Thr Pro Glu Asp Phe Pro Arg Gin Leu 85 90 95 GCC CTC ATC AAG GAG CTG GTG GAC CTC CTG GGG CTG GCG CGC CTC GAG 336 Ala Leu lie Lys Glu Leu Val Asp Leu Leu Gly Leu Ala Arg Leu Glu 100 105 110 GTC CCG GGC TAC GAG GCG GAC GAC GTC CTG GCC AGC CTG GCC AAG AAG 384 Val Pro Gly Tyr Glu Ala Asp Asp Val Leu Ala Ser Leu Ala Lys Lys 115 120 125 GCG GAA AAG GAG GGC TAC GAG GTC CGC ATC CTC ACC GCC GAC AAA GAC 432 Ala Glu Lys Glu Gly Tyr Glu Val Arg lie Leu Thr Ala Asp Lys Asp 130 135 140 CTT TAC CAG CTC CTT TCC GAC CGC ATC CAC GTC CTC CAC CCC GAG GGG 480 Leu Tvr Gin Leu Leu Ser Asp Arg lie His Val Leu His Pro Glu Gly 145 " 150 155 160 TAC CTC ATC ACC CCG GCC TGG CTT TGG GAA AAG TAC GGC CTG AGG CCC 528 Tyr Leu lie Thr Pro Ala Trp Leu Trp Glu Lys Tyr Gly Leu Arg Pro 165 170 175 GAC CAG TGG GCC GAC TAC CGG GCC CTG ACC GGG GAC GAG TCC GAC AAC 576 Asp Gin Trp Ala Asp Tyr Arg Ala Leu Thr Gly Asp Glu Ser Asp Asn 180 185 190 CTT CCC GGG GTC AAG GGC ATC GGG GAG AAG ACG GCG AGG AAG CTT CTG 624 Leu Pro Gly Val Lys Gly lie Gly Glu Lys Thr Ala Arg Lys Leu Leu 195 200 205 GAG GAG TGG GGG AGC CTG GAA GCC CTC CTC AAG AAC CTG GAC CGG CTG 672 Glu Glu Trp Gly Ser Leu Glu Ala Leu Leu Lys Asn Leu Asp Arg Leu 210 215 220 AAG CCC GCC ATC CGG GAG AAG ATC CTG GCC CAC ATG GAC GAT CTG AAG 720 Lys Pro Ala lie Arg Glu Lys lie Leu Ala His Met Asp Asp Leu Lys 225 230 235 240 CTC TCC TGG GAC CTG GCC AAG GTG CGC ACC GAC CTG CCC CTG GAG GTG 768 Leu Ser Trp Asp Leu Ala Lys Val Arg Thr Asp Leu Pro Leu Glu Val 245 250 255 GAC TTC GCC AAA AGG CGG GAG CCC GAC CGG GAG AGG CTT AGG GCC TTT 816 Asp Phe Ala Lys Arg Arg Glu Pro Asp Arg Glu Arg Leu Arg Ala Phe 260 265 270 CTG GAG AGG CTT GAG TTT GGC AGC CTC CTC CAC GAG TTC GGC CTT CTG 864 Leu Glu Arg Leu Glu Phe Gly Ser Leu Leu His Glu Phe Gly Leu Leu 275 280 285 GAA AGC CCC AAG GCC CTG GAG GAG GCC CCC TGG CCC CCG CCG GAA GGG 912 Glu Ser Pro Lys Ala Leu Glu Glu Ala Pro Trp Pro Pro Pro Glu Gly 290 295 300 GCC TTC GTG GGC TTT GTG CTT TCC CGC AAG GAG CCC ATG TGG GCC GAT 960 Ala Phe Val Gly Phe Val Leu Ser Arg Lys Glu Pro Met Trp Ala Asp 305 310 315 320 CTT CTG GCC CTG GCC GCC GCC AGG GGG GGC CGG GTC CAC CGG GCC CCC 1008 Leu Leu Ala Leu Ala Ala Ala Arg Gly Gly Arg Val His Arg Ala Pro 325 330 335 GAG CCT TAT AAA GCC CTC AGG GAC CTG AAG GAG GCG CGG GGG CTT CTC 1056 Glu Pro Tyr Lys Ala Leu Arg Asp Leu Lys Glu Ala Arg Gly Leu Leu 340 345 350 GCC AAA GAC CTG AGC GTT CTG GCC CTG AGG GAA GGC CTT GGC CTC CCG 1104 Ala Lys Asp Leu Ser Val Leu Ala Leu Arg Glu Gly Leu Gly . ' _eu Pro 355 360 365 CCC GGC GAC GAC CCC ATG CTC CTC GCC TAC CTC CTG GAC CCT TCC AAC 1152 Pro Gly Asp Asp Pro Met Leu Leu Ala Tyr Leu Leu Asp Pro Ser Asn 370 375 380 ACC ACC CCC GAG GGG GTG GCC CGG CGC TAC GGC GGG GAG TGG ACG GAG 1200 Thr Thr Pro Glu Gly Val Ala Arg Arg Tyr Gly Gly Glu Trp Thr Glu 385 390 395 400 GAG GCG GGG GAG CGG GCC GCC CTT TCC GAG AGG CTC TTC GCC AAC CTG 1248 Glu Ala Gly Glu Arg Ala Ala Leu Ser Glu Arg Leu Phe Ala Asn Leu 405 410 415 TGG GGG AGG CTT GAG GGG GAG GAG AGG CTC CTT TGG CTT TAC CGG GAG 1296 Trp Gly Arg Leu Glu Gly Glu Glu Arg Leu Leu Trp Leu Tyr Arg Glu 420 425 430 GTG GAG AGG CCC CTT TCC GCT GTC CTG GCC CAC ATG GAG GCC ACG GGG 1344 Val Glu Arg Pro Leu Ser Ala Val Leu Ala His Met Glu Ala Thr Gly 435 440 445 GTG CGC CTG GAC GTG GCC TAT CTC AGG GCC TTG TCC CTG GAG GTG GCC 1392 Val Arg Leu Asp Val Ala Tyr Leu Arg Ala Leu Ser Leu Glu Val Ala 450 455 460 GAG GAG ATC GCC CGC CTC GAG GCC GAG GTC TTC CGC CTG GCC GGC CAC 1440 Glu Glu lie Ala Arg Leu Glu Ala Glu Val Phe Arg Leu Ala Gly His 465 470 475 480 CCC TTC AAC CTC AAC TCC CGG GAC CAG CTG GAA AGG GTC CTC TTT GAC 1488 Pro Phe Asn Leu Asn Ser Arg Asp Gin Leu Glu Arg Val Leu Phe Asp 485 490 495 GAG CTA GGG CTT CCC GCC ATC GGC AAG ACG GAG AAG ACC GGC AAG CGC 1536 Glu Leu Gly Leu Pro Ala lie Gly Lys Thr Glu Lys Thr Gly Lys Arg 500 505 510 TCC ACC AGC GCC GCC GTC CTG GAG GCC CTC CGC GAG GCC CAC CCC ATC 1584 Ser Thr Ser Ala Ala Val Leu Glu Ala Leu Arg Glu Ala His Pro He 515 520 525 GTG GAG AAG ATC CTG CAG TAC CGG GAG CTC ACC AAG CTG AAG AGC ACC 1632 Val Glu Lys He Leu Gin Tyr Arg Glu Leu Thr Lys Leu Lys Ser Thr 530 535 540 TAC ATT GAC CCC TTG CCG GAC CTC ATC CAC CCC AGG ACG GGC CGC CTC 1680 Tyr He Asp Pro Leu Pro Asp Leu He His Pro Arg Thr Gly Arg Leu 545 550 555 560 CAC ACC CGC TTC AAC CAG ACG GCC ACG GCC ACG GGC AGG CTA AGT AGC 1728 His Thr Arg Phe Asn Gin Thr Ala Thr Ala Thr Gly Arg Leu Ser Ser 565 570 575 TCC GAT CCC AAC CTC CAG AAC ATC CCC GTC CGC ACC CCG CTT GGG CAG 1776 Ser Asp Pro Asn Leu Gin Asn He Pro Val Arg Thr Pro Leu Gly Gin 580 585 590 AGG ATC CGC CGG GCC TTC ATC GCC GAG GAG GGG TGG CTA TTG GTG GCC 1824 Arg He Arg Arg Ala Phe He Ala Glu Glu Gly Trp Leu Leu Val Ala 595 600 605 CTG GAC TAT AGC CAG ATA GAG CTC AGG GTG CTG GCC CAC CTC TCC GGC 1872 Leu Asp Tyr Ser Gin He Glu Leu Arg Val Leu Ala His Leu Ser Gly 610 615 620 GAC GAG AAC CTG ATC CGG GTC TTC CAG GAG GGG CGG GAC ATC CAC ACG 1920 Asp Glu Asn Leu He Arg Val Phe Gin Glu Gly Arg Asp He His Thr 625 630 635 640 GAG ACC GCC AGC TGG ATG TTC GGC GTC CCC CGG GAG GCC GTG GAC CCC 1968 Glu Thr Ala Ser Trp Met Phe Gly Val Pro Arg Glu Ala Val Asp Pro 645 650 655 CTG ATG CGC CGG GCG GCC AAG ACC ATC AAC TTC GGG GTC CTC TAC GGC 2016 Leu Met Arg Arg Ala Ala Lys Thr He Asn Phe Gly Val Leu Zyr Gly 660 665 670 ATG TCG GCC CAC CGC CTC TCC CAG GAG CTA GCC ATC CCT TAC GAG GAG 2064 Met Ser Ala His Arg Leu Ser Gin Glu Leu Ala He Pro Tyr Glu Glu 675 680 685 GCC CAG GCC TTC ATT GAG CGC TAC TTT CAG AGC TTC CCC AAG GTG CGG 2112 Ala Gin Ala Phe He Glu Arg Tyr Phe Gin Ser Phe Pro Lys Val Arg 690 695 700 GCC TGG ATT GAG AAG ACC CTG GAG GAG GGC AGG AGG CGG GGG TAC GTG 2160 Ala Trp He Glu Lys Thr Leu Glu Glu Gly Arg Arg Arg Gly Tyr Val 705 710 715 720 GAG ACC CTC TTC GGC CGC CGC CGC TAC GTG CCA GAC CTA GAG GCC CGG 2208 Glu Thr Leu Phe Gly Arg Arg Arg Tyr Val Pro Asp Leu Glu Ala Arg 725 730 735 GTG AAG AGC GTG CGG GAG GCG GCC GAG CGC ATG GCC TTC AAC ATG CCC 2256 Val Lys Ser Val Arg Glu Ala Ala Glu Arg Met Ala Phe Asn Met Pro 740 745 750 GTC CAG GGC ACC GCC GCC GAC CTC ATG AAG CTG GCT ATG GTG AAG CTC 2304 Val Gin Gly Thr Ala Ala Asp Leu Met Lys Leu Ala Met Val Lys Leu 755 760 765 TTC CCC AGG CTG GAG GAA ATG GGG GCC AGG ATG CTC CTT CAG GTC CAC 2352 Phe Pro Arg Leu Glu Glu Met Gly Ala Arg Met Leu Leu Gin Val His 770 775 780 GAC GAG CTG GTC CTC GAG GCC CCA AAA GAG AGG GCG GAG GCC GTG GCC 2400 Asp Glu Leu Val Leu Glu Ala Pro Lys Glu Arg Ala Glu Ala Val Ala 785 790 795 800 CGG CTG GCC AAG GAG GTC ATG GAG GGG GTG TAT CCC CTG GCC GTG CCC 2448 Arg Leu Ala Lys Glu Val Met Glu Gly Val Tyr Pro Leu Ala Val Pro 805 810 815 CTG GAG GTG GAG GTG GGG ATA GGG GAG GAC TGG CTC TCC GCC AAG GAG 2496 Leu Glu Val Glu Val Gly He Gly Glu Asp Trp Leu Ser Ala Lys Glu 820 825 830 TGA 2499 (2) INFORMATION FOR SEQ ID NO:2: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 832 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2: Met Arg Gly Met Leu Pro Leu Phe Glu Pro Lys Gly Arg Val Leu Leu 1 5 10 15 Val Asp Gly His His Leu Ala Tyr Arg Thr Phe His Ala Leu Lys Gly 20 25 30 Leu Thr Thr Ser Arg Gly Glu Pro Val Gin Ala Val Tyr Gly Phe Ala 35 40 45 Lys Ser Leu Leu Lys Ala Leu Lys Glu Asp Gly Asp Ala Val He Val 50 55 ' 60 Val Phe Asp Ala Lys Ala Pro Ser Phe Arg His Glu Ala Tyr Gly Gly 65 70 75 80 Tyr Lys Ala Gly Arg Ala Pro Thr Pro Glu Asp Phe Pro Arg Gin Leu 85 90 95 Ala Leu He Lys Glu Leu Val Asp Leu Leu Gly Leu Ala Arg Leu Glu 100 105 110 Val Pro Gly Tyr Glu Ala Asp Asp Val Leu Ala Ser Leu Ala Lys Lys 115 120 125 Ala Glu Lys Glu Gly Tyr Glu Val Arg He Leu Thr Ala Asp Lys Asp 130 135 140 Leu Tyr Gin Leu Leu Ser Asp Arg He His Val Leu His Pro Glu Gly 145 150 155 160 Tyr Leu He Thr Pro Ala Trp Leu Trp Glu Lys Tyr Gly Leu Arg Pro 165 170 175 Asp Gin Trp Ala Asp Tyr Arg Ala Leu Thr Gly Asp Glu Ser Asp Asn 180 185 190 Leu Pro Gly Val Lys Gly He Gly Glu Lys Thr Ala Arg Lys Leu Leu 195 200 205 Glu Glu Trp Gly Ser Leu Glu Ala Leu Leu Lys Asn Leu Asp Arg Leu 210 215 220 Lys Pro Ala He Arg Glu Lys He Leu Ala His Met Asp Asp Leu Lys 225 230 235 240 Leu Ser Trp Asp Leu Ala Lys Val Arg Thr Asp Leu Pro Leu Glu Val 245 250 255 Asp Phe Ala Lys Arg Arg Glu Pro Asp Arg Glu Arg Leu Arg Ala Phe 260 265 270 Leu Glu Arg Leu Glu Phe Gly Ser Leu Leu His Glu Phe Gly Leu Leu 275 280 285 Glu Ser Pro Lys Ala Leu Glu Glu Ala Pro Trp Pro Pro Pro Glu Gly 290 295 300 Ala Phe Val Gly Phe Val Leu Ser Arg Lys Glu Pro Met Trp Ala Asp 305 310 315 320 Leu Leu Ala Leu Ala Ala Ala Arg Gly Gly Arg Val His Arg Ala Pro 325 330 335 Glu Pro Tyr Lys Ala Leu Arg Asp Leu Lys Glu Ala Arg Gly Leu Leu 340 345 350 Ala Lys Asp Leu Ser Val Leu Ala Leu Arg Glu Gly Leu Gly Leu Pro 355 360 365 Pro Gly Asp Asp Pro Met Leu Leu Ala Tyr Leu Leu Asp Pro Ser Asn 370 375 380 Thr Thr Pro Glu Gly Val Ala Arg Arg Tyr Gly Gly Glu Trp Thr Glu 385 390 395 400 Glu Ala Gly Glu Arg Ala Ala Leu Ser Glu Arg Leu Phe Ala Asn Leu Trp Gly Arg Leu Glu Gly Glu Glu Arg Leu Leu Trp Leu Tyr Arg Glu 420 425 430 Val Glu Arg Pro Leu Ser Ala Val Leu Ala His Met Glu Ala Thr Gly 435 440 445 Val Arg Leu Asp Val Ala Tyr Leu Arg Ala Leu Ser Leu Glu Val Ala 450 455 460 Glu Glu He Ala Arg Leu Glu Ala Glu Val Phe Arg Leu Ala Cly His 465 470 475 480 Pro Phe Asn Leu Asn Ser Arg Asp Gin Leu Glu Arg Val Leu Phe Asp 485 490 -95 Glu Leu Gly Leu Pro Ala He Gly Lys Thr Glu Lys Thr Gly Lys Arg 500 505 510 Ser Thr Ser Ala Ala Val Leu Glu Ala Leu Arg Glu Ala His Pro He 515 520 525 Val Glu Lys He Leu Gin Tyr Arg Glu Leu Thr Lys Leu Lys Ser Thr 530 535 540 Tyr He Asp Pro Leu Pro Asp Leu He His Pro Arg Thr Gly Arg Leu 545 550 555 560 His Thr Arg Phe Asn Gin Thr Ala Thr Ala Thr Gly Arg Leu Ser Ser 565 570 575 Ser Asp Pro Asn Leu Gin Asn He Pro Val Arg Thr Pro Leu Gly Gin 580 585 590 Arg He Arg Arg Ala Phe He Ala Glu Glu Gly Trp Leu Leu Val Ala 595 600 605 Leu Asp Tyr Ser Gin He Glu Leu Arg Val Leu Ala His Leu Ser Gly 610 615 620 Asp Glu Asn Leu He Arg Val Phe Gin Glu Gly Arg Asp He His Thr 625 630 635 640 Glu Thr Ala Ser Trp Met Phe Gly Val Pro Arg Glu Ala Val Asp Pro 645 650 655 Leu Met Arg Arg Ala Ala Lys Thr He Asn Phe Gly Val Leu Tyr Gly 660 665 670 Met Ser Ala His Arg Leu Ser Gin Glu Leu Ala He Pro Tyr Glu Glu 675 680 685 Ala Gin Ala Phe He Glu Arg Tyr Phe Gin Ser Phe Pro Lys Val Arg 690 695 700 Ala Trp He Glu Lys Thr Leu Glu Glu Gly Arg Arg Arg Gly Tyr Val 705 710 715 720 Glu Thr Leu Phe Gly Arg Arg Arg Tyr Val Pro Asp Leu Glu Ala Arg 725 730 735 Val Lys Ser Val Arg Glu Ala Ala Glu Arg Met Ala Phe Asn Met Pro 740 745 750 Val Gin Gly Thr Ala Ala Asp Leu Met Lys Leu Ala Met Val Lys Leu 755 760 765 Phe Pro Arg Leu Glu Glu Met Gly Ala Arg Met Leu Leu Gin Val His 770 775 780 Asp Glu Leu Val Leu Glu Ala Pro Lys Glu Arg Ala Glu Ala Val Ala 785 790 795 800 Arg Leu Ala Lys Glu Val Met Glu Gly Val Tyr Pro Leu Ala Val Pro 805 810 815 Leu Glu Val Glu Val Gly He Gly Glu Asp Trp Leu Ser Ala Lys Glu 820 825 830 (2) INFORMATION FOR SEQ ID NO:3: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2682 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Thermotoga maritima (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..2679 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3: ATG GCG AGA CTA TTT CTC TTT GAT GGA ACT GCT CTG GCC TAC AGA GCG 48 Met Ala Arg Leu Phe Leu Phe Asp Gly Thr Ala Leu Ala Tyr Arg Ala 1 5 10 15 TAC TAT GCG CTC GAT AGA TCG CTT TCT ACT TCC ACC GGC ATT CCC ACA 96 Tyr Tyr Ala Leu Asp Arg Ser Leu Ser Thr Ser Thr Gly He Pro Thr 20 25 30 AAC GCC ACA TAC GGT GTG GCG AGG ATG CTG GTG AGA TTC ATC AAA GAC 144 Asn Ala Thr Tyr Gly Val Ala Arg Met Leu Val Arg Phe He Lys Asp 35 40 45 CAT ATC ATT GTC GGA AAA GAC TAC GTT GCT GTG GCT TTC GAC AAA AAA 192 His He He Val Gly Lys Asp Tyr Val Ala Val Ala Phe Asp Lys Lys 50 55 60 GCT GCC ACC TTC AGA CAC AAG CTC CTC GAG ACT TAC AAG GCT CAA AGA 240 Ala Ala Thr Phe Arg His Lys Leu Leu Glu Thr Tyr Lys Ala Gin Arg 65 70 75 80 CCA AAG ACT CCG GAT CTC CTG ATT CAG CAG CTT CCG TAC ATA AAG AAG 288 Pro Lys Thr Pro Asp Leu Leu He Gin Gin Leu Pro Tyr He Lys Lys 85 90 95 CTG GTC GAA GCC CTT GGA ATG AAA GTG CTG GAG GTA GAA GGA TAC GAA 336 Leu Val Glu Ala Leu Gly Met Lys Val Leu Glu Val Glu Gly Tyr Glu 100 105 110 GCG GAC GAT ATA ATT GCC ACT CTG GCT GTG AAG GGG CTT CCG CTT TTT 384 Ala Asp Asp He He Ala Thr Leu Ala Val Lys Gly Leu Pro Leu Phe 115 120 125 GAT GAA ATA TTC ATA GTG ACC GGA GAT AAA GAC ATG CTT CAG CTT GTG 432 Asp Glu He Phe He Val Thr Gly Asp Lys Asp Met Leu Gin Leu Val 130 135 140 AAC GAA AAG ATC AAG GTG TGG CGA ATC GTA AAA GGG ATA TCC GAT CTG 480 Asn Glu Lys He Lys Val Trp Arg He Val Lys Gly He Ser Asp Leu 145 150 155 160 GAA CTT TAC GAT GCG CAG AAG GTG AAG GAA AAA TAC GGT GTT GAA CCC 528 Glu Leu Tyr Asp Ala Gin Lys Val Lys Glu Lys Tyr Gly Val Glu Pro 165 170 175 CAG CAG ATC CCG GAT CTT CTG GCT CTA ACC GGA GAT GAA ATA GAC AAC 576 Gin Gin He Pro Asp Leu Leu Ala Leu Thr Gly Asp Glu He Asp Asn 180 185 190 ATC CCC GGT GTA ACT GGG ATA GGT GAA AAG ACT GCT GTT CAG CTT CTA 624 He Pro Gly Val Thr Gly He Gly Glu Lys Thr Ala Val Gin Leu Leu 195 200 205 GAG AAG TAC AAA GAC CTC GAA GAC ATA CTG AAT CAT GTT CGC GAA CTT 672 Glu Lys Tyr Lys Asp Leu Glu Asp He Leu Asn His Val Arg Glu Leu 210 215 220 CCT CAA AAG GTG AGA AAA GCC CTG CTT CGA GAC AGA GAA AAC GCC ATT 720 Pro Gin Lys Val Arg Lys Ala Leu Leu Arg Asp Arg Glu Asn Ala He 225 230 235 240 CTC AGC AAA AAG CTG GCG ATT CTG GAA ACA AAC GTT CCC ATT GAA ATA 768 Leu Ser Lys Lys Leu Ala He Leu Glu Thr Asn Val Pro He Glu He 245 250 255 AAC TGG GAA GAA CTT CGC TAC CAG GGC TAC GAC AGA GAG AAA CTC TTA 816 Asn Trp Glu Glu Leu Arg Tyr Gin Gly Tyr Asp Arg Glu Lys Leu Leu 260 265 270 CCA CTT TTG AAA GAA CTG GAA TTC GCA TCC ATC ATG AAG GAA CTT CAA 864 Pro Leu Leu Lys Glu Leu Glu Phe Ala Ser He Met Lys Glu Leu Gin 275 280 285 CTG TAC GAA GAG TCC GAA CCC GTT GGA TAC AGA ATA GTG AAA GAC CTA 912 Leu Tyr Glu Glu Ser Glu Pro Val Gly Tyr Arg He Val Lys Asp Leu 290 295 300 GTG GAA TTT GAA AAA CTC ATA GAG AAA CTG AGA GAA TCC CCT TCG TTC 960 Val Glu Phe Glu Lys Leu He Glu Lys Leu Arg Glu Ser Pro Ser Phe 305 310 315 320 GCC ATA GAT CTT GAG ACG TCT TCC CTC GAT CCT TTC GAC TGC GAC ATT 1008 Ala He Asp Leu Glu Thr Ser Ser Leu Asp Pro Phe Asp Cys Asp He 325 330 335 GTC GGT ATC TCT GTG TCT TTC AAA CCA AAG GAA GCG TAC TAC ATA CCA 1056 Val Gly He Ser Val Ser Phe Lys Pro Lys Glu Ala Tyr Tyr He Pro 340 345 350 CTC CAT CAT AGA AAC GCC CAG AAC CTG GAC GAA AAA GAG GTT CTG AAA 1104 Leu His His Arg Asn Ala Gin Asn Leu Asp Glu Lys Glu Val Leu Lys 355 360 365 AAG CTC AAA GAA ATT CTG GAG GAC CCC GGA GCA AAG ATC GTT GGT CAG 1152 Lys Leu Lys Glu He Leu Glu Asp Pro Gly Ala Lys He Val Gly Gin 370 375 380 AAT TTG AAA TTC GAT TAC AAG GTG TTG ATG GTG AAG GGT GTT GAA CCT 1200 Asn Leu Lys Phe Asp Tyr Lys Val Leu Met Val Lys Gly Val Glu Pro 385 390 395 400 GTT CCT CCT TAC TTC GAC ACG ATG ATA GCG GCT TAC CTT CTT GAG CCG 1248 Val Pro Pro Tyr Phe Asp Thr Met He Ala Ala Tyr Leu Leu Glu Pro 405 410 415 AAC GAA AAG AAG TTC AAT CTG GAC GAT CTC GCA TTG AAA TTT CTT GGA 1296 Asn Glu Lys Lys Phe Asn Leu Asp Asp Leu Ala Leu Lys Phe Leu Gly 420 425 430 TAC AAA ATG ACA TCT TAC CAA GAG CTC ATG TCC TTC TCT TTT CCG CTG 1344 Tyr Lys Met Thr Ser Tyr Gin Glu Leu Met Ser Phe Ser Phe Pro Leu 435 440 445 TTT GGT TTC AGT TTT GCC GAT GTT CCT GTA GAA AAA GCA GCG AAC TAC 1392 Phe Gly Phe Ser Phe Ala Asp Val Pro Val Glu Lys Ala Ala Asn Tyr 450 455 460 TCC TGT GAA GAT GCA GAC ATC ACC TAC AGA CTT TAC AAG ACC CTG AGC 1440 Ser Cys Glu Asp Ala Asp He Thr Tyr Arg Leu Tyr Lys Thr Leu Ser 465 470 475 480 TTA AAA CTC CAC GAG GCA GAT CTG GAA AAC GTG TTC TAC AAG ATA GAA 1488 Leu Lys Leu His Glu Ala Asp Leu Glu Asn Val Phe Tyr Lys He Glu 485 490 495 ATG CCC CTT GTG AAC GTG CTT GCA CGG ATG GAA CTG AAC GGT GTG TAT 1536 Met Pro Leu Val Asn Val Leu Ala Arg Met Glu Leu Asn Gly Val Tyr 500 505 510 GTG GAC ACA GAG TTC CTG AAG AAA CTC TCA GAA GAG TAC GGA AAA AAA 1584 Val Asp Thr Glu Phe Leu Lys Lys Leu Ser Glu Glu Tyr Gly Lys Lys 515 520 525 CTC GAA GAA CTG GCA GAG GAA ATA TAC AGG ATA GCT GGA GAG CCG TTC 1632 Leu Glu Glu Leu Ala Glu Glu He Tyr Arg He Ala Gly Glu Pro Phe 530 535 540 AAC ATA AAC TCA CCG AAG CAG GTT TCA AGG ATC CTT TTT GAA AAA CTC 1680 Asn He Asn Ser Pro Lys Gin Val Ser Arg He Leu Phe Glu Lys Leu 545 550 555 560 GGC ATA AAA CCA CGT GGT AAA ACG ACG AAA ACG GGA GAC TAT TCA ACA 1728 Gly He Lys Pro Arg Gly Lys Thr Thr Lys Thr Gly Asp Tyr Ser Thr 565 570 575 CGC ATA GAA GTC CTC GAG GAA CTT GCC GGT GAA CAC GAA ATC ATT CCT 1776 Arg He Glu Val Leu Glu Glu Leu Ala Gly Glu His Glu He He Pro 580 585 590 CTG ATT CTT GAA TAC AGA AAG ATA CAG AAA TTG AAA TCA ACC TAC ATA 1824 Leu He Leu Glu Tyr Arg Lys He Gin Lys Leu Lys Ser Thr Tyr He 595 600 605 GAC GCT CTT CCC AAG ATG GTC AAC CCA AAG ACC GGA AGG ATT CAT GCT 1872 Asp Ala Leu Pro Lys Met Val Asn Pro Lys Thr Gly Arg He His Ala 610 615 620 TCT TTC AAT CAA ACG GGG ACT GCC ACT GGA AGA CTT AGC AGC AGC GAT 1920 Ser Phe Asn Gin Thr Gly Thr Ala Thr Gly Arg Leu Ser Ser Ser Asp 625 630 635 640 CCC AAT CTT CAG AAC CTC CCG ACG AAA AGT GAA GAG GGA AAA GAA ATC 1968 Pro Asn Leu Gin Asn Leu Pro Thr Lys Ser Glu Glu Gly Lys Glu He 645 650 655 AGG AAA GCG ATA GTT CCT CAG GAT CCA AAC TGG TGG ATC GTC AGT GCC 2016 Arg Lys Ala He Val Pro Gin Asp Pro Asn Trp Trp He Val Ser Ala 660 665 670 GAC TAC TCC CAA ATA GAA CTG AGG ATC CTC GCC CAT CTC AGT GGT GAT 2064 Asp Tyr Ser Gin He Glu Leu Arg He Leu Ala His Leu Ser Gly Asp 675 680 685 GAG AAT CTT TTG AGG GCA TTC GAA GAG GGC ATC GAC GTC CAC ACT CTA 2112 Glu Asn Leu Leu Arg Ala Phe Glu Glu Gly He Asp Val His Thr Leu 690 695 700 ACA GCT TCC AGA ATA TTC AAC GTG AAA CCC GAA GAA GTA ACC GAA GAA 2160 Thr Ala Ser Arg He Phe Asn Val Lys Pro Glu Glu Val Thr Glu Glu 705 710 715 720 ATG CGC CGC GCT GGT AAA ATG GTT AAT TTT TCC ATC ATA TAC GGT GTA 2208 Met Arg Arg Ala Gly Lys Met Val Asn Phe Ser He He Tyr C-ly Val 725 730 735 ACA CCT TAC GGT CTG TCT GTG AGG CTT GGA GTA CCT GTG AAA GAA GCA 2256 Thr Pro Tyr Gly Leu Ser Val Arg Leu Gly Val Pro Val Lys Glu Ala 740 745 750 GAA AAG ATG ATC GTC AAC TAC TTC GTC CTC TAC CCA AAG GTG CGC GAT 2304 Glu Lys Met He Val Asn Tyr Phe Val Leu Tyr Pro Lys Val Arg Asp 755 760 765 TAC ATT CAG AGG GTC GTA TCG GAA GCG AAA GAA AAA GGC TAT GTT AGA 2352 Tyr He Gin Arg Val Val Ser Glu Ala Lys Glu Lys Gly Tyr Val Arg 770 775 780 ACG CTG TTT GGA AGA AAA AGA GAC ATA CCA CAG CTC ATG GCC CCG GAC 2400 Thr Leu Phe Gly Arg Lys Arg Asp He Pro Gin Leu Met Ala Arg Asp 785 790 795 800 AGG AAC ACA CAG GCT GAA GGA GAA CGA ATT GCC ATA AAC ACT CCC ATA 2448 Arg Asn Thr Gin Ala Glu Gly Glu Arg He Ala He Asn Thr Iro He 805 810 815 CAG GGT ACA GCA GCG GAT ATA ATA AAG CTG GCT ATG ATA GAA ATA GAC 2496 Gin Gly Thr Ala Ala Asp He He Lys Leu Ala Met He Glu He Asp 820 825 830 AGG GAA CTG AAA GAA AGA AAA ATG AGA TCG AAG ATG ATC ATA CAG GTC 2544 Arg Glu Leu Lys Glu Arg Lys Met Arg Ser Lys Met He He Gin Val 835 840 845 CAC GAC GAA CTG GTT TTT GAA GTG CCC AAT GAG GAA AAG GAC GCG CTC 2592 His Asp Glu Leu Val Phe Glu Val Pro Asn Glu Glu Lys Asp Ala Leu 850 855 860 GTC GAG CTG GTG AAA GAC AGA ATG ACG AAT GTG GTA AAG CTT TCA GTG 2640 Val Glu Leu Val Lys Asp Arg Met Thr Asn Val Val Lys Leu Ser Val 865 870 875 880 CCG CTC GAA GTG GAT GTA ACC ATC GGC AAA ACA TGG TCG TGA 2682 Pro Leu Glu Val Asp Val Thr He Gly Lys Thr Trp Ser 885 890 (2) INFORMATION FOR SEQ ID NO:4: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 893 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID N0:4: Met Ala Arg Leu Phe Leu Phe Asp Gly Thr Ala Leu Ala Tyr Arg Ala 1 5 10 15 Tyr Tyr Ala Leu Asp Arg Ser Leu Ser Thr Ser Thr Gly He Pro Thr 20 25 30 Asn Ala Thr Tyr Gly Val Ala Arg Met Leu Val Arg Phe He Lys Asp 35 40 45 His He He Val Gly Lys Asp Tyr Val Ala Val Ala Phe Asp Lys Lys 50 55 60 Ala Ala Thr Phe Arg His Lys Leu Leu Glu Thr Tyr Lys Ala Gin Arg 65 70 75 80 Pro Lys Thr Pro Asp Leu Leu He Gin Gin Leu Pro Tyr He Lys Lys 85 90 95 Leu Val Glu Ala Leu Gly Met Lys Val Leu Glu Val Glu Gly Tyr Glu 100 105 110 Ala Asp Asp He He Ala Thr Leu Ala Val Lys Gly Leu Pro Leu Phe 115 120 125 Asp Glu He Phe He Val Thr Gly Asp Lys Asp Met Leu Gin Leu Val 130 135 140 Asn Glu Lys He Lys Val Trp Arg He Val Lys Gly He Ser Asp Leu 145 150 155 160 Glu Leu Tyr Asp Ala Gin Lys Val Lys Glu Lys Tyr Gly Val Glu Pro 165 170 175 Gin Gin He Pro Asp Leu Leu Ala Leu Thr Gly Asp Glu He Asp Asn 180 185 190 He Pro Gly Val Thr Gly He Gly Glu Lys Thr Ala Val Gin Leu Leu 195 200 205 Glu Lys Tyr Lys Asp Leu Glu Asp He Leu Asn His Val Arg Glu Leu 210 215 220 Pro Gin Lys Val Arg Lys Ala Leu Leu Arg Asp Arg Glu Asn Ala He 225 230 235 240 Leu Ser Lys Lys Leu Ala He Leu Glu Thr Asn Val Pro He Glu He 245 250 255 Asn Trp Glu Glu Leu Arg Tyr Gin Gly Tyr Asp Arg Glu Lys Leu Leu 260 265 270 Pro Leu Leu Lys Glu Leu Glu Phe Ala Ser He Met Lys Glu Leu Gin 275 280 285 Leu Tyr Glu Glu Ser Glu Pro Val Gly Tyr Arg He Val Lys ^.sp Leu 290 295 300 Val Glu Phe Glu Lys Leu He Glu Lys Leu Arg Glu Ser Pro Ser Phe 305 310 315 320 Ala He Asp Leu Glu Thr Ser Ser Leu Asp Pro Phe Asp Cys Asp He 325 330 335 Val Gly He Ser Val Ser Phe Lys Pro Lys Glu Ala Tyr Tyr He Pro 340 345 350 Leu His His Arg Asn Ala Gin Asn Leu Asp Glu Lys Glu Val Leu Lys 355 360 365 Lys Leu Lys Glu He Leu Glu Asp Pro Gly Ala Lys He Val Gly Gin 370 375 380 Asn Leu Lys Phe Asp Tyr Lys Val Leu Met Val Lys Gly Val Glu Pro 385 390 395 400 Val Pro Pro Tyr Phe Asp Thr Met He Ala Ala Tyr Leu Leu Glu Pro 405 410 415 Asn Glu Lys Lys Phe Asn Leu Asp Asp Leu Ala Leu Lys Phe Leu Gly 420 425 430 Tyr Lys Met Thr Ser Tyr Gin Glu Leu Met Ser Phe Ser Phe Pro Leu 435 440 445 Phe Gly Phe Ser Phe Ala Asp Val Pro Val Glu Lys Ala Ala Asn Tyr 450 455 460 Ser Cys Glu Asp Ala Asp He Thr Tyr Arg Leu Tyr Lys Thr Leu Ser 465 470 475 480 Leu Lys Leu His Glu Ala Asp Leu Glu Asn Val Phe Tyr Lys He Glu 485 490 495 Met Pro Leu Val Asn Val Leu Ala Arg Met Glu Leu Asn Gly Val Tyr 500 505 510 Val Asp Thr Glu Phe Leu Lys Lys Leu Ser Glu Glu Tyr Gly Lys Lys 515 520 525 Leu Glu Glu Leu Ala Glu Glu He Tyr Arg He Ala Gly Glu Pro Phe 530 535 540 Asn He Asn Ser Pro Lys Gin Val Ser Arg He Leu Phe Glu Lys Leu 545 550 555 560 Gly He Lys Pro Arg Gly Lys Thr Thr Lys Thr Gly Asp Tyr Ser Thr 565 570 575 Arg He Glu Val Leu Glu Glu Leu Ala Gly Glu His Glu He He Pro 580 585 590 Leu He Leu Glu Tyr Arg Lys He Gin Lys Leu Lys Ser Thr Tyr He 595 600 * 605 Asp Ala Leu Pro Lys Met Val Asn Pro Lys Thr Gly Arg He His Ala 610 615 620 Ser Phe Asn Gin Thr Gly Thr Ala Thr Gly Arg Leu Ser Ser Ser Asp 625 630 635 640 Pro Asn Leu Gin Asn Leu Pro Thr Lys Ser Glu Glu Gly Lys Glu He 645 650 655 Arg Lys Ala He Val Pro Gin Asp Pro Asn Trp Trp He Val Ser Ala 660 665 670 Asp Tyr Ser Gin He Glu Leu Arg He Leu Ala His Leu Ser Gly Asp 675 680 685 Glu Asn Leu Leu Arg Ala Phe Glu Glu Gly He Asp Val His Thr Leu 690 695 700 Thr Ala Ser Arg He Phe Asn Val Lys Pro Glu Glu Val Thr Glu Glu 705 710 715 720 Met Arg Arg Ala Gly Lys Met Val Asn Phe Ser He He Tyr Gly Val 725 730 735 Thr Pro Tyr Gly Leu Ser Val Arg Leu Gly Val Pro Val Lys Glu Ala 740 745 750 Glu Lys Met He Val Asn Tyr Phe Val Leu Tyr Pro Lys Val Arg Asp 755 760 765 Tyr He Gin Arg Val Val Ser Glu Ala Lys Glu Lys Gly Tyr Val Arg 770 775 780 Thr Leu Phe Gly Arg Lys Arg Asp He Pro Gin Leu Met Ala Arg Asp 785 790 795 800 Arg Asn Thr Gin Ala Glu Gly Glu Arg He Ala He Asn Thr Pro He 805 810 815 Gin Gly Thr Ala Ala Asp He He Lys Leu Ala Met He Glu He Asp 820 825 830 Arg Glu Leu Lys Glu Arg Lys Met Arg Ser Lys Met He He Gin Val 835 840 845 His Asp Glu Leu Val Phe Glu Val Pro Asn Glu Glu Lys Asp Ala Leu 850 855 860 Val Glu Leu Val Lys Asp Arg Met Thr Asn Val Val Lys Leu Ser Val 865 870 875 880 Pro Leu Glu Val Asp Val Thr He Gly Lys Thr Trp Ser 885 890 (2) INFORMATION FOR SEQ ID NO:5: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2493 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Thermus species spsl7 (ix) FEATURE : (A) NAME/KEY: CDS (B) LOCATION: 1..2490 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5: ATG CTG CCC CTC TTT GAG CCC AAG GGC CGG GTC CTC CTG GTG GAC GGC 48 Met Leu Pro Leu Phe Glu Pro Lys Gly Arg Val Leu Leu Val Asp Gly 1 5 10 15 CAC CAC CTG GCC TAC CGC ACC TTT TTC GCC CTC AAG GGC CTC ACC ACC 96 His His Leu Ala Tyr Arg Thr Phe Phe Ala Leu Lys Gly Leu Thr Thr 20 25 30 AGC CGG GGC GAG CCC GTG CAG GCG GTT TAT GGC TTC GCC AAA AGC CTC 144 Ser Arg Gly Glu Pro Val Gin Ala Val Tyr Gly Phe Ala Lys Ser Leu 35 40 45 CTC AAG GCC CTG AAG GAG GAT GGG GAG GTG GCC ATC GTG GTC TTT GAC 192 Leu Lys Ala Leu Lys Glu Asp Gly Glu Val Ala He Val Val Phe Asp 50 55 60 GCC AAG GCC CCC TCC TTC CGC CAC GAG GCC TAC GAG GCC TAC AAG GCG 240 Ala Lys Ala Pro Ser Phe Arg His Glu Ala Tyr Glu Ala Tyr Lys Ala 65 70 75 80 GGC CGG GCC CCC ACC CCG GAG GAC TTT CCC CGG CAG CTC GCC CTC ATC 288 Gly Arg Ala Pro Thr Pro Glu Asp Phe Pro Arg Gin Leu Ala Leu He 85 90 95 AAG GAG CTG GTG GAC CTT TTG GGC CTC GTG CGC CTT GAG GTC CCG GGC 336 Lys Glu Leu Val Asp Leu Leu Gly Leu Val Arg Leu Glu Val Pro Gly 100 105 110 TTT GAG GCG GAC GAT GTC CTC GCC ACC CTG GCC AAG AAG GCA GAA AGG 384 Phe Glu Ala Asp Asp Val Leu Ala Thr Leu Ala Lys Lys Ala Clu Arg 115 120 125 GAG GGG TAC GAG GTG CGC ATC CTG AGC GCG GAC CGC GAC CTC TAC CAG 432 Glu Gly Tyr Glu Val Arg He Leu Ser Ala Asp Arg Asp Leu Tyr Gin 130 135 140 CTC CTT TCC GAC CGG ATC CAC CTC CTC CAC CCC GAG GGG GAG GTC CTG 480 Leu Leu Ser Asp Arg He His Leu Leu His Pro Glu Gly Glu Val Leu 145 150 155 160 ACC CCC GGG TGG CTC CAG GAG CGC TAC GGC CTC TCC CCG GAG AGG TGG 528 Thr Pro Gly Trp Leu Gin Glu Arg Tyr Gly Leu Ser Pro Glu Arg Trp 165 170 175 GTG GAG TAC CGG GCC CTG GTG GGG GAC CCT TCG GAC AAC CTC CCC GGG 576 Val Glu Tyr Arg Ala Leu Val Gly Asp Pro Ser Asp Asn Leu Pro Gly 180 185 190 GTG CCC GGC ATC GGG GAG AAG ACC GCC CTG AAG CTC CTG AAG GAG TGG 624 Val Pro Gly He Gly Glu Lys Thr Ala Leu Lys Leu Leu Lys Glu Trp 195 200 205 GGT AGC CTG GAA GCG ATT CTA AAG AAC CTG GAC CAG GTG AAG CCG GAA 672 Gly Ser Leu Glu Ala He Leu Lys Asn Leu Asp Gin Val Lys Pro Glu 210 215 220 AGG GTG CGG GAG GCC ATC CGG AAT AAC CTG GAT AAG CTC CAG ATG TCC 720 Arg Val Arg Glu Ala He Arg Asn Asn Leu Asp Lys Leu Gin Met Ser 225 230 235 240 CTG GAG CTT TCC CGC CTC CGC ACC GAC CTC CCC CTG GAG GTG GAC TTC 768 Leu Glu Leu Ser Arg Leu Arg Thr Asp Leu Pro Leu Glu Val Asp Phe 245 250 255 GCC AAG AGG CGG GAG CCC GAC TGG GAG GGG CTT AAG GCC TTT TTG GAG 816 Ala Lys Arg Arg Glu Pro Asp Trp Glu Gly Leu Lys Ala Phe Leu Glu 260 265 270 CGG CTT GAG TTC GGA AGC CTC CTC CAC GAG TTC GGC CTT CTG GAG GCC 864 Arg Leu Glu Phe Gly Ser Leu Leu His Glu Phe Gly Leu Leu Clu Ala 275 280 285 CCC AAG GAG GCG GAG GAG GCC CCC TGG CCC CCG CCT GGA GGG GCC TTT 912 Pro Lys Glu Ala Glu Glu Ala Pro Trp Pro Pro Pro Gly Gly Ala Phe 290 295 300 TTG GGC TTC CTC CTC TCC CGC CCC GAG CCC ATG TGG GCG GAG CTT TTG 960 Leu Gly Phe Leu Leu Ser Arg Pro Glu Pro Met Trp Ala Glu Leu Leu 305 310 315 320 GCC CTG GCG GGG GCC AAG GAG GGG CGG GTC CAT CGG GCG GAA GAC CCC 1008 Ala Leu Ala Gly Ala Lys Glu Gly Arg Val His Arg Ala Glu -.sp Pro 325 330 335 GTG GGG GCC CTA AAG GAC CTG AAG GAG ATC CGG GGC CTC CTC GCC AAG 1056 Val Gly Ala Leu Lys Asp Leu Lys Glu He Arg Gly Leu Leu Ala Lys 340 345 350 GAC CTC TCG GTC CTG GCC CTG AGG GAG GGC CGG GAG ATC CCG CCG GGG 1104 Asp Leu Ser Val Leu Ala Leu Arg Glu Gly Arg Glu He Pro Pro Gly 355 360 365 GAC GAC CCC ATG CTC CTC GCC TAC CTC CTG GAC CCG GGG AAC ACC AAC 1152 Asp Asp Pro Met Leu Leu Ala Tyr Leu Leu Asp Pro Gly Asn Thr Asn 370 375 380 CCC GAG GGG GTG GCC CGG CGG TAC GGG GGG GAG TGG AAG GAG GAC GCC 1200 Pro Glu Gly Val Ala Arg Arg Tyr Gly Gly Glu Trp Lys Glu Asp Ala 385 390 395 400 GCC GCC CGG GCC CTC CTT TCG GAA AGG CTC TGG CAG GCC CTT TAC CCC 1248 Ala Ala Arg Ala Leu Leu Ser Glu Arg Leu Trp Gin Ala Leu Tyr Pro 405 410 415 CGG GTG GCG GAG GAG GAA AGG CTC CTT TGG CTC TAC CGG GAG GTG GAG 1296 Arg Val Ala Glu Glu Glu Arg Leu Leu Trp Leu Tyr Arg Glu Val Glu 420 425 430 CGG CCC CTC GCC CAG GTC CTC GCC CAC ATG GAG GCC ACG GGG GTG CGG 1344 Arg Pro Leu Ala Gin Val Leu Ala His Met Glu Ala Thr Gly Val Arg 435 440 445 CTG GAT GTG CCC TAC CTG GAG GCC CTT TCC CAG GAG GTG GCC TTT GAG 1392 Leu Asp Val Pro Tyr Leu Glu Ala Leu Ser Gin Glu Val Ala - " he Glu 450 455 4*50 CTG GAG CGC CTC GAG GCC GAG GTC CAC CGC CTG GCG GGC CAC CCC TTC 1440 Leu Glu Arg Leu Glu Ala Glu Val His Arg Leu Ala Gly His Pro Phe 465 470 475 480 AAC CTG AAC TCT AGG GAC CAG CTG GAG CGG GTC CTC TTT GAC GAG CTC 1488 Asn Leu Asn Ser Arg Asp Gin Leu Glu Arg Val Leu Phe Asp Glu Leu 485 490 495 GGC CTA CCC CCC ATC GGC AAG ACG GAG AAG ACG GGC AAG CGC TCC ACC 1536 Gly Leu Pro Pro He Gly Lys Thr Glu Lys Thr Gly Lys Arg Ser Thr 500 505 510 AGC GCC GCC GTC CTG GAG CTC TTA AGG GAG GCC CAC CCC ATC GTG GGG 1584 Ser Ala Ala Val Leu Glu Leu Leu Arg Glu Ala His Pro He Val Gly 515 520 525 CGG ATC CTG GAG TAC CGG GAG CTC ATG AAG CTC AAG AGC ACC TAC ATA 1632 Arg He Leu Glu Tyr Arg Glu Leu Met Lys Leu Lys Ser Thr Tyr He 530 535 540 GAC CCC CTC CCC AGG CTG GTC CAC CCC AAA ACC GGC CGG CTC CAC ACC 1680 Asp Pro Leu Pro Arg Leu Val His Pro Lys Thr Gly Arg Leu His Thr 545 550 555 560 CGC TTC AAC CAG ACG GCC ACC GCC ACG GGC CGC CTC TCC AGC TCC GAC 1728 Arg Phe Asn Gin Thr Ala Thr Ala Thr Gly Arg Leu Ser Ser Ser Asp 565 570 575 CCC AAC CTG CAG AAC ATC CCC GTG CGC ACC CCC TTA GGC CAG CGC ATC 1776 Pro Asn Leu Gin Asn He Pro Val Arg Thr Pro Leu Gly Gin Arg He 580 585 590 CGC AAG GCC TTC ATT GCC GAG GAG GGC CAT CTC CTG GTG GCC CTG GAC 1824 Arg Lys Ala Phe He Ala Glu Glu Gly His Leu Leu Val Ala Leu Asp 595 600 605 TAT AGC CAG ATC GAG CTC CGG GTC CTC GCC CAC CTC TCG GGG GAC GAG 1872 Tyr Ser Gin He Glu Leu Arg Val Leu Ala His Leu Ser Gly Asp Glu 610 615 620 AAC CTC ATC CGG GTC TTC CGG GAA GGG AAG GAC ATC CAC ACC GAG ACC 1920 Asn Leu He Arg Val Phe Arg Glu Gly Lys Asp He His Thr Glu Thr 625 630 635 640 GCC GCC TGG ATG TTC GGC GTG CCC CCC GAG GGG GTG GAC GGG GCC ATG 1968 Ala Ala Trp Met Phe Gly Val Pro Pro Glu Gly Val Asp Gly Ala Met 645 650 655 CGC CGG GCG GCC AAG ACG GTG AAC TTC GGG GTG CTC TAC GGG ATG TCC 2016 Arg Arg Ala Ala Lys Thr Val Asn Phe Gly Val Leu Tyr Gly Met Ser 660 665 670 GCC CAC CGC CTC TCC CAG GAG CTC TCC ATC CCC TAC GAG GAG GCG GCG 2064 Ala His Arg Leu Ser Gin Glu Leu Ser He Pro Tyr Glu Glu Ala Ala 675 680 685 GCC TTC ATC GAG CGC TAC TTC CAG AGC TTC CCC AAG GTG CGG GCC TGG 2112 Ala Phe He Glu Arg Tyr Phe Gin Ser Phe Pro Lys Val Arg Ala Trp 690 695 700 ATC GCC AAA ACC TTG GAG GAG GGG CGG AAG AAG GGG TAC GTG GAG ACC 2160 He Ala Lys Thr Leu Glu Glu Gly Arg Lys Lys Gly Tyr Val Glu Thr 705 710 715 720 CTC TTC GGC CGC CGC CGC TAC GTG CCC GAC CTC AAC GCC CGG GTG AAG 2208 Leu Phe Gly Arg Arg Arg Tyr Val Pro Asp Leu Asn Ala Arg Val Lys 725 730 735 AGC GTG CGG GAG GCG GCG GAG CGC ATG GCC TTC AAC ATG CCC GTG CAG 2256 Ser Val Arg Glu Ala Ala Glu Arg Met Ala Phe Asn Met Pro Val Gin 740 745 750 GGC ACC GCC GCG GAC CTC ATG AAG CTG GCC ATG GTG AAG CTC TTC CCC 2304 Gly Thr Ala Ala Asp Leu Met Lys Leu Ala Met Val Lys Leu Phe Pro 755 760 765 AGG CTC AGG CCC TTG GGC GTT CGC ATC CTC CTC CAG GTG CAC GAC GAG 2352 Arg Leu Arg Pro Leu Gly Val Arg He Leu Leu Gin Val His Asp Glu 770 775 780 CTG GTC TTG GAG GCC CCA AAG GCG CGG GCG GAG GAG GCC GCC CAG TTG 2400 Leu Val Leu Glu Ala Pro Lys Ala Arg Ala Glu Glu Ala Ala Gin Leu 785 790 795 800 GCC AAG GAG ACC ATG GAA GGG GTT TAC CCC CTC TCC GTC CCC CTG GAG 2448 Ala Lys Glu Thr Met Glu Gly Val Tyr Pro Leu Ser Val Pro Leu Glu 805 810 815 GTG GAG GTG GGG ATG GGG GAG GAC TGG CTT TCC GCC AAG GCC 2490 Val Glu Val Gly Met Gly Glu Asp Trp Leu Ser Ala Lys Ala 820 825 830 TAG 2493 (2) INFORMATION FOR SEQ ID NO:6: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 830 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6: Met Leu Pro Leu Phe Glu Pro Lys Gly Arg Val Leu Leu Val Asp Gly 1 5 10 15 His His Leu Ala Tyr Arg Thr Phe Phe Ala Leu Lys Gly Leu Thr Thr 20 25 30 Ser Arg Gly Glu Pro Val Gin Ala Val Tyr Gly Phe Ala Lys Ser Leu 35 40 45 Leu Lys Ala Leu Lys Glu Asp Gly Glu Val Ala He Val Val Phe Asp 50 55 60 Ala Lys Ala Pro Ser Phe Arg His Glu Ala Tyr Glu Ala Tyr Lys Ala 65 70 75 80 Gly Arg Ala Pro Thr Pro Glu Asp Phe Pro Arg Gin Leu Ala Leu He 85 90 95 Lys Glu Leu Val Asp Leu Leu Gly Leu Val Arg Leu Glu Val Pro Gly 100 105 110 Phe Glu Ala Asp Asp Val Leu Ala Thr Leu Ala Lys Lys Ala Glu Arg 115 120 125 Glu Gly Tyr Glu Val Arg He Leu Ser Ala Asp Arg Asp Leu Tyr Gin 130 135 140 Leu Leu Ser Asp Arg He His Leu Leu His Pro Glu Gly Glu Val Leu 145 150 155 160 Thr Pro Gly Trp Leu Gin Glu Arg Tyr Gly Leu Ser Pro Glu Arg Trp 165 170 175 Val Glu Tyr Arg Ala Leu Val Gly Asp Pro Ser Asp Asn Leu Pro Gly 180 185 190 Val Pro Gly He Gly Glu Lys Thr Ala Leu Lys Leu Leu Lys Glu Trp 195 200 205 Gly Ser Leu Glu Ala He Leu Lys Asn Leu Asp Gin Val Lys Pro Glu 210 215 220 Arg Val Arg Glu Ala He Arg Asn Asn Leu Asp Lys Leu Gin Met Ser 225 230 235 240 Leu Glu Leu Ser Arg Leu Arg Thr Asp Leu Pro Leu Glu Val Asp Phe 245 250 255 Ala Lys Arg Arg Glu Pro Asp Trp Glu Gly Leu Lys Ala Phe Leu Glu 260 265 270 Arg Leu Glu Phe Gly Ser Leu Leu His Glu Phe Gly Leu Leu Glu Ala 275 280 285 Pro Lys Glu Ala Glu Glu Ala Pro Trp Pro Pro Pro Gly Gly Ala Phe 290 295 300 Leu Gly Phe Leu Leu Ser Arg Pro Glu Pro Met Trp Ala Glu Leu Leu 305 310 315 320 Ala Leu Ala Gly Ala Lys Glu Gly Arg Val His Arg Ala Glu Asp Pro 325 330 335 Val Gly Ala Leu Lys Asp Leu Lys Glu He Arg Gly Leu Leu Ala Lys 340 345 350 Asp Leu Ser Val Leu Ala Leu Arg Glu Gly Arg Glu He Pro Pro Gly 355 360 365 Asp Asp Pro Met Leu Leu Ala Tyr Leu Leu Asp Pro Gly Asn Thr Asn 370 375 380 Pro Glu Gly Val Ala Arg Arg Tyr Gly Gly Glu Trp Lys Glu Asp Ala 385 390 395 400 Ala Ala Arg Ala Leu Leu Ser Glu Arg Leu Trp Gin Ala Leu Tyr Pro 405 410 415 Arg Val Ala Glu Glu Glu Arg Leu Leu Trp Leu Tyr Arg Glu Val Glu 420 425 430 Arg Pro Leu Ala Gin Val Leu Ala His Met Glu Ala Thr Gly Val Arg 435 440 445 Leu Asp Val Pro Tyr Leu Glu Ala Leu Ser Gin Glu Val Ala Phe Glu 450 455 460 Leu Glu Arg Leu Glu Ala Glu Val His Arg Leu Ala Gly His Pro Phe 465 470 475 480 Asn Leu Asn Ser Arg Asp Gin Leu Glu Arg Val Leu Phe Asp Glu Leu 485 490 495 Gly Leu Pro Pro He Gly Lys Thr Glu Lys Thr Gly Lys Arg Ser Thr 500 505 510 Ser Ala Ala Val Leu Glu Leu Leu Arg Glu Ala His Pro He Val Gly 515 520 525 Arg He Leu Glu Tyr Arg Glu Leu Met Lys Leu Lys Ser Thr Tyr He 530 535 540 Asp Pro Leu Pro Arg Leu Val His Pro Lys Thr Gly Arg Leu His Thr 545 550 555 560 Arg Phe Asn Gin Thr Ala Thr Ala Thr Gly Arg Leu Ser Ser Ser Asp 565 570 575 Pro Asn Leu Gin Asn He Pro Val Arg Thr Pro Leu Gly Gin Arg He 580 585 590 Arg Lys Ala Phe He Ala Glu Glu Gly His Leu Leu Val Ala Leu Asp 595 600 605 Tyr Ser Gin He Glu Leu Arg Val Leu Ala His Leu Ser Gly Asp Glu 610 615 620 Asn Leu He Arg Val Phe Arg Glu Gly Lys Asp He His Thr Glu Thr 625 630 635 640 Ala Ala Trp Met Phe Gly Val Pro Pro Glu Gly Val Asp Gly Ala Met 645 650 655 Arg Arg Ala Ala Lys Thr Val Asn Phe Gly Val Leu Tyr Gly Met Ser 660 665 670 Ala His Arg Leu Ser Gin Glu Leu Ser He Pro Tyr Glu Glu Ala Ala 675 680 685 Ala Phe He Glu Arg Tyr Phe Gin Ser Phe Pro Lys Val Arg Ala Trp 690 695 700 He Ala Lys Thr Leu Glu Glu Gly Arg Lys Lys Gly Tyr Val Glu Thr 705 710 715 720 Leu Phe Gly Arg Arg Arg Tyr Val Pro Asp Leu Asn Ala Arg Val Lys 725 730 735 Ser Val Arg Glu Ala Ala Glu Arg Met Ala Phe Asn Met Pro Val Gin 740 745 750 Gly Thr Ala Ala Asp Leu Met Lys Leu Ala Met Val Lys Leu Phe Pro 755 760 765 Arg Leu Arg Pro Leu Gly Val Arg He Leu Leu Gin Val His Asp Glu 770 775 780 Leu Val Leu Glu Ala Pro Lys Ala Arg Ala Glu Glu Ala Ala Gin Leu 785 790 795 800 Ala Lys Glu Thr Met Glu Gly Val Tyr Pro Leu Ser Val Pro Leu Glu 805 810 815 Val Glu Val Gly Met Gly Glu Asp Trp Leu Ser Ala Lys Ala 820 825 830 (2) INFORMATION FOR SEQ ID NO:7: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2505 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Thermus species Z05 (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..2502 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7: ATG AAG GCG ATG CTT CCG CTC TTT GAA CCC AAA GGC CGG GTT CTC CTG 48 Met Lys Ala Met Leu Pro Leu Phe Glu Pro Lys Gly Arg Val Leu Leu 1 5 10 15 GTG GAC GGC CAC CAC CTG GCC TAC CGC ACC TTC TTC GCC CTA AAG GGC 96 Val Asp Gly His His Leu Ala Tyr Arg Thr Phe Phe Ala Leu Lys Gly 20 25 30 CTC ACC ACG AGC CGG GGC GAA CCG GTG CAG GCG GTT TAC GGC TTC GCC 144 Leu Thr Thr Ser Arg Gly Glu Pro Val Gin Ala Val Tyr Gly Phe Ala 35 40 45 AAG AGC CTC CTC AAG GCC CTG AAG GAG GAC GGG TAC AAG GCC GTC TTC 192 Lys Ser Leu Leu Lys Ala Leu Lys Glu Asp Gly Tyr Lys Ala Val Phe 50 55 60 GTG GTC TTT GAC GCC AAG GCC CCT TCC TTC CGC CAC GAG GCC TAC GAG 240 Val Val Phe Asp Ala Lys Ala Pro Ser Phe Arg His Glu Ala Tyr Glu 65 70 75 80 GCC TAC AAG GCA GGC CGC GCC CCG ACC CCC GAG GAC TTC CCC CGG CAG 288 Ala Tyr Lys Ala Gly Arg Ala Pro Thr Pro Glu Asp Phe Pro Arg Gin 85 90 95 CTC GCC CTC ATC AAG GAG CTG GTG GAC CTC CTG GGG TTT ACT CGC CTC 336 Leu Ala Leu He Lys Glu Leu Val Asp Leu Leu Gly Phe Thr Arg Leu 100 105 110 GAG GTT CCG GGC TTT GAG GCG GAC GAC GTC CTC GCC ACC CTG GCC AAG 384 Glu Val Pro Gly Phe Glu Ala Asp Asp Val Leu Ala Thr Leu Ala Lys 115 120 125 AAG GCG GAA AGG GAG GGG TAC GAG GTG CGC ATC CTC ACC GCC GAC CGG 432 Lys Ala Glu Arg Glu Gly Tyr Glu Val Arg He Leu Thr Ala Asp Arg 130 135 140 GAC CTT TAC CAG CTC GTC TCC GAC CGC GTC GCC GTC CTC CAC CCC GAG 480 Asp Leu Tyr Gin Leu Val Ser Asp Arg Val Ala Val Leu His Pro Glu 145 150 155 160 GGC CAC CTC ATC ACC CCG GAG TGG CTT TGG GAG AAG TAC GGC CTT AAG 528 Gly His Leu He Thr Pro Glu Trp Leu Trp Glu Lys Tyr Gly Leu Lys 165 170 175 CCG GAG CAG TGG GTG GAC TTC CGC GCC CTC GTG GGG GAC CCC TCC GAC 576 Pro Glu Gin Trp Val Asp Phe Arg Ala Leu Val Gly Asp Pro Ser Asp 180 185 190 AAC CTC CCC GGG GTC AAG GGC ATC GGG GAG AAG ACC GCC CTC AAG CTC 624 Asn Leu Pro Gly Val Lys Gly He Gly Glu Lys Thr Ala Leu Lys Leu 195 200 205 CTC AAG GAG TGG GGA AGC CTG GAA AAT ATC CTC AAG AAC CTG GAC CGG 672 Leu Lys Glu Trp Gly Ser Leu Glu Asn He Leu Lys Asn Leu Asp Arg 210 215 220 GTG AAG CCG GAA AGC GTC CGG GAA AGG ATC AAG GCC CAC CTG GAA GAC 720 Val Lys Pro Glu Ser Val Arg Glu Arg He Lys Ala His Leu Clu Asp 225 230 235 240 CTT AAG CTC TCC TTG GAG CTT TCC CGG GTG CGC TCG GAC CTC CCC CTG 768 Leu Lys Leu Ser Leu Glu Leu Ser Arg Val Arg Ser Asp Leu Pro Leu 245 250 255 GAG GTG GAC TTC GCC CGG AGG CGG GAG CCT GAC CGG GAA GGG CTT CGG 816 Glu Val Asp Phe Ala Arg Arg Arg Glu Pro Asp Arg Glu Gly Leu Arg 260 265 270 GCC TTT TTG GAG CGC TTG GAG TTC GGC AGC CTC CTC CAC GAG TTC GGC 864 Ala Phe Leu Glu Arg Leu Glu Phe Gly Ser Leu Leu His Glu Phe Gly 275 280 285 CTC CTC GAG GCC CCC GCC CCC CTG GAG GAG GCC CCC TGG CCC CCG CCG 912 Leu Leu Glu Ala Pro Ala Pro Leu Glu Glu Ala Pro Trp Pro Pro Pro 290 295 300 GAA GGG GCC TTC GTG GGC TTC GTC CTC TCC CGC CCC GAG CCC ATG TGG 960 Glu Gly Ala Phe Val Gly Phe Val Leu Ser Arg Pro Glu Pro Met Trp 305 310 315 320 GCG GAG CTT AAA GCC CTG GCC GCC TGC AAG GAG GGC CGG GTG CAC CGG 1008 Ala Glu Leu Lys Ala Leu Ala Ala Cys Lys Glu Gly Arg Val His Arg 325 330 335 GCA AAG GAC CCC TTG GCG GGG CTA AAG GAC CTC AAG GAG GTC CGA GGC 1056 Ala Lys Asp Pro Leu Ala Gly Leu Lys Asp Leu Lys Glu Val Arg Gly 340 345 350 CTC CTC GCC AAG GAC CTC GCC GTT TTG GCC CTT CGC GAG GGG CTG GAC 1104 Leu Leu Ala Lys Asp Leu Ala Val Leu Ala Leu Arg Glu Gly Leu Asp 355 360 365 CTC GCG CCT TCG GAC GAC CCC ATG CTC CTC GCC TAC CTC CTG GAC CCC 1152 Leu Ala Pro Ser Asp Asp Pro Met Leu Leu Ala Tyr Leu Leu Asp Pro 370 375 380 TCC AAC ACC ACC CCC GAG GGG GTG GCC CGG CGC TAC GGG GGG GAG TGG 1200 Ser Asn Thr Thr Pro Glu Gly Val Ala Arg Arg Tyr Gly Gly Glu Trp 385 390 395 400 ACG GAG GAC GCC GCC CAC CGG GCC CTC CTC GCC GAG CGG CTC CAG CAA 1248 Thr Glu Asp Ala Ala His Arg Ala Leu Leu Ala Glu Arg Leu Gin Gin 405 410 415 AAC CTC TTG GAA CGC CTC AAG GGA GAG GAA AAG CTC CTT TGG CTC TAC 1296 Asn Leu Leu Glu Arg Leu Lys Gly Glu Glu Lys Leu Leu Trp Leu Tyr 420 425 430 CAA GAG GTG GAA AAG CCC CTC TCC CGG GTC CTG GCC CAC ATG GAG GCC 1344 Gin Glu Val Glu Lys Pro Leu Ser Arg Val Leu Ala His Met Glu Ala 435 440 445 ACC GGG GTA AGG CTG GAC GTG GCC TAT CTA AAG GCC CTT TCC CTG GAG 1392 Thr Gly Val Arg Leu Asp Val Ala Tyr Leu Lys Ala Leu Ser Leu Glu 450 455 460 CTT GCG GAG GAG ATT CGC CGC CTC GAG GAG GAG GTC TTC CGC CTG GCG 1440 Leu Ala Glu Glu He Arg Arg Leu Glu Glu Glu Val Phe Arg Leu Ala 465 470 475 480 GGC CAC CCC TTC AAC CTG AAC TCC CGT GAC CAG CTA GAG CGG GTG CTC 1488 Gly His Pro Phe Asn Leu Asn Ser Arg Asp Gin Leu Glu Arg Val Leu 485 490 495 TTT GAC GAG CTT AGG CTT CCC GCC CTG GGC AAG ACG CAA AAG ACG GGG 1536 Phe Asp Glu Leu Arg Leu Pro Ala Leu Gly Lys Thr Gin Lys Thr Gly 500 505 510 AAG CGC TCC ACC AGC GCC GCG GTG CTG GAG GCC CTC AGG GAG GCC CAC 1584 Lys Arg Ser Thr Ser Ala Ala Val Leu Glu Ala Leu Arg Glu Ala His 515 520 525 CCC ATC GTG GAG AAG ATC CTC CAG CAC CGG GAG CTC ACC AAG CTC AAG 1632 Pro He Val Glu Lys He Leu Gin His Arg Glu Leu Thr Lys Leu Lys 530 535 540 AAC ACC TAC GTG GAC CCC CTC CCG GGC CTC GTC CAC CCG AGG ACG GGC 1680 Asn Thr Tyr Val Asp Pro Leu Pro Gly Leu Val His Pro Arg Thr Gly 545 550 555 560 CGC CTC CAC ACC CGC TTC AAC CAG ACA GCC ACG GCC ACG GGA AGG CTC 1728 Arg Leu His Thr Arg Phe Asn Gin Thr Ala Thr Ala Thr Gly Arg Leu 565 570 575 TCT AGC TCC GAC CCC AAC CTG CAG AAC ATC CCC ATC CGC ACC CCC TTG 1776 Ser Ser Ser Asp Pro Asn Leu Gin Asn He Pro He Arg Thr Pro Leu 580 585 590 GGC CAG AGG ATC CGC CGG GCC TTC GTG GCC GAG GCG GGA TGG GCG TTG 1824 Gly Gin Arg He Arg Arg Ala Phe Val Ala Glu Ala Gly Trp Ala Leu 595 600 605 GTG GCC CTG GAC TAT AGC CAG ATA GAG CTC CGG GTC CTC GCC CAC CTC 1872 Val Ala Leu Asp Tyr Ser Gin He Glu Leu Arg Val Leu Ala His Leu 610 615 620 TCC GGG GAC GAG AAC CTG ATC AGG GTC TTC CAG GAG GGG AAG GAC ATC 1920 Ser Gly Asp Glu Asn Leu He Arg Val Phe Gin Glu Gly Lys Asp He 625 630 635 640 CAC ACC CAG ACC GCA AGC TGG ATG TTC GGC GTC TCC CCG GAG GCC GTG 1968 His Thr Gin Thr Ala Ser Trp Met Phe Gly Val Ser Pro Glu Ala Val 645 650 655 GAC CCC CTG ATG CGC CGG GCG GCC AAG ACG GTG AAC TTC GGC GTC CTC 2016 Asp Pro Leu Met Arg Arg Ala Ala Lys Thr Val Asn Phe Gly Val Leu 660 665 670 TAC GGC ATG TCC GCC CAT AGG CTC TCC CAG GAG CTT GCC ATC CCC TAC 2064 Tyr Gly Met Ser Ala His Arg Leu Ser Gin Glu Leu Ala He Pro Tyr 675 680 685 GAG GAG GCG GTG GCC TTT ATA GAG CGC TAC TTC CAA AGC TTC CCC AAG 2112 Glu Glu Ala Val Ala Phe He Glu Arg Tyr Phe Gin Ser Phe Pro Lys 690 695 700 GTG CGG GCC TGG ATA GAA AAG ACC CTG GAG GAG GGG AGG AAG CGG GGC 2160 Val Arg Ala Trp He Glu Lys Thr Leu Glu Glu Gly Arg Lys Arg Gly 705 710 715 720 TAC GTG GAA ACC CTC TTC GGA AGA AGG CGC TAC GTG CCC GAC CTC AAC 2208 Tyr Val Glu Thr Leu Phe Gly Arg Arg Arg Tyr Val Pro Asp Leu Asn 725 730 735 GCC CGG GTG AAG AGC GTC AGG GAG GCC GCG GAG CGC ATG GCC TTC AAC 2256 Ala Arg Val Lys Ser Val Arg Glu Ala Ala Glu Arg Met Ala Phe Asn 740 745 750 ATG CCC GTC CAG GGC ACC GCC GCC GAC CTC ATG AAG CTC GCC ATG GTG 2304 Met Pro Val Gin Gly Thr Ala Ala Asp Leu Met Lys Leu Ala Met Val 755 760 765 AAG CTC TTC CCC CAC CTC CGG GAG ATG GGG GCC CGC ATG CTC CTC CAG 2352 Lys Leu Phe Pro His Leu Arg Glu Met Gly Ala Arg Met Leu Leu Gin 770 775 780 GTC CAC GAC GAG CTC CTC CTG GAG GCC CCC CAA GCG CGG GCC GAG GAG 2400 Val His Asp Glu Leu Leu Leu Glu Ala Pro Gin Ala Arg Ala Glu Glu 785 790 795 800 GTG GCG GCT TTG GCC AAG GAG GCC ATG GAG AAG GCC TAT CCC CTC GCC 2448 Val Ala Ala Leu Ala Lys Glu Ala Met Glu Lys Ala Tyr Pro Leu Ala 805 810 815 GTG CCC CTG GAG GTG GAG GTG GGG ATC GGG GAG GAC TGG CTT TCC GCC 2496 Val Pro Leu Glu Val Glu Val Gly He Gly Glu Asp Trp Leu Ser Ala 820 825 830 AAG GGC TGA 2505 Lys Gly (2) INFORMATION FOR SEQ ID NO:8: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 834 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:8: Met Lys Ala Met Leu Pro Leu Phe Glu Pro Lys Gly Arg Val Leu Leu 1 5 10 15 Val Asp Gly His His Leu Ala Tyr Arg Thr Phe Phe Ala Leu Lys Gly 20 25 30 Leu Thr Thr Ser Arg Gly Glu Pro Val Gin Ala Val Tyr Gly Phe Ala 35 40 45 Lys Ser Leu Leu Lys Ala Leu Lys Glu Asp Gly Tyr Lys Ala Val Phe 50 55 60 Val Val Phe Asp Ala Lys Ala Pro Ser Phe Arg His Glu Ala Tyr Glu 65 70 75 80 Ala Tyr Lys Ala Gly Arg Ala Pro Thr Pro Glu Asp Phe Pro Arg Gin 85 90 95 Leu Ala Leu He Lys Glu Leu Val Asp Leu Leu Gly Phe Thr Arg Leu 100 105 110 Glu Val Pro Gly Phe Glu Ala Asp Asp Val Leu Ala Thr Leu Ala Lys 115 120 125 Lys Ala Glu Arg Glu Gly Tyr Glu Val Arg He Leu Thr Ala Asp Arg 130 135 140 Asp Leu Tyr Gin Leu Val Ser Asp Arg Val Ala Val Leu His Pro Glu 145 150 155 160 Gly His Leu He Thr Pro Glu Trp Leu Trp Glu Lys Tyr Gly Leu Lys 165 170 175 Pro Glu Gin Trp Val Asp Phe Arg Ala Leu Val Gly Asp Pro Ser Asp 180 185 190 Asn Leu Pro Gly Val Lys Gly He Gly Glu Lys Thr Ala Leu Lys Leu 195 200 205 Leu Lys Glu Trp Gly Ser Leu Glu Asn He Leu Lys Asn Leu Asp Arg 210 215 220 Val Lys Pro Glu Ser Val Arg Glu Arg He Lys Ala His Leu Glu Asp 225 230 235 240 Leu Lys Leu Ser Leu Glu Leu Ser Arg Val Arg Ser Asp Leu Pro Leu 245 250 255 Glu Val Asp Phe Ala Arg Arg Arg Glu Pro Asp Arg Glu Gly Leu Arg 260 265 270 Ala Phe Leu Glu Arg Leu Glu Phe Gly Ser Leu Leu His Glu Phe Gly 275 280 285 Leu Leu Glu Ala Pro Ala Pro Leu Glu Glu Ala Pro Trp Pro Pro Pro 290 295 300 Glu Gly Ala Phe Val Gly Phe Val Leu Ser Arg Pro Glu Pro Met Trp 305 310 315 320 Ala Glu Leu Lys Ala Leu Ala Ala Cys Lys Glu Gly Arg Val His Arg 325 330 335 Ala Lys Asp Pro Leu Ala Gly Leu Lys Asp Leu Lys Glu Val Arg Gly 340 345 350 Leu Leu Ala Lys Asp Leu Ala Val Leu Ala Leu Arg Glu Gly Leu Asp 355 360 365 Leu Ala Pro Ser Asp Asp Pro Met Leu Leu Ala Tyr Leu Leu Asp Pro 370 375 380 Ser Asn Thr Thr Pro Glu Gly Val Ala Arg Arg Tyr Gly Gly Glu Trp 385 390 395 400 Thr Glu Asp Ala Ala His Arg Ala Leu Leu Ala Glu Arg Leu Gin Gin 405 410 415 Asn Leu Leu Glu Arg Leu Lys Gly Glu Glu Lys Leu Leu Trp Leu Tyr 420 425 430 Gin Glu Val Glu Lys Pro Leu Ser Arg Val Leu Ala His Met Glu Ala 435 440 445 Thr Gly Val Arg Leu Asp Val Ala Tyr Leu Lys Ala Leu Ser Leu Glu 450 455 460 Leu Ala Glu Glu He Arg Arg Leu Glu Glu Glu Val Phe Arg Leu Ala 465 470 475 480 Gly His Pro Phe Asn Leu Asn Ser Arg Asp Gin Leu Glu Arg Val Leu 485 490 495 Phe Asp Glu Leu Arg Leu Pro Ala Leu Gly Lys Thr Gin Lys Thr Gly 500 505 510 Lys Arg Ser Thr Ser Ala Ala Val Leu Glu Ala Leu Arg Glu Ala His 515 520 525 Pro He Val Glu Lys He Leu Gin His Arg Glu Leu Thr Lys Leu Lys 530 535 540 Asn Thr Tyr Val Asp Pro Leu Pro Gly Leu Val His Pro Arg Thr Gly 545 550 555 560 Arg Leu His Thr Arg Phe Asn Gin Thr Ala Thr Ala Thr Gly Arg Leu 565 570 575 Ser Ser Ser Asp Pro Asn Leu Gin Asn He Pro He Arg Thr Pro Leu 580 585 590 Gly Gin Arg He Arg Arg Ala Phe Val Ala Glu Ala Gly Trp Ala Leu 595 600 605 Val Ala Leu Asp Tyr Ser Gin He Glu Leu Arg Val Leu Ala His Leu 610 615 620 Ser Gly Asp Glu Asn Leu He Arg Val Phe Gin Glu Gly Lys Asp He 625 630 635 640 His Thr Gin Thr Ala Ser Trp Met Phe Gly Val Ser Pro Glu Ala Val 645 650 655 Asp Pro Leu Met Arg Arg Ala Ala Lys Thr Val Asn Phe Gly Val Leu 660 665 670 Tyr Gly Met Ser Ala His Arg Leu Ser Gin Glu Leu Ala He Pro Tyr 675 680 685 Glu Glu Ala Val Ala Phe He Glu Arg Tyr Phe Gin Ser Phe Pro Lys 690 695 700 Val Arg Ala Trp He Glu Lys Thr Leu Glu Glu Gly Arg Lys Arg Gly 705 710 715 720 Tyr Val Glu Thr Leu Phe Gly Arg Arg Arg Tyr Val Pro Asp Leu Asn 725 730 735 Ala Arg Val Lys Ser Val Arg Glu Ala Ala Glu Arg Met Ala Phe Asn 740 745 750 Met Pro Val Gin Gly Thr Ala Ala Asp Leu Met Lys Leu Ala Met Val 755 760 765 Lys Leu Phe Pro His Leu Arg Glu Met Gly Ala Arg Met Leu Leu Gin 770 775 780 Val His Asp Glu Leu Leu Leu Glu Ala Pro Gin Ala Arg Ala Glu Glu 785 790 795 800 Val Ala Ala Leu Ala Lys Glu Ala Met Glu Lys Ala Tyr Pro Leu Ala 805 810 815 Val Pro Leu Glu Val Glu Val Gly He Gly Glu Asp Trp Leu Ser Ala 820 825 830 Lys Gly (2) INFORMATION FOR SEQ ID NO:9: (I) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2505 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Thermus thermophilus (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..2502 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:9: ATG GAG GCG ATG CTT CCG CTC TTT GAA CCC AAA GGC CGG GTC CTC CTG 48 Met Glu Ala Met Leu Pro Leu Phe Glu Pro Lys Gly Arg Val Leu Leu 1 5 10 15 GTG GAC GGC CAC CAC CTG GCC TAC CGC ACC TTC TTC GCC CTG AAG GGC 96 Val Asp Gly His His Leu Ala Tyr Arg Thr Phe Phe Ala Leu Lys Gly 20 25 30 CTC ACC ACG AGC CGG GGC GAA CCG GTG CAG GCG GTC TAC GGC TTC GCC 144 Leu Thr Thr Ser Arg Gly Glu Pro Val Gin Ala Val Tyr Gly Phe Ala 35 40 45 AAG AGC CTC CTC AAG GCC CTG AAG GAG GAC GGG TAC AAG GCC GTC TTC 192 Lys Ser Leu Leu Lys Ala Leu Lys Glu Asp Gly Tyr Lys Ala Val Phe 50 55 60 GTG GTC TTT GAC GCC AAG GCC CCC TCC TTC CGC CAC GAG GCC TAC GAG 240 Val Val Phe Asp Ala Lys Ala Pro Ser Phe Arg His Glu Ala Tyr Glu 65 70 75 80 GCC TAC AAG GCG GGG AGG GCC CCG ACC CCC GAG GAC TTC CCC CGG CAG 288 Ala Tyr Lys Ala Gly Arg Ala Pro Thr Pro Glu Asp Phe Pro Arg Gin 85 90 95 CTC GCC CTC ATC AAG GAG CTG GTG GAC CTC CTG GGG TTT ACC CGC CTC 336 Leu Ala Leu He Lys Glu Leu Val Asp Leu Leu Gly Phe Thr Arg Leu 100 105 110 GAG GTC CCC GGC TAC GAG GCG GAC GAC GTT CTC GCC ACC CTG GCC AAG 384 Glu Val Pro Gly Tyr Glu Ala Asp Asp Val Leu Ala Thr Leu Ala Lys 115 120 125 AAG GCG GAA AAG GAG GGG TAC GAG GTG CGC ATC CTC ACC GCC GAC CGC 432 Lys Ala Glu Lys Glu Gly Tyr Glu Val Arg He Leu Thr Ala Asp Arg 130 135 140 GAC CTC TAC CAA CTC GTC TCC GAC CGC GTC GCC GTC CTC CAC CCC GAG 480 Asp Leu Tyr Gin Leu Val Ser Asp Arg Val Ala Val Leu His Pro Glu 145 150 155 160 GGC CAC CTC ATC ACC CCG GAG TGG CTT TGG GAG AAG TAC GGC CTC AGG 528 Gly His Leu He Thr Pro Glu Trp Leu Trp Glu Lys Tyr Gly Leu Arg 165 170 175 CCG GAG CAG TGG GTG GAC TTC CGC GCC CTC GTG GGG GAC CCC TCC GAC 576 Pro Glu Gin Trp Val Asp Phe Arg Ala Leu Val Gly Asp Pro Ser Asp 180 185 190 AAC CTC CCC GGG GTC AAG GGC ATC GGG GAG AAG ACC GCC CTC AAG CTC 624 Asn Leu Pro Gly Val Lys Gly He Gly Glu Lys Thr Ala Leu Lys Leu 195 200 205 CTC AAG GAG TGG GGA AGC CTG GAA AAC CTC CTC AAG AAC CTG GAC CGG 672 Leu Lys Glu Trp Gly Ser Leu Glu Asn Leu Leu Lys Asn Leu Asp Arg 210 215 220 GTA AAG CCA GAA AAC GTC CGG GAG AAG ATC AAG GCC CAC CTG GAA GAC 720 Val Lys Pro Glu Asn Val Arg Glu Lys He Lys Ala His Leu Clu Asp 225 230 235 240 CTC AGG CTC TCC TTG GAG CTC TCC CGG GTG CGC ACC GAC CTC CCC CTG 768 Leu Arg Leu Ser Leu Glu Leu Ser Arg Val Arg Thr Asp Leu Pro Leu 245 250 255 GAG GTG GAC CTC GCC CAG GGG CGG GAG CCC GAC CGG GAG GGG CTT AGG 816 Glu Val Asp Leu Ala Gin Gly Arg Glu Pro Asp Arg Glu Gly Leu Arg 260 265 270 GCC TTC CTG GAG AGG CTG GAG TTC GGC AGC CTC CTC CAC GAG TTC GGC 864 Ala Phe Leu Glu Arg Leu Glu Phe Gly Ser Leu Leu His Glu Phe Gly 275 280 285 CTC CTG GAG GCC CCC GCC CCC CTG GAG GAG GCC CCC TGG CCC CCG CCG 912 Leu Leu Glu Ala Pro Ala Pro Leu Glu Glu Ala Pro Trp Pro Pro Pro 290 295 300 GAA GGG GCC TTC GTG GGC TTC GTC CTC TCC CGC CCC GAG CCC ATG TGG 960 Glu Gly Ala Phe Val Gly Phe Val Leu Ser Arg Pro Glu Pro Met Trp 305 310 315 320 GCG GAG CTT AAA GCC CTG GCC GCC TGC AGG GAC GGC CGG GTG CAC CGG 1008 Ala Glu Leu Lys Ala Leu Ala Ala Cys Arg Asp Gly Arg Val His Arg 325 330 335 GCA GCA GAC CCC TTG GCG GGG CTA AAG GAC CTC AAG GAG GTC CGG GGC 1056 Ala Ala Asp Pro Leu Ala Gly Leu Lys Asp Leu Lys Glu Val Arg Gly 340 345 350 CTC CTC GCC AAG GAC CTC GCC GTC TTG GCC TCG AGG GAG GGG CTA GAC 1104 Leu Leu Ala Lys Asp Leu Ala Val Leu Ala Ser Arg Glu Gly Leu Asp 355 360 365 CTC GTG CCC GGG GAC GAC CCC ATG CTC CTC GCC TAC CTC CTG GAC CCC 1152 Leu Val Pro Gly Asp Asp Pro Met Leu Leu Ala Tyr Leu Leu Asp Pro 370 375 380 TCC AAC ACC ACC CCC GAG GGG GTG GCG CGG CGC TAC GGG GGG GAG TGG 1200 Ser Asn Thr Thr Pro Glu Gly Val Ala Arg Arg Tyr Gly Gly Glu Trp 385 390 395 400 ACG GAG GAC GCC GCC CAC CGG GCC CTC CTC TCG GAG AGG CTC CAT CGG 1248 Thr Glu Asp Ala Ala His Arg Ala Leu Leu Ser Glu Arg Leu His Arg 405 410 --15 AAC CTC CTT AAG CGC CTC GAG GGG GAG GAG AAG CTC CTT TGG CTC TAC 1296 Asn Leu Leu Lys Arg Leu Glu Gly Glu Glu Lys Leu Leu Trp Leu Tyr 420 425 430 CAC GAG GTG GAA AAG CCC CTC TCC CGG GTC CTG GCC CAC ATG GAG GCC 1344 His Glu Val Glu Lys Pro Leu Ser Arg Val Leu Ala His Met Glu Ala 435 440 445 ACC GGG GTA CGG CTG GAC GTG GCC TAC CTT CAG GCC CTT TCC CTG GAG 1392 Thr Gly Val Arg Leu Asp Val Ala Tyr Leu Gin Ala Leu Ser Leu Glu 450 455 460 CTT GCG GAG GAG ATC CGC CGC CTC GAG GAG GAG GTC TTC CGC TTG GCG 1440 Leu Ala Glu Glu He Arg Arg Leu Glu Glu Glu Val Phe Arg Leu Ala 465 470 475 480 GGC CAC CCC TTC AAC CTC AAC TCC CGG GAC CAG CTG GAA AGG GTG CTC 1488 Gly His Pro Phe Asn Leu Asn Ser Arg Asp Gin Leu Glu Arg Val Leu 485 490 495 TTT GAC GAG CTT AGG CTT CCC GCC TTG GGG AAG ACG CAA AAG ACA GGC 1536 Phe Asp Glu Leu Arg Leu Pro Ala Leu Gly Lys Thr Gin Lys Thr Gly 500 505 510 AAG CGC TCC ACC AGC GCC GCG GTG CTG GAG GCC CTA CGG GAG GCC CAC 1584 Lys Arg Ser Thr Ser Ala Ala Val Leu Glu Ala Leu Arg Glu Ala His 515 520 525 CCC ATC GTG GAG AAG ATC CTC CAG CAC CGG GAG CTC ACC AAG CTC AAG 1632 Pro He Val Glu Lys He Leu Gin His Arg Glu Leu Thr Lys Leu Lys 530 535 540 AAC ACC TAC GTG GAC CCC CTC CCA AGC CTC GTC CAC CCG AGG ACG GGC 1680 Asn Thr Tyr Val Asp Pro Leu Pro Ser Leu Val His Pro Arg Thr Gly 545 550 555 560 CGC CTC CAC ACC CGC TTC AAC CAG ACG GCC ACG GCC ACG GGG AGG CTT 1728 Arg Leu His Thr Arg Phe Asn Gin Thr Ala Thr Ala Thr Gly Arg Leu 565 570 575 AGT AGC TCC GAC CCC AAC CTG CAG AAC ATC CCC GTC CGC ACC CCC TTG 1776 Ser Ser Ser Asp Pro Asn Leu Gin Asn He Pro Val Arg Thr Iro Leu 580 585 590 GGC CAG AGG ATC CGC CGG GCC TTC GTG GCC GAG GCG GGT TGG GCG TTG 1824 Gly Gin Arg He Arg Arg Ala Phe Val Ala Glu Ala Gly Trp Ala Leu 595 600 605 GTG GCC CTG GAC TAT AGC CAG ATA GAG CTC CGC GTC CTC GCC CAC CTC 1872 Val Ala Leu Asp Tyr Ser Gin He Glu Leu Arg Val Leu Ala His Leu 610 615 620 TCC GGG GAC GAA AAC CTG ATC AGG GTC TTC CAG GAG GGG AAG GAC ATC 1920 Ser Gly Asp Glu Asn Leu He Arg Val Phe Gin Glu Gly Lys Asp He 625 630 635 640 CAC ACC CAG ACC GCA AGC TGG ATG TTC GGC GTC CCC CCG GAG GCC GTG 1968 His Thr Gin Thr Ala Ser Trp Met Phe Gly Val Pro Pro Glu Ala Val 645 650 655 GAC CCC CTG ATG CGC CGG GCG GCC AAG ACG GTG AAC TTC GGC GTC CTC 2016 Asp Pro Leu Met Arg Arg Ala Ala Lys Thr Val Asn Phe Gly Val Leu 660 665 670 TAC GGC ATG TCC GCC CAT AGG CTC TCC CAG GAG CTT GCC ATC CCC TAC 2064 Tyr Gly Met Ser Ala His Arg Leu Ser Gin Glu Leu Ala He Pro Tyr 675 680 685 GAG GAG GCG GTG GCC TTT ATA GAG CGC TAC TTC CAA AGC TTC CCC AAG 2112 Glu Glu Ala Val Ala Phe He Glu Arg Tyr Phe Gin Ser Phe Pro Lys 690 695 700 GTG CGG GCC TGG ATA GAA AAG ACC CTG GAG GAG GGG AGG AAG CGG GGC 2160 Val Arg Ala Trp He Glu Lys Thr Leu Glu Glu Gly Arg Lys Arg Gly 705 710 715 720 TAC GTG GAA ACC CTC TTC GGA AGA AGG CGC TAC GTG CCC GAC CTC AAC 2208 Tyr Val Glu Thr Leu Phe Gly Arg Arg Arg Tyr Val Pro Asp Leu Asn 725 730 735 GCC CGG GTG AAG AGC GTC AGG GAG GCC GCG GAG CGC ATG GCC TTC AAC 2256 Ala Arg Val Lys Ser Val Arg Glu Ala Ala Glu Arg Met Ala Phe Asn 740 745 750 ATG CCC GTC CAG GGC ACC GCC GCC GAC CTC ATG AAG CTC GCC ATG GTG 2304 Met Pro Val Gin Gly Thr Ala Ala Asp Leu Met Lys Leu Ala Met Val 755 760 765 AAG CTC TTC CCC CGC CTC CGG GAG ATG GGG GCC CGC ATG CTC CTC CAG 2352 Lys Leu Phe Pro Arg Leu Arg Glu Met Gly Ala Arg Met Leu Leu Gin 770 775 780 GTC CAC GAC GAG CTC CTC CTG GAG GCC CCC CAA GCG CGG GCC GAG GAG 2400 Val His Asp Glu Leu Leu Leu Glu Ala Pro Gin Ala Arg Ala Glu Glu 785 790 795 800 GTG GCG GCT TTG GCC AAG GAG GCC ATG GAG AAG GCC TAT CCC CTC GCC 2448 Val Ala Ala Leu Ala Lys Glu Ala Met Glu Lys Ala Tyr Pro Leu Ala 805 810 815 GTG CCC CTG GAG GTG GAG GTG GGG ATG GGG GAG GAC TGG CTT TCC GCC 2496 Val Pro Leu Glu Val Glu Val Gly Met Gly Glu Asp Trp Leu Ser Ala 820 825 830 AAG GGT TAG 2505 Lys Gly (2) INFORMATION FOR SEQ ID NO:10: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 834 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:10: Met Glu Ala Met Leu Pro Leu Phe Glu Pro Lys Gly Arg Val Leu Leu 1 5 10 15 Val Asp Gly His His Leu Ala Tyr Arg Thr Phe Phe Ala Leu Lys Gly 20 25 30 Leu Thr Thr Ser Arg Gly Glu Pro Val Gin Ala Val Tyr Gly Phe Ala 35 40 45 Lys Ser Leu Leu Lys Ala Leu Lys Glu Asp Gly Tyr Lys Ala Val Phe 50 55 60 Val Val Phe Asp Ala Lys Ala Pro Ser Phe Arg His Glu Ala Tyr Glu 65 70 75 80 Ala Tyr Lys Ala Gly Arg Ala Pro Thr Pro Glu Asp Phe Pro Arg Gin 85 90 95 Leu Ala Leu He Lys Glu Leu Val Asp Leu Leu Gly Phe Thr Arg Leu 100 105 110 Glu Val Pro Gly Tyr Glu Ala Asp Asp Val Leu Ala Thr Leu Ala Lys 115 120 125 Lys Ala Glu Lys Glu Gly Tyr Glu Val Arg He Leu Thr Ala Asp Arg 130 135 140 Asp Leu Tyr Gin Leu Val Ser Asp Arg Val Ala Val Leu His Pro Glu 145 150 155 160 Gly His Leu He Thr Pro Glu Trp Leu Trp Glu Lys Tyr Gly Leu Arg 165 170 175 Pro Glu Gin Trp Val Asp Phe Arg Ala Leu Val Gly Asp Pro Ser Asp 180 185 190 Asn Leu Pro Gly Val Lys Gly He Gly Glu Lys Thr Ala Leu Lys Leu 195 200 205 Leu Lys Glu Trp Gly Ser Leu Glu Asn Leu Leu Lys Asn Leu Asp Arg 210 215 220 Val Lys Pro Glu Asn Val Arg Glu Lys He Lys Ala His Leu Glu Asp 225 230 235 240 Leu Arg Leu Ser Leu Glu Leu Ser Arg Val Arg Thr Asp Leu Pro Leu 245 250 255 Glu Val Asp Leu Ala Gin Gly Arg Glu Pro Asp Arg Glu Gly Leu Arg 260 265 270 Ala Phe Leu Glu Arg Leu Glu Phe Gly Ser Leu Leu His Glu Phe Gly 275 280 285 Leu Leu Glu Ala Pro Ala Pro Leu Glu Glu Ala Pro Trp Pro Pro Pro 290 295 300 Glu Gly Ala Phe Val Gly Phe Val Leu Ser Arg Pro Glu Pro Met Trp 305 310 315 320 Ala Glu Leu Lys Ala Leu Ala Ala Cys Arg Asp Gly Arg Val His Arg 325 330 335 Ala Ala Asp Pro Leu Ala Gly Leu Lys Asp Leu Lys Glu Val Arg Gly 340 345 350 Leu Leu Ala Lys Asp Leu Ala Val Leu Ala Ser Arg Glu Gly Leu Asp 355 360 365 Leu Val Pro Gly Asp Asp Pro Met Leu Leu Ala Tyr Leu Leu Asp Pro 370 375 380 Ser Asn Thr Thr Pro Glu Gly Val Ala Arg Arg Tyr Gly Gly Glu Trp 385 390 395 ' 400 Thr Glu Asp Ala Ala His Arg Ala Leu Leu Ser Glu Arg Leu His Arg 405 410 415 Asn Leu Leu Lys Arg Leu Glu Gly Glu Glu Lys Leu Leu Trp Leu Tyr 420 425 430 His Glu Val Glu Lys Pro Leu Ser Arg Val Leu Ala His Met Glu Ala 435 440 445 Thr Gly Val Arg Leu Asp Val Ala Tyr Leu Gin Ala Leu Ser Leu Glu 450 455 460 Leu Ala Glu Glu He Arg Arg Leu Glu Glu Glu Val Phe Arg Leu Ala 465 470 475 480 Gly His Pro Phe Asn Leu Asn Ser Arg Asp Gin Leu Glu Arg Val Leu 485 490 495 Phe Asp Glu Leu Arg Leu Pro Ala Leu Gly Lys Thr Gin Lys Thr Gly 500 505 510 Lys Arg Ser Thr Ser Ala Ala Val Leu Glu Ala Leu Arg Glu Ala His 515 520 525 Pro He Val Glu Lys He Leu Gin His Arg Glu Leu Thr Lys Leu Lys 530 535 540 Asn Thr Tyr Val Asp Pro Leu Pro Ser Leu Val His Pro Arg Thr Gly 545 550 555 560 Arg Leu His Thr Arg Phe Asn Gin Thr Ala Thr Ala Thr Gly Arg Leu 565 570 575 Ser Ser Ser Asp Pro Asn Leu Gin Asn He Pro Val Arg Thr Pro Leu 580 585 590 Gly Gin Arg He Arg Arg Ala Phe Val Ala Glu Ala Gly Trp Ala Leu 595 600 605 Val Ala Leu Asp Tyr Ser Gin He Glu Leu Arg Val Leu Ala His Leu 610 615 620 Ser Gly Asp Glu Asn Leu He Arg Val Phe Gin Glu Gly Lys Asp He 625 630 635 640 His Thr Gin Thr Ala Ser Trp Met Phe Gly Val Pro Pro Glu Ala Val 645 650 655 Asp Pro Leu Met Arg Arg Ala Ala Lys Thr Val Asn Phe Gly Val Leu 660 665 670 Tyr Gly Met Ser Ala His Arg Leu Ser Gin Glu Leu Ala He Pro Tyr 675 680 685 Glu Glu Ala Val Ala Phe He Glu Arg Tyr Phe Gin Ser Phe Pro Lys 690 695 700 Val Arg Ala Trp He Glu Lys Thr Leu Glu Glu Gly Arg Lys Arg Gly 705 710 715 720 Tyr Val Glu Thr Leu Phe Gly Arg Arg Arg Tyr Val Pro Asp Leu Asn 725 730 735 Ala Arg Val Lys Ser Val Arg Glu Ala Ala Glu Arg Met Ala Phe Asn 740 745 750 Met Pro Val Gin Gly Thr Ala Ala Asp Leu Met Lys Leu Ala Met Val 755 760 765 Lys Leu Phe Pro Arg Leu Arg Glu Met Gly Ala Arg Met Leu Leu Gin 770 775 780 Val His Asp Glu Leu Leu Leu Glu Ala Pro Gin Ala Arg Ala Glu Glu 785 790 795 800 Val Ala Ala Leu Ala Lys Glu Ala Met Glu Lys Ala Tyr Pro Leu Ala 805 810 815 Val Pro Leu Glu Val Glu Val Gly Met Gly Glu Asp Trp Leu Ser Ala 820 825 830 Lys Gly (2) INFORMATION FOR SEQ ID NO:11: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2679 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Thermosipho africanus (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..2676 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:11: ATG GGA AAG ATG TTT CTA TTT GAT GGA ACT GGA TTA GTA TAC AGA GCA 48 Met Gly Lys Met Phe Leu Phe Asp Gly Thr Gly Leu Val Tyr Arg Ala 1 5 10 15 TTT TAT GCT ATA GAT CAA TCT CTT CAA ACT TCG TCT GGT TTA CAC ACT 96 Phe Tyr Ala He Asp Gin Ser Leu Gin Thr Ser Ser Gly Leu His Thr 20 25 30 AAT GCT GTA TAC GGA CTT ACT AAA ATG CTT ATA AAA TTT TTA AAA GAA 144 Asn Ala Val Tyr Gly Leu Thr Lys Met Leu He Lys Phe Leu Lys Glu 35 40 45 CAT ATC AGT ATT GGA AAA GAT GCT TGT GTT TTT GTT TTA GAT TCA AAA 192 His He Ser He Gly Lys Asp Ala Cys Val Phe Val Leu Asp Ser Lys 50 55 60 GGT GGT AGC AAA AAA AGA AAG GAT ATT CTT GAA ACA TAT AAA GCA AAT 240 Gly Gly Ser Lys Lys Arg Lys Asp He Leu Glu Thr Tyr Lys Ala Asn 65 70 75 80 AGG CCA TCA ACG CCT GAT TTA CTT TTA GAG CAA ATT CCA TAT GTA GAA 288 Arg Pro Ser Thr Pro Asp Leu Leu Leu Glu Gin He Pro Tyr Val Glu 85 90 95 GAA CTT GTT GAT GCT CTT GGA ATA AAA GTT TTA AAA ATA GAA GGC TTT 336 Glu Leu Val Asp Ala Leu Gly He Lys Val Leu Lys He Glu Gly Phe 100 105 110 GAA GCT GAT GAC ATT ATT GCT ACG CTT TCT AAA AAA TTT GAA AGT GAT 384 Glu Ala Asp Asp He He Ala Thr Leu Ser Lys Lys Phe Glu Ser Asp 115 120 125 TTT GAA AAG GTA AAC ATA ATA ACT GGA GAT AAA GAT CTT TTA CAA CTT 432 Phe Glu Lys Val Asn He He Thr Gly Asp Lys Asp Leu Leu Cln Leu 130 135 140 GTT TCT GAT AAG GTT TTT GTT TGG AGA GTA GAA AGA GGA ATA ACA GAT 480 Val Ser Asp Lys Val Phe Val Trp Arg Val Glu Arg Gly He Thr Asp 145 150 155 160 TTG GTA TTG TAC GAT AGA AAT AAA GTG ATT GAA AAA TAT GGA ATC TAC 528 Leu Val Leu Tyr Asp Arg Asn Lys Val He Glu Lys Tyr Gly He Tyr 165 170 175 CCA GAA CAA TTC AAA GAT TAT TTA TCT CTT GTC GGT GAT CAG ATT GAT 576 Pro Glu Gin Phe Lys Asp Tyr Leu Ser Leu Val Gly Asp Gin He Asp 180 185 190 AAT ATC CCA GGA GTT AAA GGA ATA GGA AAG AAA ACA GCT GTT TCG CTT 624 Asn He Pro Gly Val Lys Gly He Gly Lys Lys Thr Ala Val Ser Leu 195 200 205 TTG AAA AAA TAT AAT AGC TTG GAA AAT GTA TTA AAA AAT ATT AAC CTT 672 Leu Lys Lys Tyr Asn Ser Leu Glu Asn Val Leu Lys Asn He Asn Leu 210 215 220 TTG ACG GAA AAA TTA AGA AGG CTT TTG GAA GAT TCA AAG GAA GAT TTG 720 Leu Thr Glu Lys Leu Arg Arg Leu Leu Glu Asp Ser Lys Glu Asp Leu 225 230 235 240 CAA AAA AGT ATA GAA CTT GTG GAG TTG ATA TAT GAT GTA CCA ATG GAT 768 Gin Lys Ser He Glu Leu Val Glu Leu He Tyr Asp Val Pro Met Asp 245 250 255 GTG GAA AAA GAT GAA ATA ATT TAT AGA GGG TAT AAT CCA GAT AAG CTT 816 Val Glu Lys Asp Glu He He Tyr Arg Gly Tyr Asn Pro Asp Lys Leu 260 265 270 TTA AAG GTA TTA AAA AAG TAC GAA TTT TCA TCT ATA ATT AAG GAG TTA 864 Leu Lys Val Leu Lys Lys Tyr Glu Phe Ser Ser He He Lys C-lu Leu 275 280 285 AAT TTA CAA GAA AAA TTA GAA AAG GAA TAT ATA CTG GTA GAT AAT GAA 912 Asn Leu Gin Glu Lys Leu Glu Lys Glu Tyr He Leu Val Asp Asn Glu 290 295 300 GAT AAA TTG AAA AAA CTT GCA GAA GAG ATA GAA AAA TAC AAA ACT TTT 960 Asp Lys Leu Lys Lys Leu Ala Glu Glu He Glu Lys Tyr Lys Thr Phe 305 310 315 320 TCA ATT GAT ACG GAA ACA ACT TCA CTT GAT CCA TTT GAA GCT AAA CTG 1008 Ser He Asp Thr Glu Thr Thr Ser Leu Asp Pro Phe Glu Ala Lys Leu 325 330 335 GTT GGG ATC TCT ATT TCC ACA ATG GAA GGG AAG GCG TAT TAT ATT CCG 1056 Val Gly He Ser He Ser Thr Met Glu Gly Lys Ala Tyr Tyr He Pro 340 345 350 GTG TCT CAT TTT GGA GCT AAG AAT ATT TCC AAA AGT TTA ATA GAT AAA 1104 Val Ser His Phe Gly Ala Lys Asn He Ser Lys Ser Leu He Asp Lys 355 360 365 TTT CTA AAA CAA ATT TTG CAA GAG AAG GAT TAT AAT ATC GTT GGT CAG 1152 Phe Leu Lys Gin He Leu Gin Glu Lys Asp Tyr Asn He Val Gly Gin 370 375 380 AAT TTA AAA TTT GAC TAT GAG ATT TTT AAA AGC ATG GGT TTT TCT CCA 1200 Asn Leu Lys Phe Asp Tyr Glu He Phe Lys Ser Met Gly Phe Ser Pro 385 390 395 400 AAT GTT CCG CAT TTT GAT ACG ATG ATT GCA GCC TAT CTT TTA AAT CCA 1248 Asn Val Pro His Phe Asp Thr Met He Ala Ala Tyr Leu Leu Asn Pro 405 410 415 GAT GAA AAA CGT TTT AAT CTT GAA GAG CTA TCC TTA AAA TAT TTA GGT 1296 Asp Glu Lys Arg Phe Asn Leu Glu Glu Leu Ser Leu Lys Tyr Leu Gly 420 425 430 TAT AAA ATG ATC TCG TTT GAT GAA TTA GTA AAT GAA AAT GTA CCA TTG 1344 Tyr Lys Met He Ser Phe Asp Glu Leu Val Asn Glu Asn Val Pro Leu 435 440 445 TTT GGA AAT GAC TTT TCG TAT GTT CCA CTA GAA AGA GCC GTT GAG TAT 1392 Phe Gly Asn Asp Phe Ser Tyr Val Pro Leu Glu Arg Ala Val Glu Tyr 450 455 460 TCC TGT GAA GAT GCC GAT GTG ACA TAC AGA ATA TTT AGA AAG CTT GGT 1440 Ser Cys Glu Asp Ala Asp Val Thr Tyr Arg He Phe Arg Lys Leu Gly 465 470 475 480 AGG AAG ATA TAT GAA AAT GAG ATG GAA AAG TTG TTT TAC GAA ATT GAG 1488 Arg Lys He Tyr Glu Asn Glu Met Glu Lys Leu Phe Tyr Glu He Glu 485 490 495 ATG CCC TTA ATT GAT GTT CTT TCA GAA ATG GAA CTA AAT GGA GTG TAT 1536 Met Pro Leu He Asp Val Leu Ser Glu Met Glu Leu Asn Gly Val Tyr 500 505 510 TTT GAT GAG GAA TAT TTA AAA GAA TTA TCA AAA AAA TAT CAA GAA AAA 1584 Phe Asp Glu Glu Tyr Leu Lys Glu Leu Ser Lys Lys Tyr Gin C-lu Lys 515 520 525 ATG GAT GGA ATT AAG GAA AAA GTT TTT GAG ATA GCT GGT GAA ACT TTC 1632 Met Asp Gly He Lys Glu Lys Val Phe Glu He Ala Gly Glu Thr Phe 530 535 540 AAT TTA AAC TCT TCA ACT CAA GTA GCA TAT ATA CTA TTT GAA AAA TTA 1680 Asn Leu Asn Ser Ser Thr Gin Val Ala Tyr He Leu Phe Glu Lys Leu 545 550 555 560 AAT ATT GCT CCT TAC AAA AAA ACA GCG ACT GGT AAG TTT TCA ACT AAT 1728 Asn He Ala Pro Tyr Lys Lys Thr Ala Thr Gly Lys Phe Ser Thr Asn 565 570 575 GCG GAA GTT TTA GAA GAA CTT TCA AAA GAA CAT GAA ATT GCA AAA TTG 1776 Ala Glu Val Leu Glu Glu Leu Ser Lys Glu His Glu He Ala Lys Leu 580 585 590 TTG CTG GAG TAT CGA AAG TAT CAA AAA TTA AAA AGT ACA TAT ATT GAT 1824 Leu Leu Glu Tyr Arg Lys Tyr Gin Lys Leu Lys Ser Thr Tyr He Asp 595 600 605 TCA ATA CCG TTA TCT ATT AAT CGA AAA ACA AAC AGG GTC CAT ACT ACT 1872 Ser He Pro Leu Ser He Asn Arg Lys Thr Asn Arg Val His Thr Thr 610 615 620 TTT CAT CAA ACA GGA ACT TCT ACT GGA AGA TTA AGT AGT TCA AAT CCA 1920 Phe His Gin Thr Gly Thr Ser Thr Gly Arg Leu Ser Ser Ser Asn Pro 625 630 635 640 AAT TTG CAA AAT CTT CCA ACA AGA AGC GAA GAA GGA AAA GAA ATA AGA 1968 Asn Leu Gin Asn Leu Pro Thr Arg Ser Glu Glu Gly Lys Glu He Arg 645 650 655 AAA GCA GTA AGA CCT CAA AGA CAA GAT TGG TGG ATT TTA GGT GCT GAC 2016 Lys Ala Val Arg Pro Gin Arg Gin Asp Trp Trp He Leu Gly Ala Asp 660 665 670 TAT TCT CAG ATA GAA CTA AGG GTT TTA GCG CAT GTA AGT AAA GAT GAA 2064 Tyr Ser Gin He Glu Leu Arg Val Leu Ala His Val Ser Lys Asp Glu 675 680 685 AAT CTA CTT AAA GCA TTT AAA GAA GAT TTA GAT ATT CAT ACA ATT ACT 2112 Asn Leu Leu Lys Ala Phe Lys Glu Asp Leu Asp He His Thr He Thr 690 695 700 GCT GCC AAA ATT TTT GGT GTT TCA GAG ATG TTT GTT AGT GAA CAA ATG 2160 Ala Ala Lys He Phe Gly Val Ser Glu Met Phe Val Ser Glu C.ln Met 705 710 715 720 AGA AGA GTT GGA AAG ATG GTA AAT TTT GCA ATT ATT TAT GGA GTT TCA 2208 Arg Arg Val Gly Lys Met Val Asn Phe Ala He He Tyr Gly Val Ser 725 730 735 CCT TAT GGT CTT TCA AAG AGA ATT GGT CTT AGT GTT TCA GAG ACT AAA 2256 Pro Tyr Gly Leu Ser Lys Arg He Gly Leu Ser Val Ser Glu Thr Lys 740 745 750 AAA ATA ATA GAT AAC TAT TTT AGA TAC TAT AAA GGA GTT TTT GAA TAT 2304 Lys He He Asp Asn Tyr Phe Arg Tyr Tyr Lys Gly Val Phe Glu Tyr 755 760 765 TTA AAA AGG ATG AAA GAT GAA GCA AGG AAA AAA GGT TAT GTT ACA ACG 2352 Leu Lys Arg Met Lys Asp Glu Ala Arg Lys Lys Gly Tyr Val Thr Thr 770 775 780 CTT TTT GGA AGG CGC AGA TAT ATT CCA CAG TTA AGA TCG AAA AAT GGT 2400 Leu Phe Gly Arg Arg Arg Tyr He Pro Gin Leu Arg Ser Lys Asn Gly 785 790 795 800 AAT AGA GTT CAA GAA GGA GAA AGA ATA GCT GTA AAC ACT CCA ATT CAA 2448 Asn Arg Val Gin Glu Gly Glu Arg He Ala Val Asn Thr Pro He Gin 805 810 815 GGA ACA GCA GCT GAT ATA ATA AAG ATA GCT ATG ATT AAT ATT CAT AAT 2496 Gly Thr Ala Ala Asp He He Lys He Ala Met He Asn He His Asn 820 825 830 AGA TTG AAG AAG GAA AAT CTA CGT TCA AAA ATG ATA TTG CAG GTT CAT 2544 Arg Leu Lys Lys Glu Asn Leu Arg Ser Lys Met He Leu Gin al His 835 840 845 GAC GAG TTA GTT TTT GAA GTG CCC GAT AAT GAA CTG GAG ATT GTA AAA 2592 Asp Glu Leu Val Phe Glu Val Pro Asp Asn Glu Leu Glu He Val Lys 850 855 860 GAT TTA GTA AGA GAT GAG ATG GAA AAT GCA GTT AAG CTA GAC GTT CCT 2640 Asp Leu Val Arg Asp Glu Met Glu Asn Ala Val Lys Leu Asp Val Pro 865 870 875 880 TTA AAA GTA GAT GTT TAT TAT GGA AAA GAG TGG GAA TAA 2679 Leu Lys Val Asp Val Tyr Tyr Gly Lys Glu Trp Glu 885 890 (2) INFORMATION FOR SEQ ID NO:12: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 892 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:12: Met Gly Lys Met Phe Leu Phe Asp Gly Thr Gly Leu Val Tyr Arg Ala 1 5 10 15 Phe Tyr Ala He Asp Gin Ser Leu Gin Thr Ser Ser Gly Leu His Thr 20 25 30 Asn Ala Val Tyr Gly Leu Thr Lys Met Leu He Lys Phe Leu Lys Glu 35 40 45 His He Ser He Gly Lys Asp Ala Cys Val Phe Val Leu Asp Ser Lys 50 55 60 Gly Gly Ser Lys Lys Arg Lys Asp He Leu Glu Thr Tyr Lys Ala Asn 65 70 75 80 Arg Pro Ser Thr Pro Asp Leu Leu Leu Glu Gin He Pro Tyr Val Glu 85 90 95 Glu Leu Val Asp Ala Leu Gly He Lys Val Leu Lys He Glu Gly Phe 100 105 110 Glu Ala Asp Asp He He Ala Thr Leu Ser Lys Lys Phe Glu Ser Asp 115 120 125 Phe Glu Lys Val Asn He He Thr Gly Asp Lys Asp Leu Leu Gin Leu 130 135 140 Val Ser Asp Lys Val Phe Val Trp Arg Val Glu Arg Gly He Thr Asp 145 150 155 160 Leu Val Leu Tyr Asp Arg Asn Lys Val He Glu Lys Tyr Gly He Tyr 165 170 175 Pro Glu Gin Phe Lys Asp Tyr Leu Ser Leu Val Gly Asp Gin He Asp 180 185 190 Asn He Pro Gly Val Lys Gly He Gly Lys Lys Thr Ala Val Ser Leu 195 200 205 Leu Lys Lys Tyr Asn Ser Leu Glu Asn Val Leu Lys Asn He Asn Leu 210 215 220 Leu Thr Glu Lys Leu Arg Arg Leu Leu Glu Asp Ser Lys Glu Asp Leu 225 230 235 240 Gln Lys Ser He Glu Leu Val Glu Leu He Tyr Asp Val Pro Met Asp 245 250 255 Val Glu Lys Asp Glu He He Tyr Arg Gly Tyr Asn Pro Asp Lys Leu 260 265 270 Leu Lys Val Leu Lys Lys Tyr Glu Phe Ser Ser He He Lys Glu Leu 275 280 285 Asn Leu Gin Glu Lys Leu Glu Lys Glu Tyr He Leu Val Asp Asn Glu 290 295 300 Asp Lys Leu Lys Lys Leu Ala Glu Glu He Glu Lys Tyr Lys Thr Phe 305 310 315 320 Ser He Asp Thr Glu Thr Thr Ser Leu Asp Pro Phe Glu Ala Lys Leu 325 330 335 Val Gly He Ser He Ser Thr Met Glu Gly Lys Ala Tyr Tyr He Pro 340 345 350 Val Ser His Phe Gly Ala Lys Asn He Ser Lys Ser Leu He Asp Lys 355 360 365 Phe Leu Lys Gin He Leu Gin Glu Lys Asp Tyr Asn He Val Gly Gin 370 375 380 Asn Leu Lys Phe Asp Tyr Glu He Phe Lys Ser Met Gly Phe Ser Pro 385 390 395 400 Asn Val Pro His Phe Asp Thr Met He Ala Ala Tyr Leu Leu Asn Pro 405 410 415 Asp Glu Lys Arg Phe Asn Leu Glu Glu Leu Ser Leu Lys Tyr Leu Gly 420 425 430 Tyr Lys Met He Ser Phe Asp Glu Leu Val Asn Glu Asn Val Pro Leu 435 440 445 Phe Gly Asn Asp Phe Ser Tyr Val Pro Leu Glu Arg Ala Val Glu Tyr 450 455 460 Ser Cys Glu Asp Ala Asp Val Thr Tyr Arg He Phe Arg Lys Leu Gly 465 470 475 480 Arg Lys He Tyr Glu Asn Glu Met Glu Lys Leu Phe Tyr Glu Tie Glu 485 490 495 Met Pro Leu He Asp Val Leu Ser Glu Met Glu Leu Asn Gly Val Tyr 500 505 510 Phe Asp Glu Glu Tyr Leu Lys Glu Leu Ser Lys Lys Tyr Gin Glu Lys 515 520 525 Met Asp Gly He Lys Glu Lys Val Phe Glu He Ala Gly Glu Thr Phe 530 535 540 Asn Leu Asn Ser Ser Thr Gin Val Ala Tyr He Leu Phe Glu Lys Leu 545 550 555 560 Asn He Ala Pro Tyr Lys Lys Thr Ala Thr Gly Lys Phe Ser Thr Asn 565 570 575 Ala Glu Val Leu Glu Glu Leu Ser Lys Glu His Glu He Ala Lys Leu 580 585 590 Leu Leu Glu Tyr Arg Lys Tyr Gin Lys Leu Lys Ser Thr Tyr He Asp 595 600 605 Ser He Pro Leu Ser He Asn Arg Lys Thr Asn Arg Val His Thr Thr 610 615 620 Phe His Gin Thr Gly Thr Ser Thr Gly Arg Leu Ser Ser Ser Asn Pro 625 630 635 640 Asn Leu Gin Asn Leu Pro Thr Arg Ser Glu Glu Gly Lys Glu He Arg 645 650 655 Lys Ala Val Arg Pro Gin Arg Gin Asp Trp Trp He Leu Gly Ala Asp 660 665 670 Tyr Ser Gin He Glu Leu Arg Val Leu Ala His Val Ser Lys Asp Glu 675 680 685 Asn Leu Leu Lys Ala Phe Lys Glu Asp Leu Asp He His Thr He Thr 690 695 700 Ala Ala Lys He Phe Gly Val Ser Glu Met Phe Val Ser Glu Gin Met 705 710 715 720 Arg Arg Val Gly Lys Met Val Asn Phe Ala He He Tyr Gly Val Ser 725 730 735 Pro Tyr Gly Leu Ser Lys Arg He Gly Leu Ser Val Ser Glu Thr Lys 740 745 750 Lys He He Asp Asn Tyr Phe Arg Tyr Tyr Lys Gly Val Phe Glu Tyr 755 760 765 Leu Lys Arg Met Lys Asp Glu Ala Arg Lys Lys Gly Tyr Val Thr Thr 770 775 780 Leu Phe Gly Arg Arg Arg Tyr He Pro Gin Leu Arg Ser Lys Asn Gly 785 790 795 800 Asn Arg Val Gin Glu Gly Glu Arg He Ala Val Asn Thr Pro He Gin 805 810 815 Gly Thr Ala Ala Asp He He Lys He Ala Met He Asn He His Asn 820 825 830 Arg Leu Lys Lys Glu Asn Leu Arg Ser Lys Met He Leu Gin Val His 835 840 845 Asp Glu Leu Val Phe Glu Val Pro Asp Asn Glu Leu Glu He Val Lys 850 855 860 Asp Leu Val Arg Asp Glu Met Glu Asn Ala Val Lys Leu Asp Val Pro 865 870 875 880 Leu Lys Val Asp Val Tyr Tyr Gly Lys Glu Trp Glu 885 890 (2) INFORMATION FOR SEQ ID NO:13: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 33 nucleotides (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA probe BW33 (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (xi) SEQUENCE DESCRIPTION: SEQ ID NO:13: GATCGCTGCG CGTAACCACC ACACCCGCCG CGC 33 (2) INFORMATION FOR SEQ ID NO:14: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 30 nucleotides (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA primer BW37 (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (xi) SEQUENCE DESCRIPTION: SEQ ID NO:14: GCGCTAGGGC GCTGGCAAGT GTAGCGGTCA 30 (2) INFORMATION FOR SEQ ID NO:15: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 4 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: YES (iv) ANTI-SENSE: NO (ix) FEATURE: (A) NAME/KEY: Peptide (B) LOCATION: 1..4 (D) OTHER INFORMATION: /label Xaa /note= "Xaa = Val or Thr" (xi) SEQUENCE DESCRIPTION: SEQ ID NO:15: Ala Xaa Tyr Gly 1 (2) INFORMATION FOR SEQ ID NO:16: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 5 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: internal (xi) SEQUENCE DESCRIPTION: SEQ ID NO:16: His Glu Ala Tyr Gly 1 5 (2) INFORMATION FOR SEQ ID NO:17: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 5 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: internal (xi) SEQUENCE DESCRIPTION: SEQ ID NO:17: His Glu Ala Tyr Glu 1 5 (2) INFORMATION FOR SEQ ID NO:18: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 4 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: internal (ix) FEATURE: (A) NAME/KEY: Peptide (B) LOCATION: 1..4 (D) OTHER INFORMATION: /label= Xaa /note= "Xaa = Leu or He" (xi) SEQUENCE DESCRIPTION: SEQ ID NO:18: Xaa Leu Glu Thr 1 (2) INFORMATION FOR SEQ ID NO:19: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 7 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: internal (ix) FEATURE: (A) NAME/KEY: Peptide (B) LOCATION: 1..7 (D) OTHER INFORMATION: /label= Xaa /no e= "Xaa = Leu or He" (xi) SEQUENCE DESCRIPTION: SEQ ID NO:19: Xaa Leu Glu Thr Tyr Lys Ala 1 5 (2) INFORMATION FOR SEQ ID NO:20: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 7 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: internal (ix) FEATURE: (A) NAME/KEY: Peptide (B) LOCATION: 1..7 (D) OTHER INFORMATION: /label- Xaal-4 /note= "Xaal - He or Leu or Ala; Xaa2-4, each any amino acid" (xi) SEQUENCE DESCRIPTION: SEQ ID NO:20: Xaa Xaa Xaa Xaa Tyr Lys Ala 1 5 (2) INFORMATION FOR SEQ ID NO:21: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 22 nucleotides (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA primer MK61 (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (xi) SEQUENCE DESCRIPTION: SEQ ID NO:21: AGGACTACAA CTGCCACACA CC 22 (2) INFORMATION FOR SEQ ID NO:22: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 38 nucleotides (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA primer RAOl (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (xi) SEQUENCE DESCRIPTION: SEQ ID NO:22: CGAGGCGCGC CAGCCCCAGG AGATCTACCA GCTCCTTG 38 (2) INFORMATION FOR SEQ ID NO:23: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 nucleotides (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA primer DG29 (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (xi) SEQUENCE DESCRIPTION: SEQ ID NO:23: AGCTTATGTC TCCAAAAGCT 20 (2) INFORMATION FOR SEQ ID NO:24: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 16 nucleotides (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA primer DG30 (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (xi) SEQUENCE DESCRIPTION: SEQ ID NO:24: AGCTTTTGGA GACATA 16 (2) INFORMATION FOR SEQ ID NO:25: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 25 nucleotides (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA primer PL10 (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (xi) SEQUENCE DESCRIPTION: SEQ ID NO:25: GGCGTACCTT TGTCTCACGG GCAAC 25 (2) INFORMATION FOR SEQ ID NO:26: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 28 nucleotides (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA primer FL63 (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (xi) SEQUENCE DESCRIPTION: SEQ ID NO:26: GATAAAGGCA TGCTTCAGCT TGTGAACG 28 (2) INFORMATION FOR SEQ ID NO:27: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 27 nucleotides (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA primer FL69 (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (xi) SEQUENCE DESCRIPTION: SEQ ID NO:27: TGTACTTCTC TAGAAGCTGA ACAGCAG 27 (2) INFORMATION FOR SEQ ID NO:28: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 36 nucleotides (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA primer FL64 (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (xi) SEQUENCE DESCRIPTION: SEQ ID NO:28: CTGAAGCATG TCTTTGTCAC CGGTTACTAT CAATAT 36 (2) INFORMATION FOR SEQ ID NO:29: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 18 nucleotides (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA primer FL65 (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (xi) SEQUENCE DESCRIPTION: SEQ ID NO:29: TAGTAACCGG TGACAAAG 18 (2) INFORMATION FOR SEQ ID NO:30: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 31 nucleotides (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA primer FL66 (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (xi) SEQUENCE DESCRIPTION: SEQ ID NO:30: CTATGCCATG GATAGATCGC TTTCTACTTC C 31 (2) INFORMATION FOR SEQ ID NO:31: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 31 nucleotides (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA primer FL67 (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (xi) SEQUENCE DESCRIPTION: SEQ ID NO:31: CAAGCCCATG GAAACTTACA AGGCTCAAAG A 31 (2) INFORMATION FOR SEQ ID NO:32: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 49 nucleotides (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA primer TZA292 (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (xi) SEQUENCE DESCRIPTION: SEQ ID NO:32: GTCGGCATAT GGCTCCTGCT CCTCTTGAGG AGGCCCCCTG GCCCCCGCC 49 (2) INFORMATION FOR SEQ ID NO:33: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 37 nucleotides (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA primer TZR01 (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (xi) SEQUENCE DESCRIPTION: SEQ ID NO:33: GACGCAGATC TCAGCCCTTG GCGGAAAGCC AGTCCTC 37 (2) INFORMATION FOR SEQ ID NO:34: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 49 nucleotides (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA primer TSA288 (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (xi) SEQUENCE DESCRIPTION: SEQ ID NO:34: GTCGGCATAT GGCTCCTAAA GAAGCTGAGG AGGCCCCCTG GCCCCCGCC 49 (2) INFORMATION FOR SEQ ID NO:35: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 37 nucleotides (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA primer TSR01 (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (xi) SEQUENCE DESCRIPTION: SEQ ID NO:35: GACGCAGATC TCAGGCCTTG GCGGAAAGCC AGTCCTC 37 (2) INFORMATION FOR SEQ ID NO:36: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 41 nucleotides (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA primer DG122 (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (xi) SEQUENCE DESCRIPTION: SEQ ID NO:36: CCTCTAAACG GCAGATCTGA TATCAACCCT TGGCGGAAAG C 41 (2) INFORMATION FOR SEQ ID NO:37: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 48 nucleotides (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA primer TAFI285 (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (xi) SEQUENCE DESCRIPTION: SEQ ID NO:37: GTCGGCATAT GATTAAAGAA CTTAATTTAC AAGAAAAATT AGAAAAGG 48 (2) INFORMATION FOR SEQ ID NO:38: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 46 nucleotides (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA primer TAFR01 (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (xi) SEQUENCE DESCRIPTION: SEQ ID NO:38: CCTTTACCCC AGGATCCTCA TTCCCACTCT TTTCCATAAT AAACAT 46

Claims: WHAT IS CLAIMED IS: 1. A recombinant thermostable DNA polymerase enzyme which exhibits altered 5' to 3' exonuclease activity from that of its native DNA polymerase. 2. The recombinant thermostable DNA polymerase enzyme of claim 1 wherein a greater amount of 5' to 3' exonuclease activity is exhibited than that of the native DNA polymerase. 3. The recombinant thermostable DNA polymerase enzyme of claim 2 comprising the amino acid seguence A(X)YG wherein X is V or T (SEQ ID NO:15), and/or the amino acid seguence X A X 3 YKA wherein X A is I, L or A and X 3 is any seguence of three amino acids (SEQ ID NO:20) . 4. The recombinant thermostable DNA polymerase enzyme of claim 1 wherein a lesser amount of 5' to 3' exonuclease activity is exhibited than that of the native DNA polymerase. 5. The recombinant thermostable DNA polymerase enzyme of claim 4 which in its native form comprises the amino acid seguence A(X)YG wherein X is V or T (SEQ ID NO:15), said amino acid seguence being mutated or deleted in said recombinant enzyme. 6. The recombinant thermostable DNA polymerase enzyme of claim 5 wherein G of SEQ ID NO:15 is mutated. 7. The recombinant thermostable DNA polymerase enzyme of claim 6 wherein G of SEQ ID NO:15 is mutated to A. 8. The recombinant thermostable DNA polymerase enzyme of claim 4 which in its native form comprises the amino acid seguence HEAYG (SEQ ID NO:16), said amino acid seguence being mutated or deleted in said recombinant enzyme. 9. The recombinant thermostable DNA polymerase enzyme of claim 4 which in its native form comprises the amino acid seguence HEAYE (SEQ ID NO:17), said amino acid seguence being mutated or deleted in said recombinant enzyme. 10. The recombinant thermostable DNA polymerase enzyme of claim 4 which in its native form comprises the amino acid seguence XLET wherein X is L or I (SEQ ID NO:18), said amino acid seguence being mutated or deleted in said recombinant enzyme. 11. The recombinant thermostable DNA polymerase enzyme of claim 4 selected from the group consisting of mutant forms of Thermus species spsl7, Thermus species Z05, Thermus aguaticus. Thermus thermophilus. Thermosipho africanus and Thermotoga maritima. 12. The recombinant thermostable DNA polymerase enzyme of claim 11 wherein said enzyme is a mutant form of Thermus aguaticus comprising amino acids 77-832 of SEQ ID NO:2. 13. The recombinant thermostable DNA polymerase enzyme of claim 11 wherein said enzyme is a mutant form of Thermus aguaticus comprising amino acids 47-832 of SEQ ID NO:2. 14. The recombinant thermostable DNA polymerase enzyme of claim 11 wherein said enzyme is a mutant form of Thermus aguaticus comprising amino acids 155-832 of SEQ ID NO:2. 15. The recombinant thermostable DNA polymerase enzyme of claim 11 wherein said enzyme is a mutant form of Thermus aguaticus comprising amino acids 203-832 of SEQ ID NO:2. 16. The recombinant thermostable DNA polymerase enzyme of claim 11 wherein said enzyme is a mutant form of Thermus aguaticus comprising amino acids 290-832 of SEQ ID NO:2. 17. The recombinant thermostable DNA polymerase enzyme of claim 11 wherein said enzyme is a mutant form of Thermotoga maritima comprising amino acids 38-893 of SEQ ID NO:4. 18. The recombinant thermostable DNA polymerase enzyme of claim 11 wherein said enzyme is a mutant form of Thermotoga maritima comprising amino acids 21-893 of SEQ ID NO:4. 19. The recombinant thermostable DNA polymerase enzyme of claim 11 wherein said enzyme is a mutant form of Thermotoga maritima comprising amino acids 74-893 of SEQ ID NO:4. 20. The recombinant thermostable DNA polymerase enzyme of claim 11 wherein said enzyme is a mutant form of Thermotoga maritima comprising amino acids 140-893 of SEQ ID NO:4. 21. The recombinant thermostable DNA polymerase enzyme of claim 11 wherein said enzyme is a mutant form of Thermotoga maritima comprising amino acids 284-893 of SEQ ID NO:4. 22. The recombinant thermostable DNA polymerase enzyme of claim 11 wherein said enzyme is a mutant form of Thermus species spsl7 comprising amino acids 44-830 of SEQ ID NO:6. 23. The recombinant thermostable DNA polymerase enzyme of claim 11 wherein said enzyme is a mutant form of Thermus species spsl7 comprising amino acids 74-830 of SEQ ID NO:6. 24. The recombinant thermostable DNA polymerase enzyme of claim 11 wherein said enzyme is a mutant form of Thermus species spsl7 comprising amino acids 152-830 of SEQ ID NO:6. 25. The recombinant thermostable DNA polymerase enzyme of claim 11 wherein said enzyme is a mutant form of Thermus species spsl7 comprising amino acids 200-830 of SEQ ID NO:6. 26. The recombinant thermostable DNA polymerase enzyme of claim 11 wherein said enzyme is a mutant form of Thermus species spsl7 comprising amino acids 288-830 of SEQ ID NO:6. 27. The recombinant thermostable DNA polymerase enzyme of claim 11 wherein said enzyme is a mutant form of Thermus species Z05 comprising amino acids 47-834 of SEQ ID NO:8. 28. The recombinant thermostable DNA polymerase enzyme of claim 11 wherein said enzyme is a mutant form of Thermus species Z05 comprising amino acids 78-834 of SEQ ID NO:8. 29. The recombinant thermostable DNA polymerase enzyme of claim 11 wherein said enzyme is a mutant form of Thermus species Z05 comprising amino acids 156-834 Of SEQ ID NO:8. 30. The recombinant thermostable DNA polymerase enzyme of claim 11 wherein said enzyme is a mutant form of Thermus species Z05 comprising amino acids 204-834 of SEQ ID NO:8. 31. The recombinant thermostable DNA polymerase enzyme of claim 11 wherein said enzyme is a mutant form of Thermus species Z05 comprising amino acids 292-834 of SEQ ID NO:8. 32. The recombinant thermostable DNA polymerase enzyme of claim 11 wherein said enzyme is a mutant form of Thermus thermophilus comprising amino acids 47-834 of SEQ ID NO:10. 33. The recombinant thermostable DNA polymerase enzyme of claim 11 wherein said enzyme is a mutant form of Thermus thermophilus comprising amino acids 78-834 of SEQ ID NO:10. 34. The recombinant thermostable DNA polymerase enzyme of claim 11 wherein said enzyme is a mutant form of Thermus thermophilus comprising amino acids 156-834 of SEQ ID NO:10. 35. The recombinant thermostable DNA polymerase enzyme of claim 11 wherein said enzyme is a mutant form of Thermus thermophilus comprising amino acids 204-834 of SEQ ID NO:10. 36. The recombinant thermostable DNA polymerase enzyme of claim 11 wherein said enzyme is a mutant form of Thermus thermophilus comprising amino acids 292-834 of SEQ ID NO:10. 37. The recombinant thermostable DNA polymerase enzyme of claim 11 wherein said enzyme is a mutant form of Thermosipho africanus comprising amino acids 38-892 of SEQ ID NO:12. 38. The recombinant thermostable DNA polymerase enzyme of claim 11 wherein said enzyme is a mutant form of Thermosipho africanus comprising amino acids 94-892 of SEQ ID NO:12. 39. The recombinant thermostable DNA polymerase enzyme of claim 11 wherein said enzyme is a mutant form of Thermosipho africanus comprising amino acids 140-892 of SEQ ID NO:12. 40. The recombinant thermostable DNA polymerase enzyme of claim 11 wherein said enzyme is a mutant form of Thermosipho africanus comprising amino acids 204-892 Of SEQ ID NO:12. 41. The recombinant thermostable DNA polymerase enzyme of claim 11 wherein said enzyme is a mutant form of Thermosipho africanus comprising amino acids 285-892 of SEQ ID NO:12. 42. A DNA seguence which encodes a thermostable DNA polymerase enzyme of claim 11 wherein said enzyme is a mutant form of Thermus aguaticus, said DNA seguence comprising nucleotides 229-2499 of SEQ ID NO:l. 43. A DNA seguence which encodes a thermostable DNA polymerase enzyme of claim 11 wherein said enzyme is a mutant form of Thermus aguaticus. said DNA seguence comprising nucleotides 139-2499 of SEQ ID NO:l. 44. A DNA seguence which encodes a thermostable DNA polymerase enzyme of claim 11 wherein said enzyme is a mutant form of Thermus aguaticus. said DNA seguence comprising nucleotides 463-2499 of SEQ ID NO:l. 45. A DNA seguence which encodes a thermostable DNA polymerase enzyme of claim 11 wherein said enzyme is a mutant form of Thermus aguaticus, said DNA seguence comprising nucleotides 607-2499 of SEQ ID NO:l. 46. A DNA seguence which encodes a thermostable DNA polymerase enzyme of claim 11 wherein said enzyme is a mutant form of Thermus aguaticus. said DNA seguence comprising nucleotides 868-2499 of SEQ ID NO:l. 47. A DNA seguence which encodes a thermostable DNA polymerase enzyme of claim 11 wherein said enzyme is a mutant form of Thermotoga maritima. said DNA seguence comprising nucleotides 132-2682 of SEQ ID NO:3. 48. A DNA seguence which encodes a thermostable DNA polymerase enzyme of claim 11 wherein said enzyme is a mutant form of Thermotoga maritima. said DNA seguence comprising nucleotides 61-2682 of SEQ ID NO:3. 49. A DNA seguence which encodes a thermostable DNA polymerase enzyme of claim 11 wherein said enzyme is a mutant form of Thermotoga maritima. said DNA seguence comprising nucleotides 220-2682 of SEQ ID NO:3. 50. A DNA seguence which encodes a thermostable DNA polymerase enzyme of claim 11 wherein said enzyme is a mutant form of Thermotoga maritima. said DNA seguence comprising nucleotides 418-2682 of SEQ ID NO:3. 51. A DNA seguence which encodes a thermostable DNA polymerase enzyme of claim 11 wherein said enzyme is a mutant form of Thermotoga maritima. said DNA seguence comprising nucleotides 850-2682 of SEQ ID NO:3. 52. A DNA seguence which encodes a thermostable DNA polymerase enzyme of claim 11 wherein said enzyme is a mutant form of Thermus species spsl7, said DNA seguence comprising nucleotides 130-2493 of SEQ ID NO:5. 53. A DNA seguence which encodes a thermostable DNA polymerase enzyme of claim 11 wherein said enzyme is a mutant form of Thermus species spsl7, said DNA seguence comprising nucleotides 220-2493 of SEQ ID N0:5. 54. A DNA seguence which encodes a thermostable DNA polymerase enzyme of claim 11 wherein said enzyme is a mutant form of Thermus species spsl7, said DNA sequence comprising nucleotides 454-2493 of SEQ ID NO:5. 55. A DNA seguence which encodes a thermostable DNA polymerase enzyme of claim 11 wherein said enzyme is a mutant form of Thermus species spsl7, said DNA sequence comprising nucleotides 598-2493 of SEQ ID NO:5. 56. A DNA sequence which encodes a thermostable DNA polymerase enzyme of claim 11 wherein said enzyme is a mutant form of Thermus species spsl7, said DNA sequence comprising nucleotides 862-2493 of SEQ ID NO:5. 57. A DNA seguence which encodes a thermostable DNA polymerase enzyme of claim 11 wherein said enzyme is a mutant form of Thermus species Z05, said DNA seguence comprising nucleotides 139-2505 of SEQ ID NO:7. 58. A DNA seguence which encodes a thermostable DNA polymerase enzyme of claim 11 wherein said enzyme is a mutant form of Thermus species Z05, said DNA seguence comprising nucleotides 232-2505 of SEQ ID NO:7. 59. A DNA seguence which encodes a thermostable DNA polymerase enzyme of claim 11 wherein said enzyme is a mutant form of Thermus species Z05, said DNA sequence comprising nucleotides 476-2505 of SEQ ID NO:7. 60. A DNA sequence which encodes a thermostable DNA polymerase enzyme of claim 11 wherein said enzyme is a mutant form of Thermus species Z05, said DNA sequence comprising nucleotides 610-2505 of SEQ ID 5 NO:7. 61. A DNA seguence which encodes a thermostable DNA polymerase enzyme of claim 11 wherein said enzyme is a mutant form of Thermus species Z05, said DNA 10 seguence comprising nucleotides 874-2505 of SEQ ID NO:7. 62. A DNA seguence which encodes a thermostable DNA polymerase enzyme of claim 11 wherein said enzyme 15 is a mutant form of Thermus thermophilus. said DNA sequence comprising nucleotides 139-2505 of SEQ ID NO:9. 63. A DNA seguence which encodes a thermostable DNA 20 polymerase enzyme of claim 11 wherein said enzyme is a mutant form of Thermus thermophilus. said DNA seguence comprising nucleotides 232-2505 of SEQ ID NO:9. 25 64. A DNA seguence which encodes a thermostable DNA polymerase enzyme of claim 11 wherein said enzyme is a mutant form of Thermus thermophilus. said DNA seguence comprising nucleotides 466-2505 of SEQ ID NO:9. 30 65. A DNA seguence which encodes a thermostable DNA polymerase enzyme of claim 11 wherein said enzyme is a mutant form of Thermus thermophilus. said DNA seguence comprising nucleotides 610-2505 of SEQ ID 5 NO:9. 66. A DNA sequence which encodes a thermostable DNA polymerase enzyme of claim 11 wherein said enzyme is a mutant form of Thermus thermophilus. said DNA sequence comprising nucleotides 874-2505 of SEQ ID NO:9. 67. A DNA sequence which encodes a thermostable DNA polymerase enzyme of claim 11 wherein said enzyme is a mutant form of Thermosipho africanus. said DNA seguence comprising nucleotides 112-2679 of SEQ ID NO:11. 68. A DNA seguence which encodes a thermostable DNA polymerase enzyme of claim 11 wherein said enzyme is a mutant form of Thermosipho africanus, said DNA seguence comprising nucleotides 280-2679 of SEQ ID NO:11. 69. A DNA sequence which encodes a thermostable DNA polymerase enzyme of claim 11 wherein said enzyme is a mutant form of Thermosipho africanus. said DNA sequence comprising nucleotides 418-2679 of SEQ ID NO:ll. 70. A DNA seguence which encodes a thermostable DNA polymerase enzyme of claim 11 wherein said enzyme is a mutant form of Thermosipho africanus. said DNA seguence comprising nucleotides 610-2679 of SEQ ID NO:11. 71. A DNA seguence which encodes a thermostable DNA polymerase enzyme of claim 11 wherein said enzyme is a mutant form of Thermosipho africanus, said DNA sequence comprising nucleotides 853-2679 of SEQ ID NO:11. 72. A DNA seguence which encodes a thermostable DNA polymerase enzyme of claim 3. 73. A DNA seguence which encodes a thermostable DNA 5 polymerase enzyme of any of claim 5 through 10. 74. A recombinant DNA vector comprising the DNA seguence of any of claims 42 through 73. 10 75. A recombinant host cell transformed with the vector of claim 74.

Inventors: ABRAMSON RICHARD D, GELFAND DAVID H, ABRAMSON, RICHARD, D., GELFAND, DAVID, H.
Applicants: CETUS CORP, CETUS CORPORATION
Application year: 1991
Main classification: C12N1
IPC codes: C12N1, C12N9, C12N15, C12Q1, C12R1